NCT Number,Title,Status,Study Results,Interventions,Gender,Age,URL
NCT02884362,Prospective Melanoma Database,Recruiting,No Results Available,Other: clinical biological data collection on melanoma,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02884362
NCT03455764,MCS110 With BRAF/MEK Inhibition in Patients With Melanoma,Recruiting,No Results Available,Drug: MCS110|Drug: Dabrafenib|Drug: Trametinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03455764
NCT03101254,LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma,Recruiting,No Results Available,Drug: LY3022855|Drug: Vemurafenib|Drug: Cobimetinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03101254
NCT03272464,INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.,Recruiting,No Results Available,Drug: Trametinib|Drug: Dabrafenib|Drug: INCB039110,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03272464
NCT02915666,A Clinical Trial of Patients With Melanoma,Withdrawn,No Results Available,Drug: Digoxin Combination|Drug: Dabrafenib|Drug: Trametinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02915666
NCT03784625,Targeted Radionuclide Therapy for Metastatic Melanoma [131I] ICF 01012,Not yet recruiting,No Results Available,Drug: [131I]ICF01012 (therapeutic dose level 1)|Drug: [131I]ICF01012 (therapeutic dose level 2)|Drug: [131I]ICF01012 (therapeutic dose level 3)|Drug: [131I]ICF01012 (therapeutic dose level 4),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03784625
NCT03435302,HDI Versus Chemotherapy as Systemic Adjuvant Therapy for Resected Mucosal Melanoma,Recruiting,No Results Available,Drug: Temozolomide Plus Cisplatin|Drug: High-Dose IFN-a2b,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03435302
NCT03301636,A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma,Recruiting,No Results Available,Drug: Pembrolizumab|Drug: Nivolumab|Drug: Indoximod|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03301636
NCT03126461,SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients,Withdrawn,No Results Available,Radiation: SAbR|Drug: Ipilimumab|Drug: Nivolumab,All,"18 Years to 99 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03126461
NCT03356470,Pilot Study of Biomarkers of Response to Immune Checkpoint Blockade in Metastatic Melanoma,Enrolling by invitation,No Results Available,Other: F-FDG PET/CT,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03356470
NCT02437305,Melanoma Perception and Health Literacy in People of Color,Completed,Has Results,Behavioral: ABCDEs of Melanoma Skin Cancer|Behavioral: ABCDEs of Melanoma,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02437305
NCT02403778,Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma,"Active, not recruiting",No Results Available,Drug: VESANOID|Drug: Ipilimumab,All,"18 Years to 89 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02403778
NCT02602756,Study Assessing Two Models of Hypofractionated Protontherapy on Large Choroidal Melanomas,"Active, not recruiting",No Results Available,Radiation: Protontherapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02602756
NCT02752074,A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301),"Active, not recruiting",No Results Available,Drug: pembrolizumab + epacadostat|Drug: pembrolizumab + placebo,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02752074
NCT02862145,"Pharmacodynamics Study of MRX34, MicroRNA Liposomal Injection in Melanoma Patients With Biopsy Accessible Lesions",Withdrawn,No Results Available,Drug: MRX34|Drug: Dexamethasone,All,"18 Years to 95 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02862145
NCT02872259,BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma,Recruiting,No Results Available,Drug: BGB324+pembrolizumab|Drug: BGB324+dabrafenib and trametinib|Drug: pembrolizumab|Drug: dabrafenib and trametinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02872259
NCT01752257,EF5 in Melanoma Patients,Completed,No Results Available,Drug: EF5 Hypoxia,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01752257
NCT02671513,A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients,Unknown status,No Results Available,Drug: SHR6390,All,"18 Years to 65 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02671513
NCT02159066,"LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma","Active, not recruiting",No Results Available,Drug: LGX818|Drug: MEK162|Drug: LEE011|Drug: BGJ398|Drug: BKM120|Drug: INC280,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02159066
NCT02854124,Tracing Dissemination of Melanoma Cells in Healthy Tissues,Recruiting,No Results Available,Procedure: Melanoma and peritumoral skin excision,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02854124
NCT03149029,Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma,Recruiting,No Results Available,Drug: Pembrolizumab|Drug: Dabrafenib|Drug: Trametinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03149029
NCT02143050,"Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients",Recruiting,No Results Available,Drug: Dabrafenib|Drug: Trametinib|Drug: Metformin,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02143050
NCT02112032,Treatment of Advanced Melanoma With MK-3475 and Peginterferon,"Active, not recruiting",No Results Available,Drug: MK-3475|Drug: Peginterferon alfa-2b,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02112032
NCT02501551,"Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy",Recruiting,No Results Available,Drug: regorafenib,All,"19 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02501551
NCT02619058,A Clinical Trial of Adoptive Transfer With Autologous NKT Cells in Metastatic Melanoma Patients,Unknown status,No Results Available,Biological: NKT cells,All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02619058
NCT03138642,Mucosal Melanoma of Head and Neck in Intensity-modulated Radiotherapy Era,Recruiting,No Results Available,Radiation: RT,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03138642
NCT01638676,A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients,Recruiting,No Results Available,Drug: Vemurafenib|Drug: Metformin,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01638676
NCT03520634,PD-L1 PET Imaging in Melanoma Patients,Recruiting,No Results Available,Other: PD-L1 PET imaging,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03520634
NCT03034395,Study of 1cm Versus 2cm Margins for the Surgical Treatment of cT2N0M0 Melanoma,Recruiting,No Results Available,Procedure: Wide Local Excision,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03034395
NCT02799901,Nivolumab Plus Radiotherapy in Advanced Melanoma,Recruiting,No Results Available,Biological: Nivolumab|Radiation: hypofractionned radiotherapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02799901
NCT01782508,A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma,Unknown status,No Results Available,Drug: imatinib|Drug: Interferon,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01782508
NCT01702896,Interleukin-2 in Metastatic Melanoma,Terminated,Has Results,Drug: Interleukin-2,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01702896
NCT01970358,A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma,"Active, not recruiting",No Results Available,Biological: Poly-ICLC|Biological: Peptides,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01970358
NCT02120222,Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery,Recruiting,No Results Available,Drug: selinexor|Other: Correlative studies,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02120222
NCT03159117,Pfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma,Recruiting,No Results Available,Drug: PF-06688992,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03159117
NCT02875652,Circulating Tumoral DNA in Choroidal Melanoma (ctDNA MU),"Active, not recruiting",No Results Available,Biological: Blood sampling,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02875652
NCT02071940,PLX3397 KIT in Acral aNd mucOsal Melanoma,Recruiting,No Results Available,Drug: PLX3397,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02071940
NCT01123304,Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma,Terminated,No Results Available,Drug: MORAb028,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01123304
NCT01740297,Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma,"Active, not recruiting",Has Results,Drug: Talimogene laherparepvec|Drug: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01740297
NCT02645149,Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma,Not yet recruiting,No Results Available,Drug: Standard therapy or clinical trial|Drug: Matched targeted therapy|Drug: Trametinib and / or supportive care,All,"18 Years to 100 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02645149
NCT03417739,A Phase II Study of BVD-523 in Metastatic Uveal Melanoma,Recruiting,No Results Available,Drug: BVD-523,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03417739
NCT02975700,A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma,"Active, not recruiting",No Results Available,Drug: PLX3397,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02975700
NCT01692691,Dacarbazine and Carmustine in Metastatic Melanoma,Terminated,Has Results,Drug: Dacarbazine|Drug: Carmustine|Drug: Neulasta,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01692691
NCT02141542,Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma,"Active, not recruiting",No Results Available,Drug: Tremelimumab|Drug: MEDI3617,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02141542
NCT01604889,"A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With INCB024360 or Placebo in Subjects With Unresectable or Metastatic Melanoma",Terminated,No Results Available,Drug: INCB024360|Drug: Placebo|Drug: ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01604889
NCT03348891,TNF in Melanoma Patients Treated With Immunotherapy,Recruiting,No Results Available,Other: Tumor biopsy specimens and blood samples,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03348891
NCT01127594,Evaluate Safety/Tolerability Intra-Arterial Temozolomide in Patients w/Extremity Melanoma by Isolated Limb Infusion,Completed,No Results Available,Drug: Temozolomide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01127594
NCT01672450,A Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma,Completed,No Results Available,Drug: Intratumoral Ipilimumab and Interleukin-2,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01672450
NCT01996202,A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma,"Active, not recruiting",No Results Available,Drug: Ipilumimab|Radiation: Radiation,All,"18 Years to 100 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01996202
NCT03464604,Melanoma Accuracy Study; Phase 2,Not yet recruiting,No Results Available,Diagnostic Test: active,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03464604
NCT03033485,18F‐Labeled Picolinamide PET Imaging of Melanoma Diagnosis,Unknown status,No Results Available,Radiation: 18F-P3BZA,All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03033485
NCT02870244,Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes,Recruiting,No Results Available,Biological: Escalating Doses,All,"18 Years to 89 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02870244
NCT02074605,Cognitive Effects of Interferon in Patients With Melanoma,Completed,No Results Available,Biological: Interferon alpha,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02074605
NCT01859845,Melanoma Simulation Model With Smartphone Devices: Training Physicians for Early Detection of Melanoma,Completed,No Results Available,Other: Smartphone,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01859845
NCT02902029,Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma,Recruiting,No Results Available,Drug: Vemurafenib|Drug: Cobimetinib|Drug: Atezolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02902029
NCT00961376,Vaccination of Melanoma Patients With Total or CD25-depleted Peripheral Blood Mononuclear Cell (PBMC),Terminated,No Results Available,Biological: PBMC re-infusion|Biological: CD25 depletion,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00961376
NCT01636882,CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext),Completed,Has Results,Biological: CVA21,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01636882
NCT01764009,Safety and Efficacy of Intramuscular Electrotransfer of Plasmid AMEP in Patients Suffering From Advanced or Metastatic Melanoma,Withdrawn,No Results Available,Biological: naked DNA coding for protein AMEP,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01764009
NCT02962947,MELABLOCK: A Clinical Trial on the Efficacy and Safety of Propranolol 80 mg in Melanoma Patients,Not yet recruiting,No Results Available,Drug: Propranolol|Drug: Placebo,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02962947
NCT01878396,Circulating Melanoma Cells in Metastatic Patients Treated With Selective BRAF Inhibitors,Unknown status,No Results Available,Drug: Anti-B-RAF,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01878396
NCT01941927,Trametinib With GSK2141795 in BRAF Wild-type Melanoma,Unknown status,No Results Available,Drug: Trametinib (GSK1120212)|Drug: GSK2141795,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01941927
NCT01462773,"Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma",Completed,Has Results,Drug: Bortezomib|Drug: Interferon Alfa-2b,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01462773
NCT00846833,Haploidentical NK Cell Infusion in Malignant Melanoma,Completed,No Results Available,Biological: Haploidentical NK cell,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00846833
NCT03022565,Vorinostat in Patients With Class 2 High Risk Uveal Melanoma,Recruiting,No Results Available,Drug: Vorinostat,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03022565
NCT02489266,In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic Melanoma,Withdrawn,No Results Available,Biological: AKTi-treated TIL|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Aldesleukin,All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02489266
NCT02392871,Radiotherapy & Combi in Metastatic Melanoma,Recruiting,No Results Available,Radiation: Palliative radiotherapy|Drug: Dabrafenib and trametinib (combination),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02392871
NCT01620749,Of 18F MEL050 Using PET/CT in Metastatic Melanoma,Unknown status,No Results Available,Radiation: 18F MEL050,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01620749
NCT03422445,A Study of Apatinib Combined With Temozolomide in Patients Witn Advanced Melanoma,Recruiting,No Results Available,Drug: Apatinib|Drug: Temozolomide,All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03422445
NCT00482105,Early Diagnosis of Melanoma Using Expression Profiling and Non-Invasive Sampling of Skin Cells,Terminated,No Results Available,Other: EGIR Tape,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00482105
NCT01397708,Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma,Completed,No Results Available,Biological: INXN-2001|Drug: INXN-1001,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01397708
NCT02452281,Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma,Withdrawn,No Results Available,Drug: ipilimumab|Drug: HSPPC-96,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02452281
NCT02891616,18F-FLT PET Imaging in Patients With Advanced Melanoma,Recruiting,No Results Available,Drug: fludeoxyglucose F 18|Device: Positron emission tomography-computed tomography|Drug: 18F-fluorothymidine|Device: Positron emission tomography-magnetic resonance imaging,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02891616
NCT01933061,Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma,Withdrawn,No Results Available,Drug: Abraxane,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01933061
NCT01614301,"Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma",Unknown status,No Results Available,"Drug: dacarbazine (DTIC), Trofosfamide, Etoricoxib, Pioglitazone, Temsirolimus",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01614301
NCT02654821,Study With T-cel Receptor Gene Therapy in Metastatic Melanoma,"Active, not recruiting",No Results Available,Biological: TCR transduced T-cells|Procedure: Biopsy|Procedure: Blood taking,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02654821
NCT01045915,Safety and Efficacy Study of Electrotransfer of Plasmid AMEP to Treat Advanced or Metastatic Melanoma,Terminated,No Results Available,Biological: naked DNA coding for protein AMEP,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01045915
NCT01622933,Multiple Antigen-Engineered DC Vaccine for Melanoma,Completed,No Results Available,Biological: DC Vaccine + IFN|Biological: AdVTMM2/DC Vaccination,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01622933
NCT03754179,Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma,Recruiting,No Results Available,Drug: Dabrafenib|Drug: Trametinib|Drug: Hydroxychloroquine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03754179
NCT01052142,Safety Study of a Liposomal Vaccine to Treat Malignant Melanoma,Completed,No Results Available,Biological: Lipovaxin-MM,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01052142
NCT01813214,The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma,Terminated,Has Results,Drug: Vemurafenib|Drug: Cobimetinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01813214
NCT03448666,ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases,Not yet recruiting,No Results Available,Combination Product: Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03448666
NCT02482532,"Vaccine Enriched, Autologous, Activated T-Cells Directed to Tumor in Patients With Relapsed/Refractory Melanoma",Recruiting,No Results Available,Biological: tvs-CTL Vaccine,All,"18 Years to 66 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02482532
NCT03484923,Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma,Recruiting,No Results Available,Drug: Spartalizumab|Drug: LAG525|Drug: Capmatinib|Drug: Canakinumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03484923
NCT02434354,A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma,Recruiting,No Results Available,Drug: pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02434354
NCT00515528,Vaccination Plus Ontak in Patients With Metastatic Melanoma,"Active, not recruiting",No Results Available,Drug: 4-peptide melanoma vaccine|Drug: 4-peptide melanoma vaccine plus Ontak|Drug: ontak,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00515528
NCT03293784,TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanoma,Recruiting,No Results Available,Combination Product: Nivolumab+Ipilimumab in combination with Anti TNF-α Certolizumab|Combination Product: Nivolumab+Ipilimumab in combination with Anti TNF-α Infliximab,All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03293784
NCT01355120,THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease,Completed,No Results Available,Drug: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01355120
NCT00746746,A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma,Unknown status,No Results Available,Biological: HyperAcute vaccine|Drug: Pegylated Interferon-Alpha 2b,All,"19 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00746746
NCT03178123,The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery,Recruiting,No Results Available,Biological: humanized anti-PD-1 monoclonal antibody|Biological: high-dose recombinant interferon a-2B,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03178123
NCT01042366,Dendritic Cells (DC) Vaccine for Metastatic Melanoma,Terminated,Has Results,Biological: Vaccination,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01042366
NCT02626962,Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma,"Active, not recruiting",No Results Available,Drug: ipilimumab|Drug: Nivolumab,All,"18 Years to 99 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02626962
NCT02036086,Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases,Recruiting,No Results Available,Drug: Vemurafenib|Drug: Cobimetinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02036086
NCT01011530,Dose Escalation Study of MLN4924 in Adults With Melanoma,Completed,No Results Available,Drug: MLN4924,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01011530
NCT01781026,Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases,Completed,Has Results,Drug: Vemurafenib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01781026
NCT03391050,A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma,"Active, not recruiting",No Results Available,Drug: APR-246|Drug: Dabrafenib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03391050
NCT02828202,Follow-up of a National Cohort of Melanoma Stage IV and Unresectable Stage III Patients,Recruiting,No Results Available,Other: Biological|Other: Tissular|Other: Quality of life,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02828202
NCT00835419,Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression,Completed,No Results Available,Drug: P276-00,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00835419
NCT00701987,"Safety, Tolerability, and Preliminary Efficacy Study of ALS-357 in Patients With Cutaneous Metastatic Melanoma",Unknown status,No Results Available,Drug: ALS-357,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00701987
NCT02621021,A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab,Recruiting,No Results Available,Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Aldeslaukin|Drug: Pembrolizumab|Biological: young TIL,All,"16 Years to 70 Years   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02621021
NCT00466687,Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma,Completed,Has Results,Biological: bevacizumab|Drug: erlotinib hydrochloride|Genetic: fluorescence in situ hybridization|Genetic: gene expression analysis|Other: immunologic technique|Other: laboratory biomarker analysis|Procedure: biopsy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00466687
NCT02225366,Intratumoral Injections of LL37 for Melanoma,"Active, not recruiting",No Results Available,Biological: LL37|Other: Photographs,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02225366
NCT03712358,PVSRIPO for Patients With Unresectable Melanoma,Recruiting,No Results Available,Biological: PVSRIPO,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03712358
NCT00658437,CY503 for the Treatment of Malignant Melanoma Stage IV After Failure of Prior Therapy,Completed,No Results Available,Drug: CY-503,All,"18 Years to 90 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00658437
NCT02416232,Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma,No longer available,No Results Available,Drug: Trametinib|Drug: Dabrafenib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02416232
NCT03353402,Fecal Microbiota Transplantation (FMT) in Metastatic Melanoma Patients Who Failed Immunotherapy,Recruiting,No Results Available,Procedure: Fecal Microbiota Transplant (FMT),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03353402
NCT02190838,Comparison of Melatonin or Metformin and Dacarbazine Combination Versus Dacarbazine Alone in Disseminated Melanoma,Unknown status,No Results Available,Drug: Metformin|Drug: Melatonin|Drug: Dacarbazine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02190838
NCT01388569,Biomarkers in Blood Samples From Patients With Stage IV Melanoma Previously Treated With Sargramostim,Completed,No Results Available,Other: flow cytometry|Other: immunologic technique|Other: laboratory biomarker analysis,All,"18 Years to 120 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01388569
NCT01124734,High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma,Unknown status,No Results Available,Drug: Interleukin-2|Drug: Temozolomide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01124734
NCT01973608,MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma,Terminated,Has Results,Drug: MSB0010445 (0.3 milligram per kilogram [mg/kg])|Drug: MSB0010445 (1.0 mg/kg)|Drug: MSB0010445 (1.8 mg/kg)|Drug: MSB0010445 (2.4 mg/kg)|Radiation: Stereotactic Body Radiation Therapy (SBRT),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01973608
NCT01376713,Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma,Completed,No Results Available,Biological: Ofatumumab|Biological: Ofatumumab plus Dacarbazine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01376713
NCT02142335,Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma,Unknown status,No Results Available,Drug: Rituxan,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02142335
NCT02608437,A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients,Unknown status,No Results Available,Drug: SGI-110|Drug: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02608437
NCT03757689,Neoadjuvant PD-1 Blockade in Patients With Stage IIB/C Melanoma,Not yet recruiting,No Results Available,Drug: Pembrolizumab|Procedure: Wide Excision and Sentinel Lymph Node (SLN) Biopsy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03757689
NCT03225365,Nivolumab +/- Ipilimumab Immunomonitoring in Metastatic Melanoma,Not yet recruiting,No Results Available,Biological: Blood and biopsy sampling,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03225365
NCT00421317,Imatinib in Adult Patients With Metastatic Ocular Melanoma,Terminated,No Results Available,Drug: Imatinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00421317
NCT02054520,Immunotherapy Study for Patients With Stage IV Melanoma,Unknown status,No Results Available,Drug: HyperAcute®-Melanoma (HAM) Immunotherapy|Drug: Ipilimumab|Drug: Pembrolizumab|Drug: Nivolumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02054520
NCT03311308,A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma,Recruiting,No Results Available,Drug: Pembrolizumab Injection [Keytruda]|Drug: Metformin,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03311308
NCT01983124,Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemurafenib,Completed,No Results Available,Drug: Fotemustine + Vemurafenib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01983124
NCT01082198,Melanoma Vaccine in Treating Patients With Stage III Melanoma After Surgery to Remove Lymph Nodes,Unknown status,No Results Available,Biological: HLA-A1-binding MAGE-1/MAGE-3 multipeptide-pulsed autologous dendritic cell vaccine|Biological: HLA-A2-binding TYR/MART-1/gp100 multipeptide-pulsed autologous dendritic cell vaccine|Biological: autologous melanoma lysate-pulsed autologous dendritic cell vaccine|Biological: autologous melanoma lysate/KLH-pulsed autologous dendritic cell vaccine|Biological: dendritic cell-idiotype-keyhole limpet hemocyanin vaccine|Other: flow cytometry|Procedure: adjuvant therapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01082198
NCT01943422,Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma,Completed,No Results Available,Drug: High-dose Interferon alfa-2b|Drug: Vemurafenib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01943422
NCT00758797,A Novel Treatment for Metastatic Melanoma,Terminated,No Results Available,Other: Photoimmunotherapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00758797
NCT02967692,"A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma",Recruiting,No Results Available,Biological: Spartalizumab (PDR001)|Other: Placebo|Drug: Dabrafenib|Drug: Trametinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02967692
NCT01153763,A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma,Completed,Has Results,Drug: GSK2118436,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01153763
NCT01942993,The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma,Terminated,No Results Available,Drug: Vemurafenib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01942993
NCT00615160,PTK/ZK in Disseminated Malignant Melanoma,Suspended,No Results Available,Drug: PTK787/ZK 222584|Drug: Dacarbazine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00615160
NCT00590824,Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma,"Active, not recruiting",No Results Available,Drug: hu14.18-IL2,All,"15 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00590824
NCT03354962,Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA),Recruiting,No Results Available,Combination Product: Nivolumab + Ipilimumab|Combination Product: Combined treatment schema,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03354962
NCT01944709,Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Patients With Inoperable Stage III and Stage IV Melanoma,Terminated,No Results Available,Biological: Dendritic cell application,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01944709
NCT02285413,Platin-based Chemotherapeutics to Enhance Dendritic Cell Vaccine Efficacy in Melanoma Patients,Completed,No Results Available,Biological: DC vaccination|Biological: DC vaccination with cisplatinum,All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02285413
NCT02023710,Bevacizumab Combined With Carboplatin Plus Paclitaxel Chemotherapy to Treat Metastatic Mucosal Melanoma,Recruiting,No Results Available,Drug: Paclitaxel|Drug: Carboplatin|Drug: Bevacizumab,All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02023710
NCT02731729,Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy,"Active, not recruiting",No Results Available,Drug: ipilimumab|Drug: nivolumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02731729
NCT02706353,APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma,Recruiting,No Results Available,Drug: APX005M|Drug: Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02706353
NCT01557114,Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma,Terminated,No Results Available,Drug: Ipilimumab|Radiation: Radiotherapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01557114
NCT01500304,Minimally Invasive Groin Dissection for Melanoma,Completed,No Results Available,Procedure: Minimally invasive inguinal lymph node dissection,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01500304
NCT03727087,Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Melanoma,Recruiting,No Results Available,Other: Blood Sample Collection,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03727087
NCT03385486,Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors,Not yet recruiting,No Results Available,Biological: TBX-3400,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03385486
NCT01586403,Transfer of Genetically Engineered Lymphocytes in Melanoma Patients,"Active, not recruiting",No Results Available,Biological: Dose 1|Biological: Dose 2|Biological: Dose 3|Biological: Dose 4,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01586403
NCT03772899,Fecal Microbial Transplantation in Combination With Immunotherapy in Melanoma Patients (MIMic),Not yet recruiting,No Results Available,Drug: Fecal Microbial Transplantation,All,"19 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03772899
NCT01247623,Trial With Telomerase Peptide Vaccine In Combination With Temozolomide in Patients With Advanced Malignant Melanoma,Completed,No Results Available,Biological: GV1001,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01247623
NCT02565992,Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA),Recruiting,No Results Available,Biological: CAVATAK|Drug: Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02565992
NCT03116412,A Randomized Trial to Assess the Role of Imaging During Follow up After Radical Surgery of High Risk Melanoma,Recruiting,No Results Available,Procedure: CT or PET scans,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03116412
NCT00626860,The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma,Completed,No Results Available,Biological: DC/tumor fusion vaccine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00626860
NCT00591370,Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma,Completed,Has Results,Drug: Temozolomide (TMZ),All,"16 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00591370
NCT00937781,Study of Tumor Tissue From Patients With Melanoma Treated on Clinical Trial EST-1690,Completed,No Results Available,Genetic: RNA analysis|Genetic: gene expression analysis|Genetic: microarray analysis|Genetic: polymerase chain reaction|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis,All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00937781
NCT03420508,Treating Patients With Melanoma and ALK Alterations With Ensartinib,Recruiting,No Results Available,Drug: Ensartinib|Diagnostic Test: ALKATI by Customized Nanostring Assay,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03420508
NCT02447939,Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma,Withdrawn,No Results Available,Drug: Dabrafenib|Drug: Trametinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02447939
NCT03711188,A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma,Recruiting,No Results Available,Drug: Nivolumab|Drug: Ipilimumab|Drug: IMM-101,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03711188
NCT03771859,A Study of Patients Receiving Adjuvant Nivolumab Therapy for Melanoma That Has Been Removed,Not yet recruiting,No Results Available,Other: Non-Interventional,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03771859
NCT00219843,Intralesional PV-10 Chemoablation of Metastatic Melanoma,Completed,No Results Available,"Drug: PV-10 (rose bengal disodium, 10%)",All,"18 Years to 85 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00219843
NCT02068196,A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma.,"Active, not recruiting",No Results Available,Procedure: Blood sampling for Pre-existing immunity|Drug: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02068196
NCT00535314,Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma,Withdrawn,No Results Available,Drug: RTA 402 Dose1|Drug: RTA 402 Dose2,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00535314
NCT02719015,Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma,Withdrawn,No Results Available,Drug: rAd.CD40L|Drug: Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02719015
NCT03683550,Comparing SLNE With or Without Preoperative Hybrid SPECT/CT in Melanoma,Recruiting,No Results Available,Procedure: SLNE with preoperative hybrid SPECT/CT|Procedure: Standard SLNE,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03683550
NCT01078961,An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma,Completed,No Results Available,Drug: bortezomib|Drug: sorafenib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01078961
NCT03341143,Fecal Microbiota Transplant (FMT) in Melanoma Patients,Recruiting,No Results Available,Drug: Fecal Microbiota Transplant with Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03341143
NCT00303251,Safety of TKI258 in Advanced/Metastatic Melanoma Subjects,Completed,No Results Available,Drug: TKI258,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00303251
NCT03450876,Long Term Quality of Life in Melanoma Patients in Netherlands,Recruiting,No Results Available,Other: Non-Interventional,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03450876
NCT02302339,A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma,Terminated,No Results Available,Drug: glembatumumab vedotin|Drug: glembatumumab vedotin and varlilumab|Drug: glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab)|Drug: glembatumumab vedotin and CDX-301,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02302339
NCT01453361,Phase II FANG™ in Advanced Melanoma,Terminated,Has Results,Biological: Vigil™ Vaccine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01453361
NCT03765229,An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma,Not yet recruiting,No Results Available,Drug: Entinostat|Drug: Pembrolizumab,All,"18 Years to 99 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03765229
NCT03454919,Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations,Not yet recruiting,No Results Available,Drug: Palbociclib,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03454919
NCT03528408,Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma,Recruiting,No Results Available,Drug: Nivolumab|Drug: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03528408
NCT03617328,"Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma",Recruiting,No Results Available,Biological: 6MHP|Drug: Montanide ISA-51|Drug: polyICLC|Drug: Cyclophosphamide|Drug: CDX-1127,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03617328
NCT01827111,Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma,"Active, not recruiting",No Results Available,Drug: ABI-007|Drug: Ipilimumab|Behavioral: Phone Call,All,"12 Years to 70 Years   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01827111
NCT02626065,Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies,"Active, not recruiting",No Results Available,Biological: blood sampling|Drug: Nivolumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02626065
NCT02922283,IL2 Imaging in Metastatic Melanoma,Recruiting,No Results Available,Device: IL2-PET scan|Procedure: Tumor biopsy|Device: CT scan|Procedure: Biopsy of non-target tissue,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02922283
NCT03430297,A Phase Ⅲ Study to Investigate JS001 Versus Dacarbazine as the First Line Therapy for Unresectable or Metastatic Melanoma,Recruiting,No Results Available,Biological: JS001 240mg Q2W|Drug: Dacarbazine 1000mg/m2 Q3W,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03430297
NCT00185302,Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma,Completed,No Results Available,"Drug: Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00185302
NCT00306514,Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients,Completed,No Results Available,Biological: CYT004-MelQbG10,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00306514
NCT02307149,Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI),Recruiting,No Results Available,Biological: CAVATAK|Drug: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02307149
NCT03732560,A Comparison of Nivolumab-based Treatments in a Real-world PD-L1 Positive Metastatic Melanoma Population in the US,"Active, not recruiting",No Results Available,Other: Non-Interventional,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03732560
NCT01227551,A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM ),Completed,Has Results,Biological: Coxsackievirus A21 (CVA21),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01227551
NCT03552549,SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron) vs. INTRON®A as Adjuvant Therapy for Melanoma (MK-4031-002),Terminated,No Results Available,Biological: PEG-Intron|Biological: INTRON A,All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03552549
NCT03092453,Dendritic Cell Vaccination in Patients With Advanced Melanoma,Recruiting,No Results Available,Biological: Mature dendritic cell (DC) vaccine|Drug: Cyclophosphamide 300mg/m^2|Drug: Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03092453
NCT03374839,Combined Therapy of Nivolumab and Adoptive T Cell Therapy in Metastatic Melanoma Patients,Recruiting,No Results Available,Drug: TIL + IL-2 + Nivolumab,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03374839
NCT00091572,Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267),Completed,Has Results,Drug: Temozolomide|Drug: Dacarbazine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00091572
NCT01009775,A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma,Completed,No Results Available,Drug: YM155|Drug: Docetaxel,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01009775
NCT00881049,Trial of Imatinib (Gleevec®) in Selected Patients With Metastatic Melanoma,Completed,No Results Available,Drug: Imatinib (Gleevec),All,"18 Years to 85 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00881049
NCT03696069,A Study is to Understand the Treatment Patterns for Immunotherapy Agents and BRAF/MEK Inhibitors Used in the Treatment of Advanced Melanoma,"Active, not recruiting",No Results Available,Other: Non-Interventional,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03696069
NCT01993719,Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma,Recruiting,No Results Available,Drug: Aldesleukin|Drug: Fludarabine|Drug: Cyclophosphamide|Biological: Young Tumor Infiltrating Lymphocytes (Young TIL)|Drug: Pembrolizumab (Keytruda),All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01993719
NCT01511913,"A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma","Active, not recruiting",No Results Available,Other: Non-Interventional,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01511913
NCT03553836,Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716),Recruiting,No Results Available,Biological: Pembrolizumab|Other: Placebo,All,"12 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03553836
NCT00522834,Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma,Terminated,No Results Available,Drug: Elesclomol (STA-4783)|Drug: Paclitaxel,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00522834
NCT03165422,A Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma in Japan,"Active, not recruiting",No Results Available,Other: Non-Interventional,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03165422
NCT00539591,Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma,Completed,Has Results,Drug: Peginterferon alfa-2b|Drug: Temozolomide|Drug: Recombinant interferon alfa-2b,All,"up to 21 Years   (Child, Adult)",https://ClinicalTrials.gov/show/NCT00539591
NCT01018004,Comparing Follow-Up Schedules in Patients With Newly Diagnosed Stage IB or Stage II Melanoma,Unknown status,No Results Available,Other: follow-up care|Other: questionnaire administration|Procedure: quality-of-life assessment,All,"18 Years to 85 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01018004
NCT01336270,"Characterisation of T Lymphocytes, NK Cells and Macrophages in Melanoma Patients",Completed,No Results Available,Other: biological collection,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01336270
NCT02500576,"Study of MK-3475 in Conjunction With Lymphodepletion, TIL, and High or Low Dose Interleukin-2 (IL-2) in Patients With Metastatic Melanoma",Recruiting,No Results Available,Drug: Cyclophosphamide|Drug: Mesna|Drug: Fludarabine|Procedure: TIL (T-cells)|Drug: IL-2|Drug: MK-347|Behavioral: Questionnaires|Behavioral: Phone Calls,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02500576
NCT01983748,Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma,Recruiting,No Results Available,Biological: Autologous Dendritic Cells loaded with autologous Tumor RNA,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01983748
NCT03758729,"Phase II Study of Nivolumab in Combination With Radiation Therapy as Definitive Treatment for Patients With Locally Advanced, Unresectable Head and Neck Mucosal Melanoma.",Not yet recruiting,No Results Available,Drug: Nivolumab|Radiation: Radiation Therapy,All,"19 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03758729
NCT03470922,A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma,"Active, not recruiting",No Results Available,Biological: Relatlimab|Biological: Nivolumab,All,"12 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03470922
NCT03635983,A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma,Recruiting,No Results Available,Biological: NKTR-214|Biological: Nivolumab,All,"12 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03635983
NCT00432107,A Study to Assess APO866 for the Treatment of Advanced Melanoma,Completed,No Results Available,Drug: APO866,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00432107
NCT03472027,Phase I Study of BCD-145 (Anti-CTLA-4) in Patients With Unresectable/Metastatic Melanoma,Recruiting,No Results Available,Biological: BCD-145,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03472027
NCT01972347,Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma,"Active, not recruiting",No Results Available,Drug: Dabrafenib|Drug: Trametinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01972347
NCT03013101,Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma,"Active, not recruiting",No Results Available,Biological: humanized anti-PD-1 monoclonal antibody,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03013101
NCT00962845,Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery,Completed,No Results Available,Drug: hydroxychloroquine,All,"18 Years to 120 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00962845
NCT03313323,Uptake and Biodistribution of 89Zirconium-labeled Ipilimumab in Ipilimumab Treated Patients With Metastatic Melanoma,Recruiting,No Results Available,Biological: 89Zirconium-labeled ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03313323
NCT02697630,Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye,Recruiting,No Results Available,Drug: Pembrolizumab|Drug: Entinostat,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02697630
NCT03328247,Achieving Self-directed Integrated Cancer Aftercare (ASICA) in Melanoma,Not yet recruiting,No Results Available,Other: ASICA digital app,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03328247
NCT01005537,"Cyclophosphamide, Autologous Lymphocytes, and Aldesleukin in Treating Patients With Metastatic Melanoma",No longer available,No Results Available,Biological: aldesleukin|Biological: therapeutic autologous lymphocytes|Drug: cyclophosphamide,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01005537
NCT02838433,Study of Anti-telomerase T CD4 Immunity in Melanoma,Unknown status,No Results Available,Other: biological samples,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02838433
NCT01683188,HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma,Terminated,No Results Available,Drug: vemurafenib + HD IL-2,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01683188
NCT03448497,Study of First-line Treatment Patterns and Clinical Outcomes in Patients With Advanced Melanoma in the United Kingdom,"Active, not recruiting",No Results Available,Other: Non-interventional,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03448497
NCT02823405,X4P-001 and Pembrolizumab in Patients With Advanced Melanoma,Completed,No Results Available,Drug: X4P-001|Drug: Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02823405
NCT02970981,Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma,"Active, not recruiting",No Results Available,Biological: Nivolumab|Biological: Ipilimumab,All,"16 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02970981
NCT03241927,Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT),"Active, not recruiting",No Results Available,Biological: Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03241927
NCT00976573,"Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma",Completed,Has Results,Biological: bevacizumab|Drug: carboplatin|Drug: everolimus|Drug: paclitaxel,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00976573
NCT03565406,A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma,Recruiting,No Results Available,Drug: Mocetinostat Induction Phase + Ipilimumab + Nivolumab|Drug: Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab,All,"18 Years to 100 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03565406
NCT03743766,"Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting",Not yet recruiting,No Results Available,Drug: Relatlimab|Drug: Nivolumab|Drug: Relatlimab + Nivolumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03743766
NCT03476174,Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma,Recruiting,No Results Available,Drug: Pembrolizumab|Drug: Interleukin-2,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03476174
NCT00735332,Efficacy Study of TLN-232 in Patients With Recurring Metastatic Melanoma,Terminated,No Results Available,Drug: TLN-232,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00735332
NCT01590082,"Doxycycline, Temozolomide and Ipilimumab in Melanoma",Terminated,No Results Available,Drug: Doxycycline|Drug: Ipilimumab|Drug: Temozolomide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01590082
NCT01597908,Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma,"Active, not recruiting",Has Results,Drug: Dabrafenib|Drug: Vemurafenib|Drug: Trametinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01597908
NCT00602199,ABT-510 in Treating Patients With Metastatic Melanoma,Completed,No Results Available,Drug: ABT-510|Other: immunoenzyme technique|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Other: pharmacological study|Procedure: biopsy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00602199
NCT03665597,Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555),Recruiting,No Results Available,Biological: Pembrolizumab Dose C|Biological: Pembrolizumab Dose A|Biological: Pembrolizumab Dose B|Biological: Pembrolizumab Dose D,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03665597
NCT02694965,Understanding Immunotherapy Resistance Mechanisms in Advanced Melanoma,Enrolling by invitation,No Results Available,Other: observational,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02694965
NCT03269565,International Trial of the Efficacy and Safety of BCD-100 in Patients With Melanoma,"Active, not recruiting",No Results Available,Biological: BCD-100,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03269565
NCT02574377,myDC/pDC in Stage III Melanoma Patients,"Active, not recruiting",No Results Available,Drug: A: myDC vaccination|Drug: B: pDC vaccination|Drug: C: combined myDC/pDC vaccination,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02574377
NCT03504696,"Effectiveness, Safety and Use of Nivolumab Administered During the French Temporary Authorization for Use in Patients With Advanced Melanoma",Completed,No Results Available,Other: Non-interventional,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03504696
NCT02562625,Trial of Pembrolizumab and Radiotherapy in Melanoma,"Active, not recruiting",No Results Available,Drug: Pembrolizumab|Radiation: Radiotherapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02562625
NCT02147951,"Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma",No longer available,No Results Available,Drug: Talimogene Laherparepvec,All,"18 Years to 95 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02147951
NCT03064763,Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma,Recruiting,No Results Available,Drug: Talimogene laherparepvec,All,"18 Years to 99 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03064763
NCT01585350,A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients,Completed,No Results Available,Biological: MELITAC 12.1 + Montanide ISA-51 + lipopolysaccharide (LPS)|Biological: MELITAC 12.1 + Montanide ISA-51 + polyICLC,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01585350
NCT03394937,Study to Assess Safety and Tolerability of Intranodal ECI-006 in Melanoma Patients With no Evidence of Disease,Recruiting,No Results Available,Biological: ECI-006,All,"18 Years to 80 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03394937
NCT01176474,Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma,"Active, not recruiting",No Results Available,Biological: NY-ESO-1 157-165 (165V)|Drug: Nivolumab|Biological: gp100:280-288 (288V)|Drug: Montanide ISA 51 vegetable grade (VG)|Drug: Ipilimumab|Procedure: Apheresis Procedure,All,"16 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01176474
NCT03445533,A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301),Recruiting,No Results Available,Drug: Ipilimumab|Drug: IMO-2125,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03445533
NCT03563729,Melanoma Metastasized to the Brain and Steroids,Recruiting,No Results Available,Drug: Pembrolizumab Injection [Keytruda]|Drug: Ipilimumab Injection [Yervoy]|Drug: Nivolumab Injection [Opdivo],All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03563729
NCT03259425,"Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma",Recruiting,No Results Available,Drug: Nivolumab|Drug: HF10,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03259425
NCT03352947,Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma,Recruiting,No Results Available,Drug: Dabrafenib|Drug: Trametinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03352947
NCT03026517,Clinical Trial of Phenformin in Combination With Dabrafenib and Trametinib for Patients With BRAF-mutated Melanoma,Recruiting,No Results Available,Drug: Dabrafenib|Drug: Trametinib|Drug: Phenformin,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03026517
NCT03580382,"Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma",Recruiting,No Results Available,Drug: Trametinib daily Until PD|Drug: CDX-3379 (ERBB3 antibody),All,"18 Years to 100 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03580382
NCT01740401,CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma,Terminated,Has Results,Drug: Cyclophosphamide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01740401
NCT03199846,Treatment Patterns and Outcomes Study in Patients With Unresectable Stage III and Metastatic (Stage IV) Melanoma in the United States,Completed,No Results Available,Other: Non-Interventional,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03199846
NCT02983006,Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma,Recruiting,No Results Available,Biological: DS-8273a|Biological: Nivolumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02983006
NCT01028222,A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation,Completed,Has Results,Drug: Nilotinib|Drug: DTIC,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01028222
NCT00755976,Sulindac and Epirubicin in Treating Patients With Metastatic Malignant Melanoma,Completed,No Results Available,Drug: epirubicin hydrochloride|Drug: sulindac|Other: immunologic technique,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00755976
NCT02818023,Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma,Recruiting,No Results Available,Drug: Pembrolizumab|Drug: Vemurafenib|Drug: Cobimetinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02818023
NCT01174238,A Two Arm Trial of Axitinib and Carboplatin/Paclitaxel in Melanoma,Completed,Has Results,Drug: Axitinib|Drug: Carboplatin|Drug: Paclitaxel,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01174238
NCT03205722,The Effectiveness of Nivolumab Monotherapy as First-Line Therapy in Adults With Advanced Melanoma in Germany,Withdrawn,No Results Available,Other: Non-Interventional,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03205722
NCT03089606,Pembrolizumab TX-naive Distant Mets Melanoma and Use of AMT (PET) at Baseline as Imaging Biomarker,Recruiting,No Results Available,Diagnostic Test: FDG PET/CT scan|Diagnostic Test: C11-AMT PET scan|Drug: Pembrolizumab|Diagnostic Test: FDG PET/CT scan with IV contrast,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03089606
NCT00936221,Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients,Completed,Has Results,Drug: AZD6244|Drug: Dacarbazine|Drug: Placebo,All,"18 Years to 130 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00936221
NCT01894672,"BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation",Completed,Has Results,Drug: LGX818,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01894672
NCT00005617,Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma,Completed,No Results Available,Biological: dendritic cell-MART-1 peptide vaccine|Procedure: leukapheresis,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00005617
NCT03095079,Rh-endostatin in Combination With Dacarbazine and Cisplatin as the First Line Therapy for Metastatic Melanoma,Recruiting,No Results Available,Drug: recombinant human endostatin,All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03095079
NCT01909453,Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma,"Active, not recruiting",No Results Available,Drug: LGX818|Drug: MEK162|Drug: vemurafenib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01909453
NCT00168870,Study of Metastatic Ocular Melanoma,Unknown status,No Results Available,Drug: Gemcitabine|Drug: Treosulfan,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00168870
NCT00667901,Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery,Terminated,No Results Available,Drug: riluzole|Genetic: protein expression analysis|Genetic: reverse transcriptase-polymerase chain reaction|Genetic: western blotting|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Other: pharmacological study|Procedure: neoadjuvant therapy|Procedure: therapeutic conventional surgery,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00667901
NCT00726739,Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma,Completed,Has Results,Biological: aldesleukin|Biological: allogeneic large multivalent immunogen vaccine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00726739
NCT02273219,Trial of AEB071 in Combination With BYL719 in Patients With Melanoma,"Active, not recruiting",No Results Available,Drug: AEB071|Drug: BYL719,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02273219
NCT01530698,Single-step Antigen Loading and TLR Activation of Dendritic Cells in Melanoma Patients,Completed,No Results Available,Biological: autologous dendritic cell vaccine,All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01530698
NCT00863330,Laboratory-Treated Autologous Lymphocytes and Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Metastatic Melanoma,Terminated,Has Results,Biological: Tumor Infiltrating Lymphocytes (TIL),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00863330
NCT01619774,An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor,Completed,Has Results,Drug: GSK2118436|Drug: GSK1120212,All,"16 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01619774
NCT02821182,A Phase II Trial of Stereotactic Body Radiotherapy With Concurrent Anti-PD1 Treatment in Metastatic Melanoma.,"Active, not recruiting",No Results Available,Radiation: stereotactic body radiotherapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02821182
NCT01416844,Study of Immune Responses in Patients With Metastatic Melanoma,Withdrawn,No Results Available,Biological: anti-OX40,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01416844
NCT02696356,Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma,Completed,No Results Available,Biological: GRN-1201,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02696356
NCT01654692,A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma,Completed,No Results Available,Drug: Ipilimumab and Fotemustine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01654692
NCT01409174,IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma,Terminated,No Results Available,Drug: Ipilimumab|Drug: Temozolomide|Drug: Cisplatin|Drug: Interferon Alfa-2b|Drug: Interleukin-2,All,"18 Years to 65 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01409174
NCT01946373,T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma,Recruiting,No Results Available,Drug: Cyclophosphamide|Drug: Fludarabine|Biological: T cells|Biological: Interleukin-2|Biological: Dendritic cell vaccine,All,"18 Years to 74 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01946373
NCT00790010,Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma,"Active, not recruiting",No Results Available,Drug: Bevacizumab Plus Ipilimumab Cohort 1|Drug: Bevacizumab Plus Ipilimumab Cohort 2|Drug: Bevacizumab Plus Ipilimumab Cohort 3|Drug: Bevacizumab Plus Ipilimumab Cohort 4,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00790010
NCT02493361,Trial of pIL-12/MK-3475 in Metastatic Melanoma,"Active, not recruiting",No Results Available,Drug: Pembrolizumab|Drug: pIL-12,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02493361
NCT02498756,Cytokine-induced Killer Study for Patients With Stage II Melanoma,Not yet recruiting,No Results Available,Biological: Cytokine-induced killer cells|Drug: Ipilimumab,All,"18 Years to 80 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02498756
NCT00560118,Fotemustine in Treating Patients With Metastatic Melanoma,Completed,No Results Available,Drug: fotemustine|Genetic: gene expression analysis|Genetic: polymerase chain reaction,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00560118
NCT02858921,"Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma",Recruiting,No Results Available,Drug: Dabrafenib|Drug: Trametinib|Drug: Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02858921
NCT00609011,Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma,Completed,No Results Available,Drug: MPC-6827 + Temozolomide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00609011
NCT00912418,"Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) - in - Adjuvant, Followed by Systemic Low-dose-interleukin-2 (IL-2) Administration, in Patients With High Risk Melanoma",Completed,No Results Available,Biological: autologous tumor cells plus GM-CSF-in Adjuvant,All,"18 Years to 85 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00912418
NCT01245062,GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma,Completed,Has Results,Drug: GSK1120212|Drug: Chemotherapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01245062
NCT00729807,0794GCC: Pentamidine in Treating Patients With Relapsed or Refractory Melanoma,Completed,Has Results,Drug: pentamidine|Genetic: gene expression analysis|Genetic: polymerase chain reaction|Genetic: western blotting|Other: bioluminescence|Other: immunoenzyme technique|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis,All,"18 Years to 120 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00729807
NCT00538005,"Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma",Unknown status,No Results Available,Biological: bevacizumab|Drug: oxaliplatin|Drug: sorafenib tosylate,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00538005
NCT00568763,Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV Melanoma,Completed,No Results Available,Biological: sargramostim|Other: immunoenzyme technique|Other: immunohistochemistry staining method|Other: immunologic technique|Other: laboratory biomarker analysis|Procedure: biopsy|Procedure: cryosurgery|Procedure: radiofrequency ablation,All,"18 Years to 120 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00568763
NCT00658892,Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma,Completed,No Results Available,Biological: B7-DC cross-linking antibody rHIgM12B7|Other: flow cytometry|Other: immunologic technique|Other: laboratory biomarker analysis,All,"18 Years to 120 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00658892
NCT00514085,Interleukin-21 in Treating Patients With Metastatic or Recurrent Malignant Melanoma,Completed,No Results Available,Biological: recombinant human interleukin-21|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Other: pharmacological study,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00514085
NCT00975520,Neurotropic Melanoma of the Head and Neck,Recruiting,No Results Available,Other: Observation|Radiation: Radiation Therapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00975520
NCT00256282,Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma,Completed,Has Results,Drug: Vinorelbine|Drug: Docetaxel|Drug: Sargramostim,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00256282
NCT00563823,Vatalanib in Treating Patients With Metastatic Cutaneous Melanoma That Cannot be Removed by Surgery,Completed,No Results Available,Drug: vatalanib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00563823
NCT02905266,A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma,"Active, not recruiting",Has Results,Biological: Nivolumab|Biological: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02905266
NCT02400385,A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma,Withdrawn,No Results Available,Drug: sunitinib|Drug: nivolumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02400385
NCT02300935,Study of Trametinib and Nab-paclitaxel in Patients With Melanoma,Withdrawn,No Results Available,Drug: trametinib|Drug: nab-paclitaxel,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02300935
NCT00324155,Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma,Completed,Has Results,Drug: Ipilimumab|Drug: Placebo|Drug: Dacarbazine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00324155
NCT00521001,Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery,Completed,Has Results,Drug: everolimus|Drug: temozolomide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00521001
NCT00254579,"Study of CP-675,206 in Refractory Melanoma",Completed,No Results Available,"Drug: CP-675,206",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00254579
NCT02393001,Analysis of Skin Lesions for Melanoma Presence by Volatile Spectroscopy Techniques,Completed,No Results Available,Other: Dermatology patients,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02393001
NCT02821000,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151),"Active, not recruiting",No Results Available,Biological: Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02821000
NCT03319693,Molecular Characterization of Primary Mucosal Melanoma,Recruiting,No Results Available,Genetic: Somatic Genetic,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03319693
NCT03338777,Suicide Plus Immune Gene Therapy for Advanced Melanoma,Recruiting,No Results Available,Biological: Suicide plus immunogene therapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03338777
NCT00940004,Toll-like Receptor (TLR) Ligand Matured Dendritic Cell Vaccination in Melanoma Patients,Completed,No Results Available,Biological: autologous dendritic cell vaccination,All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00940004
NCT01335009,Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma,"Active, not recruiting",No Results Available,Biological: MORAb-004 (monoclonal antibody),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01335009
NCT03595683,Pembrolizumab and EDP1503 in Advanced Melanoma,Recruiting,No Results Available,Drug: Pembrolizumab|Biological: EDP1503,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03595683
NCT01368276,An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma,Completed,Has Results,Biological: Talimogene Laherparepvec|Drug: Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01368276
NCT03068455,An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma,"Active, not recruiting",No Results Available,Biological: nivolumab|Biological: ipilimumab,All,"12 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03068455
NCT01216657,Trial of Single Agent Sunitinib for Patients With Chemo-refractory Metastatic Melanoma,Terminated,No Results Available,Drug: Sunitinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01216657
NCT01009177,Effect of Bosentan in Patients With Metastatic Melanoma Treated With Dacarbazine (DTIC),Completed,No Results Available,Drug: Bosentan|Drug: Placebo,All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01009177
NCT02557321,PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma,Recruiting,No Results Available,Drug: PV-10|Drug: Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02557321
NCT00301067,Phase I/II Study of High-Dose Calcitriol Plus Temodar for Patients With Metastatic Melanoma,Completed,Has Results,Dietary Supplement: Calcitriol|Drug: Temozolomide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00301067
NCT00289640,Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma,Completed,No Results Available,"Drug: ipilimumab (MDX-010, BMS-734016)|Drug: Ipilimumab",All,"16 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00289640
NCT01409187,IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma,Withdrawn,No Results Available,Drug: Ipilimumab|Drug: Interferon|Drug: Interleukin-2 (Aldesleukin),All,"18 Years to 65 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01409187
NCT01209299,Biomarkers in Predicting Response to Chemotherapy in Patients With Advanced or Metastatic Melanoma Previously Treated With Carboplatin and Paclitaxel With or Without Sorafenib Tosylate,Completed,No Results Available,Genetic: DNA methylation analysis|Genetic: gene expression analysis|Other: laboratory biomarker analysis,All,"18 Years to 120 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01209299
NCT03139513,A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU]),Completed,No Results Available,Drug: Cobimetinib|Drug: Vemurafenib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03139513
NCT01876212,Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma,"Active, not recruiting",No Results Available,Biological: DC vaccine|Drug: Dasatinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01876212
NCT01288963,"IL-2 ""SELECT"" Tissue Collection Protocol in Patients With Advanced Melanoma","Active, not recruiting",No Results Available,Drug: IL-2,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01288963
NCT01740557,Study of Lymphodepletion Plus Adoptive Cell Transfer With T-Cells Transduced With CXCR2 and NGFR Followed by High Dose Interleukin-2 in Patients With Metastatic Melanoma,Recruiting,No Results Available,Drug: Cytoxan|Drug: Mesna|Drug: Fludarabine monophosphate|Procedure: T cell Infusion|Drug: IL-2|Other: Questionnaire,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01740557
NCT02451488,Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma,Recruiting,No Results Available,Drug: GM-CSF|Other: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02451488
NCT03649529,Treatment of Malignant Melanoma With GPA-TriMAR-T Cell Therapy,Recruiting,No Results Available,Biological: GPA-TriMAR-T,All,"18 Years to 65 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03649529
NCT00450372,Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery,Completed,Has Results,Biological: ADI-PEG-20|Other: Pharmacology Studies,All,"18 Years to 120 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00450372
NCT01264731,Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma,Completed,No Results Available,Biological: MELITAC 12.1|Drug: Imiquimod,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01264731
NCT00398450,Azacitidine and Interferon Alfa in Treating Patients With Metastatic Melanoma,Unknown status,No Results Available,Biological: recombinant interferon alfa-2b|Drug: azacitidine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00398450
NCT00866840,Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery,Completed,No Results Available,Drug: riluzole,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00866840
NCT01565837,Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma,Unknown status,No Results Available,Drug: Ipilimumab|Radiation: Stereotactic Ablative Radiosurgery (SART),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01565837
NCT02600169,Retrospective Analysis of Response Markers and Adverse Events in Melanoma Patients Treated With Pembrolizumab,Recruiting,No Results Available,Drug: Pemprolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02600169
NCT03002376,An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1),"Active, not recruiting",No Results Available,Drug: REGN2810,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03002376
NCT01334008,Study of Circulating Tumoral DNA in Metastatic Choroidal Melanoma,Completed,No Results Available,Biological: Blood sampling,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01334008
NCT01216696,Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1,Completed,No Results Available,Drug: ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01216696
NCT02410733,Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma,Recruiting,No Results Available,Biological: Lipo-MERIT,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02410733
NCT03167177,QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy,Not yet recruiting,No Results Available,Biological: Avelumab|Biological: Bevacizumab|Drug: Capecitabine|Drug: Cisplatin|Drug: Cyclophosphamide|Drug: 5-fluorouracil|Drug: Leucovorin|Drug: nab-paclitaxel|Biological: Nivolumab|Drug: omega-3-acid ethyl esters|Radiation: Stereotactic Body Radiation Therapy|Biological: ALT-803|Biological: ETBX-011|Biological: ETBX-051|Biological: ETBX-061|Biological: GI-6207|Biological: GI-6301|Biological: haNK,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03167177
NCT00394134,Targeted Intervention for Melanoma Prevention,"Active, not recruiting",No Results Available,Behavioral: Interview,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00394134
NCT01026051,"Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma",Terminated,No Results Available,Biological: MKC1106-MT,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01026051
NCT02180061,Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041),Completed,Has Results,Biological: Pembrolizumab,All,"20 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02180061
NCT00409383,Abraxane and Temodar Plus Genasense in Advanced Melanoma,Unknown status,No Results Available,Drug: Genasense® (oblimersen)|Drug: Abraxane® (paclitaxel protein-bound particles for injectable suspension)|Drug: Temodar® (temozolomide),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00409383
NCT01955460,Study of Lymphodepletion Plus Adoptive Cell Transfer With TGF-beta Resistant (DNRII) and NGFR Transduced T-Cells Followed by High Dose Interleukin-2 in Participants With Metastatic Melanoma,Recruiting,No Results Available,Drug: Cyclophosphamide|Drug: Mesna|Drug: Fludarabine monophosphate|Biological: T-Cells|Drug: Interleukin-2 (IL-2),All,"12 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01955460
NCT02796352,A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study,Terminated,Has Results,Drug: High dose bolus interleukin-2 (HD IL2),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02796352
NCT01331915,Safety and Toxicity Study of Vaccination for Advanced Metastatic Melanoma Patients,Unknown status,No Results Available,Biological: Theravac,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01331915
NCT01308294,Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients,Terminated,No Results Available,"Biological: 2 vaccine injections in 1 limb|Biological: 2 vaccine injections in different limbs|Biological: 2 vaccine injections in different limbs, the vaccine does not contain the MHC class II peptide MAGE-A3-DP4",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01308294
NCT02425306,Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma,Terminated,No Results Available,Biological: 6MHP|Drug: Montanide ISA-51|Drug: polyICLC|Drug: Cyclophosphamide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02425306
NCT00568048,Temozolomide and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery,Completed,No Results Available,Biological: bevacizumab|Drug: temozolomide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00568048
NCT00203879,Study of MAGE-3/Melan-A/gp 100/NA17 and rhIL-12 With/Out Low Dose IL-2 in Metastatic Melanoma,Completed,No Results Available,"Drug: MAGE-3/Melan-A/gp100/NA PBMC, rhIL-12 (drug)|Drug: MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 with IL-2",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00203879
NCT02990611,Real-Life Efficacy and Safety of Nivolumab Monotherapy or in Combination With Ipilimumab in Patients With Advanced (Unresectable or Metastatic) Melanoma and in Patients With Adjuvant Nivolumab Therapy,Recruiting,No Results Available,Other: Non_Interventional|Other: Non-Interventional,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02990611
NCT03384836,Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery,Recruiting,No Results Available,Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab|Drug: Propranolol Hydrochloride,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03384836
NCT00977145,Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma,Terminated,No Results Available,Biological: A combination of intratumoral IFN-gamma plus systemic vaccination with MELITAC 12.1,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00977145
NCT01820364,LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma,Terminated,Has Results,Drug: LGX818,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01820364
NCT01573494,Study of Circulating Tumor Cells Before and After Treatment in Patients With Metastatic Melanoma,Completed,No Results Available,Other: Sampling of blood,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01573494
NCT02297529,Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma,No longer available,No Results Available,Drug: Talimogene Laherparepvec,All,"18 Years to 95 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02297529
NCT01469455,DNA Repair Inhibitor & Irradiation on Melanoma,Completed,No Results Available,Drug: DT01,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01469455
NCT00404235,Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery,Completed,Has Results,Drug: carboplatin|Drug: paclitaxel albumin-stabilized nanoparticle formulation,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00404235
NCT02385669,A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma,Recruiting,No Results Available,Drug: Ipilimumab|Biological: 6MHP,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02385669
NCT01211262,Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma,Completed,No Results Available,Drug: IMCgp100,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01211262
NCT00060710,CP-461 in the Treatment of Patients With Advanced Melanoma,Terminated,No Results Available,Drug: CP-461,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00060710
NCT02427893,Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma,Withdrawn,No Results Available,Drug: Cobimetinib|Drug: Vemurafenib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02427893
NCT00626405,Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery,Completed,Has Results,Biological: bevacizumab|Drug: carboplatin|Drug: paclitaxel albumin-stabilized nanoparticle formulation|Drug: temozolomide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00626405
NCT01295931,Nuclear and Near-Infrared (NIR) Imaging in Melanoma,Completed,No Results Available,Drug: Indocyanine Green (IC-Green)|Procedure: Imaging,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01295931
NCT01689974,Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma,Terminated,Has Results,Drug: Ipilimumab|Radiation: Radiation Therapy,All,"19 Years to 80 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01689974
NCT03674502,Safety of ADU-1604 in Adults With Metastatic Melanoma,Recruiting,No Results Available,Drug: ADU-1604,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03674502
NCT01748448,Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome,Recruiting,No Results Available,Drug: Vitamin D|Drug: arachides oleum raffinatum,All,"18 Years to 80 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01748448
NCT02545075,A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine,"Active, not recruiting",No Results Available,Drug: Ipilimumab|Drug: Dacarbazine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02545075
NCT03153085,A Study of Combination With TBI-1401(HF10) and Ipilimumab in Japanese Patients With Unresectable or Metastatic Melanoma,"Active, not recruiting",No Results Available,Biological: TBI-1401(HF10)|Drug: Ipilimumab,All,"20 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03153085
NCT02301611,Phase IIB TL + YCWP + DC in Melanoma,Recruiting,No Results Available,Drug: TLPLDC|Drug: Placebo,All,"18 Years to 99 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02301611
NCT02659540,A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma,"Active, not recruiting",No Results Available,Drug: Ipilimumab|Drug: Nivolumab|Radiation: Radiotherapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02659540
NCT01010984,LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma,Completed,Has Results,Device: LC beads loaded with Doxorubicin,All,"18 Years to 99 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01010984
NCT00661336,A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant Melanoma,Withdrawn,No Results Available,Drug: buthionine sulfoximine|Drug: melphalan|Genetic: microarray analysis|Other: high performance liquid chromatography|Other: laboratory biomarker analysis|Other: pharmacological study|Procedure: biopsy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00661336
NCT01689870,Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma,Withdrawn,No Results Available,Drug: Anti-OX40|Drug: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01689870
NCT02581228,"Multi-Centre, Retrospective, Open Label Study, to Validate ML-PrediCare by Patients With Melanoma Under 1st and 2nd Lines of Immunotherapy",Unknown status,No Results Available,Device: ML-PrediCare,All,"18 Years to 120 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02581228
NCT02372708,Clinical Research on the Treatments on Advanced Malignant Melanoma by Combining in Situ Immunotherapy and Laser Therapy,Completed,No Results Available,Drug: dinitrophenyl(DNP)|Radiation: Radiation,All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02372708
NCT03602547,Study of the Combination of CM082 With JS001 in Patients With Advanced Mucinous Melanoma.,Not yet recruiting,No Results Available,Drug: CM082 plus JS001,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03602547
NCT01055522,Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma,Terminated,No Results Available,Drug: Arm 1: L19IL2 + Dacarbazine|Drug: Arm 3: Dacarbazine|Drug: ARM 2: L19IL2 + Dacarbazine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01055522
NCT01200342,"Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma",Terminated,Has Results,Drug: Genasense|Drug: Paclitaxel|Drug: Carboplatin,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01200342
NCT00688090,Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma.,Completed,No Results Available,Biological: Biological: MKC1106-MT|Biological: Biological: MKCC1106-MT,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00688090
NCT00436930,Vaccine Therapy and GM-CSF in Treating Patients With Recurrent or Metastatic Melanoma,Completed,No Results Available,Biological: autologous tumor cell vaccine|Biological: sargramostim|Biological: therapeutic autologous dendritic cells,All,"16 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00436930
NCT01990859,Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients,Completed,Has Results,Biological: Ipilimumab,All,"20 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01990859
NCT02714218,"A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma","Active, not recruiting",No Results Available,Biological: Nivolumab 3 mg/kg IV|Biological: Ipilimumab 1 mg/kg IV|Biological: Nivolumab 1 mg/kg IV|Biological: Ipilimumab 3 mg/kg IV|Biological: Nivolumab 6 mg/kg IV,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02714218
NCT03743298,Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma,Not yet recruiting,No Results Available,Drug: AV-MEL-1,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03743298
NCT00068211,Study of ILX651 in Patients With Inoperable Locally Advanced or Metastatic Melanoma,Completed,No Results Available,Drug: ILX651,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00068211
NCT03803397,Study of Dendritic Cells Pulsed With Tumor Lysate in Advanced Melanoma Dendritic Cells in Advanced Melanoma,Not yet recruiting,No Results Available,Biological: Dendritic Cells,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03803397
NCT01253759,Long Term Results of Combined Transpupillary Thermotherapy (TTT) Indocyanine Green (ICG) Based Photodynamic Therapy (PDT) in Choroidal Melanoma,Completed,No Results Available,Procedure: TTT + ICG-based PDT,All,"18 Years to 95 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01253759
NCT03655756,pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma,Recruiting,No Results Available,Biological: IFx-Hu2.0,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03655756
NCT02908672,A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma,"Active, not recruiting",No Results Available,Drug: Atezolizumab|Drug: Atezolizumab Placebo|Drug: Cobimetinib|Drug: Vemurafenib|Drug: Vemurafenib Placebo,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02908672
NCT00912574,Evaluation of the Effects of Local Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Adjuvant Administration on Dendritic Cells in Skin of Melanoma Patients and in Sentinel Lymph Nodes: MEL38,Completed,No Results Available,Drug: GM-CSF-in-adjuvant|Drug: Montanide ISA-51|Biological: GM-CSF and Montanide ISA-51|Drug: Saline,All,"18 Years to 85 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00912574
NCT00896480,Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma,Completed,No Results Available,Biological: Immunotherapeutic GSK2132231A,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00896480
NCT00189332,Use of 852A in Metastatic Cutaneous Melanoma.,Completed,No Results Available,Drug: 852A,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00189332
NCT00671554,Trial of Melaxin Cancer Vaccine Plus Bacillus Calmette-Guerin (BCG) to Treat Malignant Melanoma,Terminated,Has Results,Biological: Melaxin (autologous dendritoma vaccine) and BCG,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00671554
NCT02723006,"Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma",Terminated,No Results Available,Drug: TAK-580|Drug: TAK-202|Drug: vedolizumab|Drug: nivolumab|Drug: ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02723006
NCT02650492,Immunostimulating Interstitial Laser Thermotherapy in Malignant Melanoma,Unknown status,No Results Available,Device: Immunostimulating Interstitial Laser Thermotherapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02650492
NCT02599402,Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma,"Active, not recruiting",No Results Available,Drug: Nivolumab|Drug: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02599402
NCT02068079,A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma,Withdrawn,No Results Available,Drug: Vemurafenib and Trientine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02068079
NCT01280565,Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit,Recruiting,No Results Available,Drug: Masitinib|Drug: Dacarbazine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01280565
NCT00128583,Vaccine Therapy in Treating Patients With Malignant Melanoma,Unknown status,No Results Available,Biological: polyvalent melanoma vaccine,All,"18 Years to 80 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00128583
NCT02791594,Imaging FDG Flare in Melanoma,Recruiting,No Results Available,Drug: Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02791594
NCT00098553,Everolimus in Treating Patients With Stage IV Melanoma,Completed,No Results Available,Drug: everolimus,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00098553
NCT01425749,Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI,Completed,Has Results,Biological: recMAGE-A3 + AS15 ASCI,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01425749
NCT01864538,A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma,Terminated,Has Results,Drug: TH-302,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01864538
NCT01729663,"Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients",Unknown status,No Results Available,"Biological: CSF470 vaccine, BCG, Molgramostim|Drug: interferon alpha 2b",All,"18 Years to 65 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01729663
NCT00510302,Melanoma Risk-Reduction Among Patients and Family Members,"Active, not recruiting",No Results Available,Behavioral: Questionnaire|Behavioral: Interview,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00510302
NCT01264081,Lapatinib in Stage IV Melanoma With ERBB4 Mutations,Terminated,Has Results,Drug: Lapatinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01264081
NCT00002845,Interleukin-2 in Treating Patients With Metastatic Melanoma,Unknown status,No Results Available,Biological: aldesleukin,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00002845
NCT00811759,Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV Melanoma,Unknown status,No Results Available,Drug: sorafenib tosylate|Drug: temozolomide|Genetic: gene expression analysis|Genetic: mutation analysis|Other: laboratory biomarker analysis|Other: pharmacological study|Procedure: biopsy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00811759
NCT01856023,HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma,Terminated,No Results Available,Drug: High Dose Interleukin-2|Drug: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01856023
NCT00815607,Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma,Completed,No Results Available,Drug: INXN-1001|Biological: INXN-3001,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00815607
NCT02968680,Sonazoid-Enhanced Ultrasound in Detecting Sentinel Lymph Node in Patients With Cutaneous Melanoma,Recruiting,No Results Available,Procedure: Sentinel Lymph Node Biopsy|Device: Ultrasonography|Drug: Sonazoid,All,"19 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02968680
NCT00109863,Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced Melanoma,Completed,No Results Available,Biological: hu14.18-IL2 fusion protein,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00109863
NCT02414750,Vemurafenib Plus Cobimetinib in Metastatic Melanoma,Recruiting,No Results Available,Drug: Vemurafenib plus cobimetinib|Device: Positron Emission Tomography|Procedure: Tissue sampling|Procedure: Blood sampling,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02414750
NCT00816374,Tailored Intervention for Melanoma Patient's Families,Completed,No Results Available,Other: Reading materials and discussions|Other: Questionnaires,All,"21 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00816374
NCT02583516,Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma,"Active, not recruiting",No Results Available,Drug: vemurafenib and cobimetinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02583516
NCT02138292,A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma,Completed,No Results Available,Drug: Trametinib (2mg)/Digoxin (.25mg),All,"19 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02138292
NCT01984255,"A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients",Terminated,No Results Available,Drug: Arm A-Bavituximab 3mg/kg IV over 90 minutes weekly x 3 followed by Bavituximab 3mg/kg IV over 90 minutes weekly x 12 plus ipilimumab 3mg/kg IV|Drug: Arm B-Ipilimumab 3mg/kg IV over 90 minutes day 1 followed three weeks later by ipilimumab every 3 weeks x 3.,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01984255
NCT02994498,DCB-BO1301 for Advanced Melanoma,Not yet recruiting,No Results Available,Drug: DCB-BO1301,All,"20 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02994498
NCT03383237,Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma,Recruiting,No Results Available,Drug: Apatinib,All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03383237
NCT00317759,Fludarabine Followed By Adoptive Immunotherapy in Treating Patients With Stage IV Melanoma,Completed,No Results Available,Biological: therapeutic autologous lymphocytes|Drug: fludarabine phosphate,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00317759
NCT01092728,"Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma",Terminated,Has Results,Drug: Dasatinib|Procedure: Surgical Resection,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01092728
NCT02434107,"Complete Lymph Node Dissection vs Watchful Waiting in Patients With Malignant Melanoma (Thickness of 1,0mm+ and Evidence of Metastases in the Sentinel Node)","Active, not recruiting",No Results Available,Procedure: Completion Lymphadenectomy|Procedure: Clinical Monitoring (Palpation and node ultrasound),All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02434107
NCT01350401,Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma,Terminated,Has Results,"Genetic: Autologous genetically modified T cells, NY-ESO-1ᶜ²⁵⁹T",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01350401
NCT00126685,Vaccine Therapy in Treating Patients With Stage IV Melanoma,Unknown status,No Results Available,Biological: autologous tumor cell vaccine|Biological: therapeutic autologous dendritic cells,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00126685
NCT02272855,A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma,Completed,No Results Available,Biological: HF10 plus Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02272855
NCT02155322,A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400),Completed,Has Results,Biological: Pegylated Interferon Alfa-2b,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02155322
NCT01841463,Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation,Suspended,No Results Available,Drug: P1446A-05|Drug: Vemurafenib (Zelboraf®),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01841463
NCT01753089,Dendritic Cell Activating Scaffold in Melanoma,Recruiting,No Results Available,Biological: WDVAX,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01753089
NCT02362594,Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054),"Active, not recruiting",Has Results,Biological: pembrolizumab|Drug: placebo,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02362594
NCT03646617,Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma,Recruiting,No Results Available,Radiation: Hypofractionated Radiation Therapy (HFRT)|Drug: Nivolumab|Drug: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03646617
NCT02263508,Pembrolizumab With or Without Talimogene Laherparepvec or Talimogene Laherparepvec Placebo in Unresected Melanoma (KEYNOTE-034),"Active, not recruiting",No Results Available,Drug: talimogene laherparepvec|Drug: pembrolizumab (MK-3475)|Drug: placebo,All,"18 Years to 95 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02263508
NCT00602576,Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma,Unknown status,No Results Available,Drug: sorafenib tosylate|Drug: temozolomide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00602576
NCT00357461,Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma,Withdrawn,No Results Available,Biological: gp100:209-217(210M) peptide vaccine|Biological: gp100:280-288(288V) peptide vaccine|Biological: incomplete Freund's adjuvant|Biological: ipilimumab,All,"16 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00357461
NCT00087477,A Pilot Study of Pivanex in Patients With Malignant Melanoma,Terminated,No Results Available,Drug: Pivanex,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00087477
NCT00942162,A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma,Completed,Has Results,Biological: Immunotherapeutic GSK2132231A,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00942162
NCT02083484,Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030),No longer available,No Results Available,Biological: Pembrolizumab,All,"12 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02083484
NCT00521053,Phase 2 Study of Intralesional PV-10 for Metastatic Melanoma,Completed,Has Results,Drug: PV-10 (10% rose bengal disodium),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00521053
NCT00434252,A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma,Completed,Has Results,Drug: bevacizumab|Drug: carboplatin|Drug: paclitaxel|Drug: placebo,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00434252
NCT00304200,Temodar and Sutent as Therapy for Melanoma,Terminated,No Results Available,Drug: Temozolomide and SU11248,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00304200
NCT00515983,Vaccination of Melanoma Patients With Dendritic Cells Loaded With Allogeneic Apoptotic-Necrotic Melanoma Cells,Completed,No Results Available,Biological: DC/Apo-Nec,All,"17 Years to 60 Years   (Child, Adult)",https://ClinicalTrials.gov/show/NCT00515983
NCT00324623,Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma,Completed,No Results Available,"Biological: Melan-A VLP vaccine, IMP321 adjuvant|Biological: adoptive immunotherapy|Biological: therapeutic autologous lymphocytes|Drug: cyclophosphamide|Drug: fludarabine phosphate",All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00324623
NCT02612168,Melanoma Image Analysis Algorithm (MIAA) Validation Study,Recruiting,No Results Available,Device: Melanoma Image Analysis Algorithm (MIAA),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02612168
NCT01495988,Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma,Terminated,Has Results,Drug: Vemurafenib|Drug: Bevacizumab|Drug: Cobimetinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01495988
NCT01682083,Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).,"Active, not recruiting",Has Results,Drug: Dabrafenib|Drug: Trametinib|Drug: Placebos,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01682083
NCT02768766,Intermittent Selumetinib for Uveal Melanoma,Recruiting,No Results Available,Drug: Selumetinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02768766
NCT00003792,Vaccine Therapy in Treating Patients With Metastatic Melanoma,Completed,No Results Available,Biological: MART-1 antigen|Biological: filgrastim|Biological: flu matrix peptide p58-66|Biological: gp100 antigen|Biological: recombinant MAGE-3.1 antigen|Biological: tyrosinase peptide|Procedure: in vitro-treated peripheral blood stem cell transplantation,All,"18 Years to 80 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00003792
NCT01009515,"Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma",Terminated,Has Results,"Drug: Paclitaxel, carboplatin, temozolomide",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01009515
NCT01897116,A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma,Completed,No Results Available,Drug: Hydroxychloroquine (HCQ)|Drug: Vemurafenib (VEM),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01897116
NCT03326973,Long-Term Quality of Life in Patients With Metastatic Melanoma Treated With Checkpoint Inhibitors,"Active, not recruiting",No Results Available,Behavioral: EuroQoL EQ-5D-3L|Behavioral: EORTC QLQ-C30|Other: PRO-CTCAE|Behavioral: Fatigue severity score questionnaire|Behavioral: The COST|Behavioral: Physician information,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03326973
NCT00002781,Boron Neutron Capture Therapy in Treating Patients With Stage III Melanoma,Unknown status,No Results Available,Drug: boronophenylalanine-fructose complex,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00002781
NCT01048554,Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System,Completed,No Results Available,Drug: Temozolomide|Drug: Bevacizumab,All,"18 Years to 90 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01048554
NCT00706992,Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients,Terminated,Has Results,Biological: ALVAC-MART-1 vaccine|Biological: MART-1:26-35(27L) peptide vaccine|Biological: Aldesleukin|Biological: autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes|Biological: incomplete Freund's adjuvant,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00706992
NCT00680225,Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma,Completed,Has Results,Drug: Ranibizumab injection and TTT - ICG based,All,"18 Years to 90 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00680225
NCT03190824,"Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma Patients",Recruiting,No Results Available,Drug: OBP-301,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03190824
NCT03597282,A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma,Recruiting,No Results Available,Biological: NEO-PV-01|Biological: Nivolumab|Other: Adjuvant|Biological: APX005M|Biological: ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03597282
NCT01690377,Natural Dendritic Cell Vaccines in Metastatic Melanoma Patients,Completed,No Results Available,Biological: PDC or myDC,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01690377
NCT00005968,Irofulven in Treating Patients With Stage IV Melanoma,Completed,No Results Available,Drug: irofulven,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00005968
NCT00142454,NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting),Completed,No Results Available,Biological: NY-ESO-1 protein|Drug: Imiquimod,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00142454
NCT00003665,Vaccine Therapy in Treating Patients With Stage IV Melanoma,Completed,No Results Available,Biological: dendritic cell-MART-1 peptide vaccine|Biological: gp100 antigen|Biological: therapeutic tumor infiltrating lymphocytes|Biological: tyrosinase peptide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00003665
NCT01959633,Study of the Combination Vemurafenib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation,Unknown status,No Results Available,Drug: Vemurafenib|Drug: Peg-interferon,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01959633
NCT01760499,"Detection of Immune Cell Infiltration Into Melanomas Treated by PV-10, a Feasibility Study",Completed,No Results Available,Drug: PV-10|Procedure: Surgery,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01760499
NCT02117362,Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma,"Active, not recruiting",No Results Available,Biological: 1 mg/kg GR-MD-02|Biological: 2 mg/kg GR-MD-02|Biological: 4 mg/kg GR-MD-02|Biological: 8 mg/kg GR-MD-02|Biological: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02117362
NCT00898183,S9431: Studying Genes and Immune Response in Tumor Samples From Patients With Locally Advanced or Metastatic Melanoma,Completed,No Results Available,Genetic: gene expression analysis|Genetic: polymorphism analysis,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00898183
NCT02862743,Molecular Characterization of Advanced Stage Melanoma by Blood Sampling,Recruiting,No Results Available,Other: patients with metastatic melanoma,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02862743
NCT03815058,A Study to Evaluate The Efficacy And Safety Of RO7198457 In Combination With Pembrolizumab Versus Pembrolizumab Alone In Participants With Previously Untreated Advanced Melanoma.,Recruiting,No Results Available,Biological: RO7198457|Drug: Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03815058
NCT03475134,TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL),Recruiting,No Results Available,Other: TIL|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Interleukin-2|Drug: Nivolumab,All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03475134
NCT00289627,A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma,Completed,No Results Available,"Drug: ipilimumab (MDX-010, BMS-734016)",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00289627
NCT00104884,FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma,Terminated,Has Results,Drug: Depsipeptide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00104884
NCT03407170,Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161),Recruiting,No Results Available,Biological: pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03407170
NCT00504582,Fibrin Melanoma Axillary Node Study in Patients With Melanoma,"Active, not recruiting",No Results Available,Drug: Fibrin Sealant,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00504582
NCT00204529,Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB,Completed,No Results Available,Drug: pegylated interferon-alpha-2a|Drug: interferon-alpha-2a,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00204529
NCT03070392,Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma,Recruiting,No Results Available,Biological: IMCgp100|Drug: Dacarbazine|Biological: Ipilimumab|Biological: Pembrolizumab,All,"18 Years to 99 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03070392
NCT00014625,E7070 in Treating Patients With Stage IV Melanoma,Completed,No Results Available,Drug: indisulam,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00014625
NCT01067066,A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma,Terminated,No Results Available,Drug: TPI 287|Drug: Temodar (Temozolomide),All,"15 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01067066
NCT00861406,Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine,Completed,No Results Available,Drug: Pegylated Interferon-Alfa 2b (PEG Intron)|Drug: GP-100 Peptide Vaccine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00861406
NCT02320058,"An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself","Active, not recruiting",No Results Available,Drug: Ipilimumab|Drug: Nivolumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02320058
NCT00095953,SB-715992 in Treating Patients With Metastatic or Recurrent Malignant Melanoma,Completed,No Results Available,Drug: ispinesib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00095953
NCT01584648,A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma,"Active, not recruiting",Has Results,Drug: dabrafenib|Drug: dabrafenib plus trametinib placebo|Drug: Trametinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01584648
NCT00005875,Nitrocamptothecin in Treating Patients With Metastatic Melanoma,Completed,No Results Available,Drug: rubitecan,All,"16 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00005875
NCT01888081,A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for Treatment of Stage IV Melanoma,Terminated,No Results Available,Drug: A-dmDT390-bisFv(UCHT1) (Resimmune®)|Radiation: Ionizing Radiation,All,"18 Years to 80 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01888081
NCT01551693,STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma,Terminated,Has Results,Drug: STA-9090,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01551693
NCT01213472,Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma,Completed,No Results Available,Biological: GSK Biologicals' 2241658A Antigen-Specific Cancer Immunotherapeutic (ASCI),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01213472
NCT00005943,Gene Therapy in Treating Patients With Metastatic Melanoma,Completed,No Results Available,Biological: aldesleukin|Biological: staphylococcal enterotoxin B,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00005943
NCT00104897,17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Malignant Melanoma,Completed,No Results Available,Drug: tanespimycin,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00104897
NCT03197636,Co-stimulatory Markers and Vitamin D Status in Anti-PD1 Treated Melanoma Patients,Enrolling by invitation,No Results Available,Drug: Pembrolizumab,All,"18 Years to 90 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03197636
NCT00492505,"Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma",Unknown status,No Results Available,Drug: cisplatin|Drug: sorafenib tosylate|Drug: tamoxifen citrate|Procedure: adjuvant therapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00492505
NCT01556503,Sensitivity/Specificity Study of Non-invasive Imaging for Melanoma Diagnosis,Completed,No Results Available,Device: VivaScope System,All,"12 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01556503
NCT02278887,Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma,Recruiting,No Results Available,Procedure: Translational research|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Interleukin-2|Drug: Ipilimumab infusion,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02278887
NCT00091338,Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma,Completed,No Results Available,Biological: MART-1 antigen|Biological: gp100 antigen|Biological: incomplete Freund's adjuvant|Biological: recombinant interleukin-7,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00091338
NCT03132675,Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Pembrolizumab or Nivolumab Treatment,Recruiting,No Results Available,Biological: tavokinogene telseplasmid|Biological: Pembrolizumab|Device: ImmunoPulse,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03132675
NCT00826995,Comparison of Video-Based Versus Written Patient Education on Melanoma,Completed,No Results Available,Other: Patient Educational Materials,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00826995
NCT01542255,Metronomic Therapy in Patients With Metastatic Melanoma,Terminated,Has Results,Drug: vinblastine|Drug: Cyclophosphamide|Drug: dacarbazine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01542255
NCT01079741,Safety Study of Adjuvant Vaccine to Treat Melanoma Patients,Completed,Has Results,Biological: NY-ESO-1 protein; Poly-ICLC; Montanide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01079741
NCT02203864,Dose Escalation Study to Evaluate Safety and Tolerability of an Allogeneic Tumor Vaccine BIWB 2 in Patients With Advanced Malignant Melanoma,Completed,No Results Available,Biological: BIBW2 component A|Biological: BIBW2 component B,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02203864
NCT00667953,Study of Temzolomide and Gleevec in Advanced Melanoma,Completed,No Results Available,Drug: Gleevec + Temozolomide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00667953
NCT01496807,Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma,Completed,Has Results,Drug: Sylatron|Drug: Yervoy,All,"16 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01496807
NCT02360579,"Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma","Active, not recruiting",No Results Available,Biological: Lifileucel,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02360579
NCT03047928,Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma,Recruiting,No Results Available,Drug: Nivolumab|Biological: PD-L1/IDO peptide vaccine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03047928
NCT00828126,PET-CT in the Management of Patients With Stage III or IV Metastatic Melanoma,Completed,No Results Available,Procedure: PET-CT Scan,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00828126
NCT00604136,Treatment of Metastatic Melanoma With Tumor Infiltrating Lymphocytes and IL-2 Following Lympho-depleting Chemotherapy,Recruiting,No Results Available,Biological: tumor infiltrating lymphocytes,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00604136
NCT02978443,A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab,Recruiting,No Results Available,Drug: Nivolumab|Drug: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02978443
NCT03241186,Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma,Recruiting,No Results Available,Drug: Ipilimumab|Drug: Nivolumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03241186
NCT00138229,Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating Patients With Refractory or Recurrent Metastatic Melanoma,Terminated,No Results Available,Biological: aldesleukin|Biological: filgrastim|Biological: therapeutic autologous lymphocytes|Drug: cyclophosphamide|Drug: fludarabine phosphate,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00138229
NCT00565968,Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg,Completed,No Results Available,Drug: melphalan|Drug: sorafenib tosylate|Genetic: gene expression analysis|Genetic: protein expression analysis|Genetic: western blotting|Other: pharmacological study,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00565968
NCT01340729,Open-Label Study of TPI 287 for Patients With Metastatic Melanoma,Withdrawn,No Results Available,Drug: TPI 287,All,"15 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01340729
NCT00849875,A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients,Terminated,Has Results,Biological: Immunotherapeutic GSK2132231A|Drug: Dacarbazine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00849875
NCT00791271,Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion,Terminated,No Results Available,Drug: Decitabine|Drug: Pegylated Interferon Alpha-2b,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00791271
NCT03776136,Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004),Not yet recruiting,No Results Available,Drug: lenvatinib|Biological: pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03776136
NCT01681212,Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma,Completed,Has Results,Drug: Ipilimumab|Drug: Dacarbazine,All,"20 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01681212
NCT00002767,Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma,Unknown status,No Results Available,Biological: Detox-B adjuvant|Biological: recombinant interferon alfa,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00002767
NCT02959905,Treatment of Metastatic Melanoma With TSA-CTL(Tumor Specific Antigen-Induced Cytotoxic T Lymphocytes),Unknown status,No Results Available,Biological: TSA-CTL(Tumor Specific Antigen Induced Cytotoxic Lymphocyte)|Drug: Cyclophosphamide|Drug: Fludarabine,All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02959905
NCT01502293,Trial of pIL-12 Electroporation Malignant Melanoma,Completed,No Results Available,Biological: Plasmid INTERLEUKIN-12|Device: Intratumoral Electroporation,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01502293
NCT00085423,"Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma",Completed,Has Results,Biological: aldesleukin|Biological: sargramostim|Drug: cyclophosphamide|Drug: fludarabine phosphate,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00085423
NCT00003747,Carboplatin and Temozolomide in Treating Patients With Unresectable or Metastatic Melanoma,Unknown status,No Results Available,Drug: carboplatin|Drug: temozolomide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00003747
NCT00471887,"Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma",Completed,No Results Available,"Biological: CP-675,206",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00471887
NCT02843386,Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma,"Active, not recruiting",No Results Available,Drug: Adjuvant chemotherapy by Fotemustin|Other: Intensive surveillance,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02843386
NCT01838200,A Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) and Followed by Ipilimumab Therapy in Patients With Advanced Metastatic Melanoma,Terminated,No Results Available,Biological: Bacillus Calmette-Guérin (BCG) vaccine|Drug: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01838200
NCT00003556,Vaccine Therapy in Treating Patients With Melanoma,Completed,No Results Available,Biological: ALVAC-hB7.1|Biological: canarypox-hIL-12 melanoma vaccine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00003556
NCT00023647,Vaccine Therapy in Treating Patients With Stage IV Melanoma,Completed,No Results Available,Biological: Synchrotope TA2M,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00023647
NCT00003060,Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Metastatic Melanoma,Unknown status,No Results Available,Biological: filgrastim|Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Drug: methotrexate|Procedure: allogeneic bone marrow transplantation,All,"16 Years to 44 Years   (Child, Adult)",https://ClinicalTrials.gov/show/NCT00003060
NCT00889980,Melanoma Molecular Profiling Analysis,Recruiting,No Results Available,Other: Biospecimen banking,All,"12 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00889980
NCT00085059,Boron Neutron Capture Therapy Using Boronophenylalanine-Fructose Complex in Treating Patients With Metastatic Melanoma,Terminated,No Results Available,Drug: boronophenylalanine-fructose complex,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00085059
NCT01657591,Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma,"Active, not recruiting",No Results Available,Drug: XL888|Drug: Vemurafenib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01657591
NCT01721772,"Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma","Active, not recruiting",Has Results,Biological: BMS-936558 (Nivolumab)|Biological: Placebo matching BMS-936558 (Nivolumab)|Drug: Dacarbazine|Drug: Placebo matching Dacarbazine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01721772
NCT01546571,"Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients","Active, not recruiting",No Results Available,Biological: POL-103A|Biological: POL-103A without API,All,"18 Years to 80 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01546571
NCT02663258,A Study of Anti-PD-1 (Pembrolizumab) Therapy in Metastatic Melanoma (ADAPTeM),Withdrawn,No Results Available,Drug: Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02663258
NCT03405155,Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery,Recruiting,No Results Available,Biological: Nivolumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03405155
NCT01432860,A Comparison of Interventions to Teach Melanoma Patients Skin Self-examination,Completed,No Results Available,Behavioral: In-person counseling|Behavioral: Workbook|Behavioral: Tablet Computer-Based Education,All,"18 Years to 80 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01432860
NCT00022464,CCI-779 in Treating Patients With Metastatic Melanoma,Completed,No Results Available,Drug: temsirolimus,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00022464
NCT00003897,Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma,Completed,No Results Available,Biological: gp100 antigen|Biological: sargramostim,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00003897
NCT01449279,Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy,"Active, not recruiting",Has Results,Drug: Ipilimumab|Radiation: Radiation Therapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01449279
NCT00107718,Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma,Completed,No Results Available,Drug: SB-485232,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00107718
NCT02334735,A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence,Recruiting,No Results Available,Biological: DC Vaccine|Biological: Montanide Vaccine|Biological: Poly-ICLC,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02334735
NCT02993315,Melanoma Patients Immunized With Natural DenDritic Cells,Recruiting,No Results Available,Biological: nDC vaccination|Biological: placebo injection,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02993315
NCT01754376,Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma,Terminated,Has Results,Drug: Aldesleukin|Drug: Vemurafenib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01754376
NCT02156804,"A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)","Active, not recruiting",No Results Available,Drug: Nivolumab (BMS-936558),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02156804
NCT00970996,"Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma",Completed,No Results Available,Drug: Temozolomide|Drug: Abraxane|Drug: Cisplatin|Biological: Interleukin-2|Biological: Interferon alpha 2b,All,"18 Years to 65 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00970996
NCT00254397,Melanoma Vaccine With Peptides and Leuprolide,Completed,No Results Available,Drug: Leuprolide|Biological: GP100: 209-217(210M) Peptide|Biological: MAGE-3 Peptide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00254397
NCT01689519,A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma,"Active, not recruiting",Has Results,Drug: Placebo|Drug: Vemurafenib|Drug: Cobimetinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01689519
NCT00003229,Vaccine Therapy in Treating Patients With Metastatic Melanoma Who Are Undergoing Surgery for Lymph Node and Tumor Removal,Completed,No Results Available,Biological: aldesleukin|Biological: gp100 antigen|Biological: tyrosinase peptide,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00003229
NCT02941744,A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases,Completed,No Results Available,Drug: nivolumab|Drug: ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02941744
NCT00004104,Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma,Completed,No Results Available,Biological: liposomal interleukin-2|Biological: polyvalent melanoma vaccine|Biological: recombinant interferon alfa,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00004104
NCT00017355,Vaccine Therapy in Treating Patients With Metastatic Melanoma,Unknown status,No Results Available,Biological: filgrastim|Biological: therapeutic autologous dendritic cells,All,"21 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00017355
NCT00019383,Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma,Completed,No Results Available,Biological: aldesleukin|Biological: incomplete Freund's adjuvant|Biological: sargramostim|Biological: tyrosinase peptide|Biological: tyrosinase-related protein-1,All,"16 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00019383
NCT01709162,Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma,Terminated,Has Results,Biological: Ipilimumab|Drug: Chemotherapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01709162
NCT00003715,Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma,Terminated,No Results Available,Biological: BCG vaccine|Biological: autologous tumor cell vaccine|Biological: recombinant interferon alfa|Drug: chemotherapy|Drug: cyclophosphamide,All,"18 Years to 120 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00003715
NCT02385214,MelmarT Melanoma Margins Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma,"Active, not recruiting",No Results Available,Procedure: Wide Local Excision = 1cm Margin|Procedure: Wide Local Excision = 2cm Margin,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02385214
NCT00074230,Vaccine Therapy in Treating Patients With Stage IV Cutaneous Melanoma,Completed,No Results Available,"Biological: Autologous Dendritic Cells loaded with MAGE-A3, MelanA and Survivin",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00074230
NCT01256359,Docetaxel With or Without AZD6244 in Melanoma,"Active, not recruiting",No Results Available,Drug: Docetaxel and AZD6244|Drug: Docetaxel and placebo,All,"16 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01256359
NCT01014351,Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma,Completed,Has Results,Drug: Paclitaxel|Drug: Carboplatin|Drug: Everolimus,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01014351
NCT00085462,Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma,Completed,No Results Available,Biological: aldesleukin|Biological: filgrastim|Biological: gp100-fowlpox vaccine|Biological: therapeutic autologous lymphocytes|Biological: therapeutic tumor infiltrating lymphocytes|Drug: cyclophosphamide|Drug: fludarabine phosphate,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00085462
NCT01531244,"Isolated Limb Infusion Chemotherapy With Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma",Withdrawn,No Results Available,Biological: dactinomycin|Drug: melphalan|Biological: Conditionally replicative adenovirus 3/5-delta,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01531244
NCT01682213,Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation,"Active, not recruiting",No Results Available,Drug: Dabrafenib,All,"16 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01682213
NCT02379195,Peginterferon and TIL Therapy for Metastatic Melanoma,"Active, not recruiting",No Results Available,Drug: Cyclophosphamide|Drug: Fludarabine|Biological: TIL infusion|Drug: Interleukin-2|Drug: Peginterferon alfa-2b,All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02379195
NCT01608594,Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for Melanoma,Completed,No Results Available,Drug: administration of ipilimumab10mg/kg|Drug: administration of ipilimumab 3mg/kg + HDI,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01608594
NCT00019734,Vaccine Therapy in Treating Patients With Metastatic Melanoma,Completed,No Results Available,Biological: aldesleukin|Biological: fowlpox virus vaccine vector|Biological: vaccinia-tyrosinase vaccine,All,"16 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00019734
NCT03084640,Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Participants With Advanced Melanoma,Recruiting,No Results Available,Drug: CMP-001|Drug: Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03084640
NCT03416933,Therapeutic Drug Monitoring of BRAF-mutated Advanced Melanoma,Recruiting,No Results Available,Other: Blood sampling,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03416933
NCT00518895,Trial of Dacarbazine With or Without Genasense in Advanced Melanoma,Completed,No Results Available,Drug: dacarbazine plus Genasense|Drug: dacarbazine plus placebo,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00518895
NCT00026520,Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma,Completed,No Results Available,Biological: recombinant interferon alfa|Drug: thalidomide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00026520
NCT00505635,Biochemotherapy With Temozolomide for Metastatic Melanoma,Terminated,Has Results,Drug: Temozolomide|Drug: Velban|Drug: Cisplatin|Drug: Interleukin-2|Drug: Intron-A|Drug: Thalidomide,All,"18 Years to 65 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00505635
NCT00022568,Vaccine Therapy in Treating Patients With Metastatic Melanoma,Unknown status,No Results Available,Biological: recombinant vaccinia-TRICOM vaccine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00022568
NCT00200577,Tumor Infiltrating Lymphocytes Adjuvant Therapy of Melanoma,Completed,No Results Available,Drug: TIL + IL2,All,"up to 75 Years   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00200577
NCT00091104,"Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma",Completed,No Results Available,Biological: MART-1:27-35 peptide vaccine|Biological: aldesleukin|Biological: filgrastim|Biological: incomplete Freund's adjuvant|Biological: therapeutic autologous lymphocytes|Biological: therapeutic tumor infiltrating lymphocytes|Drug: cyclophosphamide|Drug: fludarabine phosphate|Procedure: autologous hematopoietic stem cell transplantation|Procedure: in vitro-treated peripheral blood stem cell transplantation|Radiation: total-body irradiation,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00091104
NCT01121718,NIR-Guided Sentinel Lymph Node Mapping in Melanoma,Completed,No Results Available,Drug: ICG Intervention,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01121718
NCT00072085,Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma,Completed,No Results Available,Biological: aldesleukin|Biological: gp100 antigen|Biological: incomplete Freund's adjuvant,All,"16 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00072085
NCT01866319,Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006),"Active, not recruiting",Has Results,Biological: Pembrolizumab|Biological: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01866319
NCT01489059,Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma,Completed,No Results Available,Biological: BMS-982470 (recombinant interleukin-21)|Biological: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01489059
NCT00005971,Flavopiridol in Treating Patients With Metastatic Malignant Melanoma,Completed,No Results Available,Drug: alvocidib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00005971
NCT01667419,A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma,"Active, not recruiting",Has Results,Drug: Vemurafenib|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01667419
NCT00045357,Biological Therapy in Treating Patients With Metastatic Melanoma,Completed,No Results Available,Biological: therapeutic autologous lymphocytes,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00045357
NCT02354690,Vemurafenib and TIL Therapy for Metastatic Melanoma,"Active, not recruiting",No Results Available,Drug: Vemurafenib|Drug: Lymphodepleting chemotherapy|Drug: TIL infusion|Drug: Interleukin-2,All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02354690
NCT03581188,A Research Study of Patient-led Surveillance Compared to Clinician-led Surveillance in People Treated for Localised Melanoma.,Enrolling by invitation,No Results Available,Behavioral: Self-examination of the skin,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03581188
NCT00796445,"A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor",Terminated,No Results Available,Drug: GSK 2132231A|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00796445
NCT00019721,Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma,Completed,No Results Available,Biological: MART-1 antigen|Biological: aldesleukin|Biological: gp100 antigen|Biological: incomplete Freund's adjuvant,All,"16 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00019721
NCT00039325,Vaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant Melanoma,Completed,No Results Available,Biological: dendritic cell-MART-1 peptide vaccine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00039325
NCT00577382,SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma,Completed,Has Results,Drug: Sunitinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00577382
NCT02938728,Definition of an Immune Signature Predictive of Anti-PD1 (Programmed Death-1) Antibody in the Treatment of Advanced Melanoma,Not yet recruiting,No Results Available,Other: Biopsies,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02938728
NCT00033228,Vaccine Therapy in Treating Patients With Stage IV Melanoma,Completed,No Results Available,Biological: MKC1106-MT,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00033228
NCT00071981,Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma,Completed,Has Results,Biological: incomplete Freund's adjuvant|Biological: melanoma helper peptide vaccine|Biological: multi-epitope melanoma peptide vaccine|Biological: sargramostim|Biological: tetanus peptide melanoma vaccine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00071981
NCT00072124,Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma,Completed,No Results Available,Drug: cisplatin|Drug: dacarbazine|Procedure: conventional surgery,All,"16 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00072124
NCT00963664,Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma,Withdrawn,No Results Available,Drug: lovastatin|Drug: interferon alfa-2b,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00963664
NCT01611675,Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma,Terminated,No Results Available,Drug: Vemurafenib|Drug: Leflunomide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01611675
NCT00020397,Vaccine Therapy in Treating Patients With Refractory Metastatic Melanoma,Completed,No Results Available,Biological: NY-ESO-1 peptide vaccine|Biological: aldesleukin,All,"16 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00020397
NCT00085579,Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma,Withdrawn,No Results Available,Biological: aldesleukin|Biological: sargramostim|Procedure: adjuvant therapy,All,"16 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00085579
NCT00002669,"Combination Chemotherapy, Interferon Alfa, and Interleukin-2 in Treating Patients With Metastatic Melanoma",Completed,No Results Available,Biological: aldesleukin|Biological: recombinant interferon alfa|Drug: cisplatin|Drug: dacarbazine,All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00002669
NCT00104988,S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery,Completed,No Results Available,Drug: temozolomide|Drug: thalidomide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00104988
NCT01251978,Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2),Completed,Has Results,Drug: Ranibizumab 2 mg|Drug: 0.5 mg Ranibizumab,All,"50 Years to 90 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01251978
NCT00049530,PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma,Completed,Has Results,Biological: PEG-interferon alfa-2b,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00049530
NCT00463892,High-resolution Magnetic Resonance Imaging (MRI) Scans to Look for Spread of Melanoma to Nearby Lymph Nodes,Completed,No Results Available,Procedure: High-resolution contrast-enhanced MRI scan,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00463892
NCT00016055,Biological Therapy and Temozolomide in Treating Patients With Metastatic Melanoma,Unknown status,No Results Available,Biological: lymphokine-activated killer cells|Drug: temozolomide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00016055
NCT00045149,Biological Therapy in Treating Patients With Metastatic Melanoma,Completed,No Results Available,Biological: aldesleukin|Biological: therapeutic tumor infiltrating lymphocytes,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00045149
NCT00623402,Combined Treatment of Sorafenib and Pegylated Interferon α2b in Stage IV Metastatic Melanoma,Completed,No Results Available,Drug: Sorafenib|Drug: pegylated interferon α-2b,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00623402
NCT00077532,Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma,Completed,No Results Available,Biological: gp100 antigen|Biological: incomplete Freund's adjuvant|Biological: ipilimumab,All,"16 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00077532
NCT00053781,Perifosine in Treating Patients With Metastatic or Recurrent Malignant Melanoma,Completed,No Results Available,Drug: perifosine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00053781
NCT00706238,MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive Metastatic Cutaneous Melanoma,Terminated,No Results Available,Biological: GSK Biologicals' Recombinant MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK1203486A,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00706238
NCT00278122,Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery,Suspended,No Results Available,Biological: sargramostim|Drug: paclitaxel,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00278122
NCT02775851,Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery,Recruiting,No Results Available,Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab|Procedure: Therapeutic Conventional Surgery,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02775851
NCT00003274,Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery,Completed,No Results Available,Biological: gp100 antigen|Biological: incomplete Freund's adjuvant|Biological: sargramostim|Biological: tyrosinase peptide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00003274
NCT00002786,Biological Therapy in Treating Patients With Metastatic Melanoma,Completed,No Results Available,Biological: aldesleukin|Biological: therapeutic tumor infiltrating lymphocytes,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00002786
NCT01515189,Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab,Completed,Has Results,Biological: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01515189
NCT00002763,High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma,Unknown status,No Results Available,Biological: recombinant interferon alfa,All,"16 Years to 75 Years   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00002763
NCT00096382,"Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma",Completed,Has Results,Biological: aldesleukin|Biological: filgrastim|Biological: therapeutic tumor infiltrating lymphocytes|Drug: cyclophosphamide|Drug: fludarabine phosphate|Radiation: radiation therapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00096382
NCT03136783,New Tumor Models in Three Dimensions and in a Human Skin Environment for Personalized Melanoma Therapy,Recruiting,No Results Available,Other: Development of the most specific physiologically relevant experimental patient models,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03136783
NCT00012064,Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma,Completed,No Results Available,Biological: therapeutic autologous dendritic cells,All,"16 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00012064
NCT03161431,SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab,Recruiting,No Results Available,Drug: SX-682|Biological: Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03161431
NCT02740920,Assessment of Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography (CT) Texture Analysis as a Predictive Biomarker,Recruiting,No Results Available,Drug: Pembrolizumab|Procedure: CT Scan,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02740920
NCT00160992,Adoptive Cell Transfer Combined With Peptide Vaccination in Transiently Immunosuppressed Melanoma Patients,Suspended,No Results Available,Biological: Melan-A analog peptide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00160992
NCT00019994,Vaccine Therapy in Treating Patients With Metastatic Melanoma,Completed,No Results Available,Biological: MART-1 antigen|Biological: aldesleukin|Biological: gp100 antigen|Biological: incomplete Freund's adjuvant,All,"16 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00019994
NCT00017316,Thalidomide and SU5416 in Treating Patients With Metastatic Melanoma,Completed,No Results Available,Drug: semaxanib|Drug: thalidomide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00017316
NCT00019175,Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Recurrent Metastatic Melanoma,Completed,No Results Available,Biological: aldesleukin|Biological: fowlpox virus vaccine vector|Biological: gp100 antigen,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00019175
NCT00036816,Vaccine Therapy in Treating Patients With Melanoma of the Eye,Terminated,No Results Available,Biological: MART-1 antigen|Biological: NA17-A antigen|Biological: gp100 antigen|Biological: tyrosinase peptide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00036816
NCT00462423,"Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study",Completed,Has Results,Drug: Avastin|Drug: Abraxane,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00462423
NCT00086489,"CP-675,206 In Patients With Advanced Melanoma",Completed,No Results Available,"Drug: CP-675,206",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00086489
NCT00571116,Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy,Terminated,No Results Available,Drug: Disulfiram|Drug: Arsenic trioxide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00571116
NCT00019214,Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma,Completed,No Results Available,Biological: MART-1 antigen|Biological: aldesleukin|Biological: gp100 antigen,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00019214
NCT00006249,Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma,Unknown status,No Results Available,Biological: pegylated interferon alfa|Procedure: adjuvant therapy,All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00006249
NCT01264874,MelaViD: A Trial on Vitamin D Supplementation for Resected Stage II Melanoma Patients,Terminated,No Results Available,Drug: Vitamin D3 ( Colecalciferol)|Other: placebo,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01264874
NCT00085488,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma,Completed,No Results Available,Biological: autologous tumor cell vaccine|Biological: therapeutic autologous dendritic cells,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00085488
NCT00054535,Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma,Completed,No Results Available,Biological: aldesleukin|Biological: recombinant fowlpox-tyrosinase vaccine|Biological: vaccinia-tyrosinase vaccine,All,"16 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00054535
NCT01253096,Intratumoral Application of L19IL2 in Patients With Malignant Melanoma,Completed,No Results Available,Drug: Intratumoral injections of L19IL2,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01253096
NCT00470015,"Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma","Active, not recruiting",No Results Available,Biological: MART-1 antigen|Biological: IL-2|Biological: gp100 antigen|Biological: GM-CSF|Biological: MART-1a peptide,All,"18 Years to 120 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00470015
NCT00308607,"Bevacizumab, Dacarbazine and Interferon-Alfa to Treat Metastatic Melanoma",Completed,No Results Available,Drug: Bevacizumab (Avastin)|Drug: dacarbazine|Drug: interferon-alfa-2a (Roferon-A),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00308607
NCT00591734,RAD001 Plus Bevacizumab in Metastatic Melanoma,Completed,Has Results,Drug: Bevacizumab|Drug: Everolimus,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00591734
NCT01032122,Rituximab in Metastatic Melanoma,Terminated,No Results Available,Drug: rituximab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01032122
NCT02678572,Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma,Recruiting,No Results Available,Combination Product: Melphalan/HDS,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02678572
NCT00019487,Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma,Completed,No Results Available,Biological: aldesleukin|Biological: gp209-2M antigen|Biological: incomplete Freund's adjuvant,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00019487
NCT01659151,Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma,"Active, not recruiting",No Results Available,Drug: High Dose Interleukin-2 (IL-2)|Procedure: ACT with TIL Infusion|Drug: Vemurafenib|Drug: Lymphodepletion,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01659151
NCT00079144,"Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma",Completed,No Results Available,Biological: NY-ESO-1 peptide vaccine|Biological: aldesleukin|Biological: filgrastim|Biological: incomplete Freund's adjuvant|Biological: therapeutic autologous lymphocytes|Drug: cyclophosphamide|Drug: fludarabine phosphate,All,"16 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00079144
NCT00107159,Vaccine Therapy in Treating Patients With Unresected Stage III or Stage IV Melanoma,Completed,No Results Available,Biological: autologous dendritic cell-allogeneic melanoma tumor cell lysate vaccine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00107159
NCT00847106,Augmentation of Dendritic Cell-Based Vaccines in Melanoma Patients by Depletion of Regulatory T Cells in Stage IV Melanoma Patients,Completed,No Results Available,Drug: Daclizumab|Biological: Dendritic cells,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00847106
NCT00937625,T-cell Based Immunotherapy for of Melanoma,Completed,No Results Available,"Biological: cyclophosphamide, fludarabine, T-cells, Interleukin-2",All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00937625
NCT00003641,High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma,Terminated,Has Results,Biological: interferon alfa-2b|Other: observation,All,"18 Years and older   (Adult, Older Adult)",
NCT00003568,Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma,Completed,No Results Available,Biological: aldesleukin|Biological: gp100 antigen|Biological: incomplete Freund's adjuvant,All,"16 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00003568
NCT00019669,Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma,Completed,No Results Available,Biological: aldesleukin|Biological: fowlpox virus vaccine vector|Biological: gp100 antigen,All,"16 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00019669
NCT01676779,mRNA Electroporated Autologous Dendritic Cells for Stage III/IV Melanoma,Completed,No Results Available,Biological: Dendritic cell therapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01676779
NCT00525031,Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients,Completed,Has Results,Drug: Temozolomide (TMZ)|Drug: Pegylated Interferon Alpha-2b (PGI),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00525031
NCT00928902,"Trial for the Evaluation of the Effect of Systemic Low-dose Interleukin-2 (IL-2) on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With High Risk Melanoma",Completed,No Results Available,Drug: low-dose IL-2|Biological: melanoma vaccine,All,"18 Years to 85 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00928902
NCT01474551,Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation,Terminated,Has Results,Drug: vemurafenib,All,"19 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01474551
NCT00004022,Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma,Completed,No Results Available,Biological: aldesleukin|Biological: autologous tumor cell vaccine|Biological: muromonab-CD3|Biological: therapeutic autologous lymphocytes|Procedure: surgical procedure,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00004022
NCT02828345,Bio-marker Analysis Using Circulating Tumor Cells in Patients With Melanoma,Recruiting,No Results Available,Other: Specimen Collection,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02828345
NCT00112216,Immunotherapy of Melanoma Patients,Completed,No Results Available,Biological: Melan-A analog peptide|Biological: FluMa peptide|Biological: Mage-A10 peptide|Biological: SB AS-2 adjuvant|Biological: Montanide adjuvant,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00112216
NCT01814046,Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma,Terminated,Has Results,Drug: Aldesleukin|Drug: Cyclophosphamide|Drug: Fludarabine|Biological: Young Tumor Infiltrating Lymphocytes (TIL),All,"16 Years to 75 Years   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01814046
NCT02303951,Neoadjuvant Vemurafenib + Cobimetinib in Melanoma: NEO-VC,Recruiting,No Results Available,Drug: Vemurafenib + cobimetinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02303951
NCT00204594,Local Treatment of Metastatic Melanoma With Autologous Lymphocytes and the Bispecific Antibody rM28,Completed,No Results Available,Drug: rM28|Drug: autologous PBMCs,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00204594
NCT01435499,Safety Study of a Melanoma Vaccine (GVAX) With or Without Cyclophosphamide in Patients With Surgically Resected Melanoma,Completed,No Results Available,Biological: melanoma GVAX|Drug: Cyclophosphamide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01435499
NCT02768207,A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma,"Active, not recruiting",No Results Available,Drug: Cobimetinib|Drug: Vemurafenib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02768207
NCT00003509,Antineoplaston Therapy in Treating Patients With Stage IV Melanoma,Terminated,No Results Available,Drug: Antineoplaston therapy (Atengenal + Astugenal),All,"18 Years to 99 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00003509
NCT01216436,Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma,Terminated,No Results Available,Biological: Vaccination with RNA-transfected mature autologous DC,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01216436
NCT00005633,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma,Completed,No Results Available,Biological: OVA BiP peptide|Biological: gp209-2M antigen|Biological: recombinant 70-kD heat-shock protein|Biological: tyrosinase peptide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00005633
NCT00003362,Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma,Completed,No Results Available,Biological: QS21|Biological: gp100 antigen|Biological: incomplete Freund's adjuvant|Biological: sargramostim|Biological: tyrosinase peptide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00003362
NCT00049010,Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma,Completed,No Results Available,Genetic: comparative genomic hybridization|Genetic: cytogenetic analysis|Genetic: fluorescence in situ hybridization|Other: immunohistochemistry staining method,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00049010
NCT00130442,Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma,Completed,No Results Available,Drug: PI-88 and dacarbazine|Drug: dacarbazine or DTIC,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00130442
NCT00022438,Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma That Has Not Responded to Previous Treatment,Completed,No Results Available,Biological: aldesleukin|Biological: incomplete Freund's adjuvant|Biological: recombinant tyrosinase-related protein-2,All,"16 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00022438
NCT00005052,Vaccine Therapy in Treating Patients With Primary Stage II Melanoma,Unknown status,No Results Available,Biological: GM2-KLH vaccine|Biological: QS21|Procedure: adjuvant therapy,All,"18 Years to 80 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00005052
NCT00014092,Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With Surgery,Completed,No Results Available,Biological: aldesleukin|Biological: recombinant interferon alfa|Biological: sargramostim|Drug: temozolomide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00014092
NCT03178851,Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma,Recruiting,No Results Available,Biological: Atezolizumab|Drug: Cobimetinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03178851
NCT01363206,Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma,Unknown status,No Results Available,Biological: Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)|Biological: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01363206
NCT00938223,"Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma",Completed,No Results Available,Biological: 4-peptide and 12-peptide melanoma vaccines,All,"18 Years to 85 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00938223
NCT00002535,Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma,Completed,No Results Available,Biological: aldesleukin|Biological: lymphokine-activated killer cells|Biological: therapeutic tumor infiltrating lymphocytes|Drug: cyclophosphamide|Drug: indomethacin,All,"17 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00002535
NCT00118313,"Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma",Completed,No Results Available,Biological: incomplete Freund's adjuvant|Biological: multi-epitope melanoma peptide vaccine|Biological: sargramostim|Biological: tetanus toxoid helper peptide|Drug: dimethyl sulfoxide|Drug: imiquimod|Procedure: adjuvant therapy,All,"12 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00118313
NCT02308553,Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic Melanoma,Recruiting,No Results Available,Drug: Nintedanib|Drug: Nintedanib-Placebo|Drug: Paclitaxel,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02308553
NCT00287131,Adoptive Cell Therapy Following Non-myeloablate Chemotherapy in Metastatic Melanoma Patients,Unknown status,No Results Available,Procedure: Procedure - Adoptive cell transfer,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00287131
NCT03501368,Study of Ceritinib in Patients With Unresectable Melanoma,Recruiting,No Results Available,Drug: Ceritinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03501368
NCT02644967,A Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination With Ipilimumab or Pembrolizumab in Patients With Metastatic Melanoma,Recruiting,No Results Available,Drug: IMO-2125|Drug: Ipilimumab|Drug: Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02644967
NCT02535078,Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Cutaneous Melanoma,"Active, not recruiting",No Results Available,Drug: IMCgp100|Drug: durvalumab|Drug: tremelimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02535078
NCT00289016,A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma,Completed,Has Results,Drug: Talimogene Laherparepvec,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00289016
NCT00062036,Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma,Completed,No Results Available,Biological: aldesleukin|Biological: filgrastim|Biological: incomplete Freund's adjuvant|Biological: interleukin-2 gene|Biological: therapeutic tumor infiltrating lymphocytes|Drug: cyclophosphamide|Drug: fludarabine phosphate,All,"18 Years to 120 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00062036
NCT00769704,Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma,Completed,Has Results,Biological: Talimogene laherparepvec|Biological: GM-CSF,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00769704
NCT01119508,Ipilimumab + Temozolomide in Metastatic Melanoma,Completed,No Results Available,Drug: Ipilimumab|Drug: Temozolomide,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01119508
NCT02288897,PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma,"Active, not recruiting",No Results Available,"Drug: PV-10 (10% rose bengal disodium)|Drug: Dacarbazine, temozolomide or talimogene laherparepvec",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02288897
NCT00897624,Bone Marrow and Blood Samples From Patients With Metastatic Choroid Melanoma,Completed,No Results Available,Genetic: gene expression analysis|Genetic: reverse transcriptase-polymerase chain reaction|Other: laboratory biomarker analysis,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00897624
NCT01092585,Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH,Unknown status,No Results Available,Drug: Tesetaxel,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01092585
NCT00004184,Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma,Completed,No Results Available,Biological: monoclonal antibody 4B5 anti-idiotype vaccine|Biological: sargramostim|Drug: alum adjuvant,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00004184
NCT00004148,Vaccine Therapy in Treating Patients With Unresectable Metastatic Melanoma,Completed,No Results Available,Biological: recombinant vaccinia-B7.1 vaccine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00004148
NCT01308762,"A Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 in Adult Melanoma Cancer Patients",Completed,Has Results,Biological: Heat killed whole cell M. obuense (IMM-101) 0.1 mg|Biological: Heat-killed whole cell M.obuense (IMM-101) 0.5 mg|Biological: Heat killed whole cell M.obuense (IMM-101) 1.0 mg,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01308762
NCT00299689,Phase II Trial of Ontak With Metastatic Melanoma,Completed,Has Results,Drug: Denileukin diftitox,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00299689
NCT01245556,Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma,Completed,No Results Available,Drug: BMS-908662|Drug: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01245556
NCT00002817,Vaccine Therapy in Treating Patients With Metastatic Melanoma,Unknown status,No Results Available,Biological: sargramostim|Biological: vaccinia-GM-CSF vaccine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00002817
NCT01138410,Study of a DNA Immunotherapy to Treat Melanoma,Terminated,No Results Available,Biological: SCIB1,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01138410
NCT02275416,Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma,"Active, not recruiting",No Results Available,Drug: Ipilimumab|Biological: UV1 vaccine|Biological: GM-CSF,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02275416
NCT02375984,A Study Using Tumor-Reactive Autologous Tumor Infiltrating Lymphocytes (TIL) in Metastatic Melanomas,Terminated,No Results Available,Biological: Tumor Infiltrating Lymphocytes (TIL),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02375984
NCT00003027,Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma,Completed,No Results Available,Biological: aldesleukin|Biological: filgrastim|Biological: recombinant interferon alfa|Drug: cisplatin|Drug: dacarbazine|Drug: vinblastine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00003027
NCT02050321,A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma,Terminated,Has Results,Drug: Acitretin|Drug: Vemurafenib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02050321
NCT00039000,Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma,Completed,No Results Available,Drug: HSPPC-96 or Oncophage,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00039000
NCT00006385,Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma,Completed,No Results Available,Biological: MART-1 antigen|Biological: gp100 antigen|Biological: incomplete Freund's adjuvant|Biological: recombinant interferon alfa|Biological: sargramostim|Biological: tyrosinase peptide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00006385
NCT00257465,"Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma",Completed,No Results Available,"Biological: Autologous, DNP-modified vaccine (M-Vax)|Biological: Autologous, DNP-Modified Melanoma Vaccine|Biological: Autologous, DNP-Modified Vaccine",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00257465
NCT02410863,Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma,Terminated,No Results Available,Drug: Dabrafenib|Drug: Trametinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02410863
NCT01077050,SciBase International Melanoma Pivotal Study,Completed,Has Results,Device: SciBase III Electrical Impedance Spectrometer,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01077050
NCT00412581,Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic Melanoma,Completed,No Results Available,Drug: Lenalidomide|Drug: Dacarbazine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00412581
NCT01152788,Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma,Completed,Has Results,Drug: rIL-21|Drug: Dacarbazine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01152788
NCT00007969,Photodynamic Therapy in Treating Patients With Stage III or Stage IV Melanoma,Completed,No Results Available,Biological: Detox-B adjuvant|Drug: verteporfin,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00007969
NCT00223899,A Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma,Completed,No Results Available,Genetic: VCL-IM01 (encoding IL-2) with Electroporation,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00223899
NCT00445783,Study of Families With Melanoma,Recruiting,No Results Available,Genetic: gene expression analysis|Genetic: mutation analysis|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Procedure: examination|Procedure: mutation carrier screening|Procedure: study of high risk factors,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00445783
NCT00118274,"Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma",Completed,No Results Available,Biological: incomplete Freund's adjuvant|Biological: melanoma helper peptide vaccine|Biological: multi-epitope melanoma peptide vaccine|Biological: tetanus toxoid helper peptide|Drug: cyclophosphamide,All,"18 Years to 120 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00118274
NCT01893099,Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma,Completed,No Results Available,Drug: Sorafenib|Device: Radioembolization with SIR-Spheres® (Yttrium Microspheres),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01893099
NCT00675727,Safety Study of CADI-05 in Patients With Advanced Stage Melanoma,Terminated,No Results Available,Biological: CADI-05,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00675727
NCT01323517,Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity,Completed,Has Results,"Drug: Ipilimumab, Melphalan and Dactinomycin",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01323517
NCT02601378,A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.,Recruiting,No Results Available,Drug: LXS196|Drug: LXS196 and HDM201,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02601378
NCT01995344,TIL Therapy in Metastatic Melanoma and IL2 Dose Assessment,Unknown status,No Results Available,Drug: Cyclophosphamide|Drug: Fludarabine|Genetic: Tumour Infiltrating Lymphocytes|Drug: Interleukin-2,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01995344
NCT00081042,ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma,Completed,No Results Available,Drug: paclitaxel albumin-stabilized nanoparticle formulation,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00081042
NCT00002860,SWOG-9430: Surgery in Treating Patients With Metastatic Melanoma,Completed,No Results Available,Procedure: Surgery,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00002860
NCT00871533,Pilot Study of IFN α2b for Melanoma Patients,Terminated,No Results Available,Drug: IFNα2b|Drug: PEG- IFNα2b,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00871533
NCT02166788,Evaluation of Groin Lymphadenectomy Extent For Metastatic Melanoma,Recruiting,No Results Available,Procedure: Inguinal Lymphadenectomy|Procedure: Ilio-inguinal Lymphadenectomy,All,"15 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02166788
NCT03567889,Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C Melanoma Patients,Recruiting,No Results Available,Drug: Daromun|Procedure: Surgery alone|Procedure: Surgery,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03567889
NCT00101166,Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in Melanoma,Completed,Has Results,Biological: Bystander-Based Autologous Tumor Cell Vaccine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00101166
NCT01656642,A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma,"Active, not recruiting",No Results Available,Drug: Atezolizumab|Drug: Cobimetinib|Drug: Vemurafenib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01656642
NCT02038348,Interest of the 18F-DOPA-PET Imaging in Metastatic Melanoma Treated With B-RAF Inhibitors: a Pilot Study,Unknown status,No Results Available,Device: PET with 18F-FDOPA,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02038348
NCT01302496,Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma,Completed,No Results Available,Biological: TriMix-DC and ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01302496
NCT02990416,A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma,Unknown status,No Results Available,Biological: A-dmDT390-bisFv(UCHT1)|Biological: Pembrolizumab|Radiation: Ionizing Radiation,All,"18 Years to 80 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02990416
NCT00429312,A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma,Completed,No Results Available,Biological: JX-594,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00429312
NCT00006233,"Combination Chemotherapy, Total-Body Irradiation, Peripheral Stem Cell Transplantation, and Lymphocyte Infusion in Treating Patients With Stage IV Melanoma",Completed,No Results Available,Biological: therapeutic allogeneic lymphocytes|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy,All,18 Years to 64 Years   (Adult),https://ClinicalTrials.gov/show/NCT00006233
NCT00972933,Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma,Completed,No Results Available,Drug: ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00972933
NCT01416831,Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma.,"Active, not recruiting",No Results Available,Other: Radiation therapy and high-dose IL-2|Drug: High-dose IL-2,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01416831
NCT02875132,Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma,Recruiting,No Results Available,Drug: pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02875132
NCT00006237,S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma,Completed,Has Results,Biological: interleukin-2|Biological: filgrastim|Biological: interferon alfa|Drug: cisplatin|Drug: dacarbazine|Drug: vinblastine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00006237
NCT00086866,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery,Unknown status,No Results Available,Biological: D1/3-MAGE-3-His fusion protein|Biological: SB-AS02B adjuvant|Biological: SB-AS15 adjuvant,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00086866
NCT02437279,Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients,"Active, not recruiting",No Results Available,Procedure: Surgery of the tumor|Drug: Infusion with ipilimumab 3 mg/kg q3wks|Drug: Infusion with nivolumab 1 mg/kg q3wks,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02437279
NCT02678741,Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.,Recruiting,No Results Available,Drug: TLPLDC Vaccine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02678741
NCT01801358,A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma,Terminated,Has Results,Drug: AEB071|Drug: MEK162,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01801358
NCT00350597,GM-CSF as Adjuvant Therapy of Melanoma,Completed,No Results Available,Drug: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF),All,"14 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00350597
NCT01006252,A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma,Terminated,Has Results,Drug: Tasisulam-sodium|Drug: Paclitaxel,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01006252
NCT02186249,Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma,No longer available,No Results Available,Drug: Nivolumab|Drug: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02186249
NCT00004152,PET and CT Scans to Evaluate Patients With Stage III or Stage IV Melanoma,Completed,No Results Available,Drug: iodinated contrast dye|Procedure: computed tomography|Procedure: positron emission tomography|Radiation: fludeoxyglucose F 18,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00004152
NCT00091143,Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma,Completed,No Results Available,Biological: gp100 antigen|Biological: incomplete Freund's adjuvant|Biological: keyhole limpet hemocyanin|Drug: fludarabine phosphate|Procedure: peripheral blood stem cell transplantation,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00091143
NCT02907827,Whole-body DW-MRI and cfDNA Analysis for the Surveillance of Melanoma Patients at High Risk for Recurrence.,Recruiting,No Results Available,Other: follow up DW MRI,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02907827
NCT00003346,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma,Completed,No Results Available,Drug: acetaminophen|Drug: acetylcysteine|Drug: carmustine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00003346
NCT00745862,Illness Related Distress in Women With Clinically Localized Cutaneous Melanoma,Completed,No Results Available,"Behavioral: questionnaire on-line or if uncomfortable with a computer interface, paper copies will be provided",Female,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00745862
NCT01005472,Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma,Completed,No Results Available,Drug: sunitinib malate|Drug: temozolomide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01005472
NCT00246012,"A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma",Completed,Has Results,Drug: Intetumumab|Drug: Dacarbazine|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00246012
NCT00281541,A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma,Completed,No Results Available,Drug: YM155,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00281541
NCT00090896,"CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery",Completed,No Results Available,Biological: maximum tolerated dose of anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00090896
NCT01833767,Low-dose Cyclophosphamide and Outpatient IV Interleukin-2 in Metastatic Melanoma,Withdrawn,No Results Available,Drug: Cyclophosphamide and Interleukin 2,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01833767
NCT00683670,Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma,Completed,No Results Available,Drug: cyclophosphamide|Biological: Mature dendritic cell vaccine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00683670
NCT02009397,A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients,Unknown status,No Results Available,Drug: Ipilimumab|Drug: GM-CSF,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02009397
NCT03132090,Early Therapy Response Monitoring in Melanoma Patients Using PET/MRI,Recruiting,No Results Available,Diagnostic Test: PET/MR (Biograph mMR),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03132090
NCT03005639,ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma,Withdrawn,No Results Available,Drug: Vemurafenib and Cobimetinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03005639
NCT02523313,Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED,Recruiting,No Results Available,Drug: Nivolumab + Placebo|Drug: Nivolumab + Ipilimumab|Drug: Double Placebo Control,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02523313
NCT01435369,"Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma",Completed,No Results Available,Drug: CT-011,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01435369
NCT00963261,Quality of Life and Psychological Well-being in Patients With Malignant Melanoma,Unknown status,No Results Available,Behavioral: psycho-oncological intervention,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00963261
NCT01723813,Peptide Vaccinations Plus GM-CT-01 in Melanoma,Unknown status,No Results Available,Biological: Tumor specific peptides: MAGE-3.A1 and / or NA17.A2|Biological: Galectin-3 inhibitor: GM-CT-01 systemic injections|Biological: Galectin-3 inhibitor: GM-CT-01 Peri-tumoral administration,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01723813
NCT02424916,Adoptive Transfer of Specific Melanoma Antigens CD8+ T Cells in Metastatic Melanoma Patients: a Phase I/II Study,Recruiting,No Results Available,Biological: Melanoma antigens-specific CD8+ T lymphocytes,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02424916
NCT03551626,Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes,Recruiting,No Results Available,Drug: Dabrafenib|Drug: Trametinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03551626
NCT01920516,Isolated Limb Perfusion of Melphalan for Melanoma and Sarcoma Treatment,Recruiting,No Results Available,Drug: Melphalan,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01920516
NCT02310451,Study of Molecular Mechanisms Implicated in the Pathogenesis of Melanoma. Role of Exosomes,Unknown status,No Results Available,Biological: blood test,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02310451
NCT03754140,Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases,Not yet recruiting,No Results Available,Drug: Polidocanol Injection,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03754140
NCT00003222,Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma,Completed,Has Results,Biological: aldesleukin|Biological: gp100 antigen|Biological: incomplete Freund's adjuvant|Biological: sargramostim|Biological: tetanus peptide melanoma vaccine|Biological: tyrosinase peptide,All,"18 Years to 79 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00003222
NCT01898403,Lymph Node Mapping Using Indocyanine Green Solution in Diagnosing Patients With Malignant Melanoma,Completed,Has Results,Drug: Indocyanine green solution|Drug: Isosulfan blue (ISB)|Diagnostic Test: Lymphoscintigraphy with 99-technetium (99Tc) sulfur colloid (TSC),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01898403
NCT00010309,"Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma",Unknown status,No Results Available,Biological: MART-1 antigen|Biological: gp100 antigen,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00010309
NCT01512251,BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma,Completed,Has Results,Drug: BKM120 Combined with Vemurafenib (PLX4032),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01512251
NCT03052127,Study in Subjects With Small to Medium Primary Choroidal Melanoma,Recruiting,No Results Available,Drug: Light-activated AU-011,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03052127
NCT01065467,Panobinostat (LBH589) in Patients With Metastatic Melanoma,Completed,No Results Available,Drug: LBH589,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01065467
NCT00338377,Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma,Recruiting,No Results Available,Biological: Dendritic Cell Immunization|Drug: Cyclophosphamide|Drug: Fludarabine|Biological: T-Cells|Biological: Interleukin-2|Drug: Mesna|Biological: Intrathecal T-Cells|Biological: Intrathecal Interleukin-2,All,"12 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00338377
NCT00598507,Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma,Completed,Has Results,Drug: ZK-EPO,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00598507
NCT02263898,Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations,Withdrawn,No Results Available,Drug: Raf kinase inhibitor LGX818|Drug: binimetinib|Other: laboratory biomarker analysis,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02263898
NCT00803374,Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma,Withdrawn,No Results Available,Drug: AntiCD137|Drug: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00803374
NCT02115243,Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma,Completed,No Results Available,Drug: Ipilimumab,All,"18 Years to 99 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02115243
NCT00037037,Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma,Unknown status,No Results Available,Biological: MAGE-10.A2|Biological: MART-1 antigen|Biological: NY-ESO-1 peptide vaccine|Biological: sargramostim|Biological: tyrosinase peptide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00037037
NCT01528774,Culture and Characterization of Circulating Tumor Cells (CTC) in Melanoma and Other Cancers,Completed,No Results Available,Other: Blood Draw,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01528774
NCT01898585,An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma,"Active, not recruiting",No Results Available,Drug: Zelboraf,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01898585
NCT00199342,"A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma",Terminated,No Results Available,Drug: KW-2871,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00199342
NCT00109005,Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma,Completed,Has Results,Drug: Revlimid,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00109005
NCT02700763,[18F]Dabrafenib Molecular Imaging in Melanoma Brain Metastasis,Recruiting,No Results Available,Other: [18F]dabrafenib molecular imaging,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02700763
NCT00003444,"Interferon Alfa-2b With or Without Radiation Therapy in Treating Patients With Melanoma That Has Metastasized to Lymph Nodes in the Neck, Under the Arm, or in the Groin",Completed,No Results Available,Biological: recombinant interferon alfa|Radiation: radiation therapy,Female,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00003444
NCT00112229,Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients,Completed,No Results Available,Biological: group 1|Biological: group 2|Biological: group 3|Biological: group 4,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00112229
NCT01430416,Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients,"Active, not recruiting",No Results Available,Drug: AEB071,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01430416
NCT00005961,O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma,Completed,No Results Available,Drug: O6-benzylguanine|Drug: carmustine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00005961
NCT00673361,"Pilot Trial of ""Chemo-Switch"" Regimen to Treat Advanced Melanoma",Terminated,Has Results,Drug: Concurrent decrescendo biochemotherapy regimen|Drug: Low-dose Temozolomide plus Sorafenib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00673361
NCT00053391,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma,Completed,No Results Available,Biological: recombinant CD40-ligand|Biological: therapeutic autologous dendritic cells,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00053391
NCT01875653,Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma,Terminated,No Results Available,Biological: Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC)|Biological: Autologous PBMCs in GM-CSF (MC),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01875653
NCT00006035,Bleomycin With or Without Electroporation Therapy in Treating Patients With Stage III or Stage IV Melanoma,Unknown status,No Results Available,Biological: bleomycin sulfate|Drug: electroporation therapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00006035
NCT00612664,"Phase II, 2nd Line Melanoma - RAND Monotherapy",Completed,No Results Available,Drug: Anti-CD137 (4-1BB) (BMS-663513),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00612664
NCT00112242,Immunotherapy of Stage III/IV Melanoma Patients,Completed,No Results Available,Biological: Montanide + Melan-A analogue peptide|Biological: Montanide + Melan-A analog peptide + NY-ESO-1 analog peptide + Mage10 peptide|Biological: Montanide + CpG-7909 / PF-3512676+Melan-A analog peptide + NY-ESO-1 analog peptide + Mage10 peptide|Biological: Montanide + CpG-7909/PF-3512676 + Melan-A native and analog peptides + NY-ESO-1 long peptide + Mage10 peptide|Biological: Montanide + CpG-7909/PF-3512676 + Melan-A native and analog peptides + NY-ESO-1 long peptide + Mage10 peptide + low dose IL-2,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00112242
NCT00471133,Safety and Immunogenicity of a Melanoma DNA Vaccine Delivered by Electroporation,Completed,No Results Available,Biological: Xenogeneic Tyrosinase DNA Vaccine|Device: TriGrid Delivery System for Intramuscular Electroporation,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00471133
NCT00615095,Differential Risks for Melanoma: p16 and DNA Repair,Completed,No Results Available,"Other: self-administered questionnaire and blood draw|Other: health questionnaire, blood draw and skin exam",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00615095
NCT02739386,Study of Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune Diseases,Completed,No Results Available,Biological: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02739386
NCT00004025,Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma,Unknown status,No Results Available,Biological: aldesleukin|Biological: dendritic cell-gp100-MART-1 antigen vaccine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00004025
NCT00715793,Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma,Completed,Has Results,Drug: Decitabine|Drug: Temozolomide|Procedure: biopsy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00715793
NCT02617849,Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma,Recruiting,No Results Available,Drug: Pembrolizumab|Drug: Carboplatin|Drug: Paclitaxel,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02617849
NCT03224208,Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma Patients,Not yet recruiting,No Results Available,Drug: Vemurafenib|Drug: Cobimetinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03224208
NCT00984464,Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma,Completed,No Results Available,Biological: REOLYSIN|Drug: Carboplatin|Drug: Paclitaxel,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00984464
NCT00004196,Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis,Completed,No Results Available,Biological: recombinant interferon alfa|Procedure: lymphangiography|Drug: Observation,All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00004196
NCT02350972,Inducing Systemic Immunity and Regressions in Metastatic Melanoma,Completed,No Results Available,Biological: Autologous cytokines,All,"21 Years to 80 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02350972
NCT00596362,Treatment With Intravitreal Avastin for Large Uveal Melanomas,Completed,Has Results,Drug: AVASTIN,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00596362
NCT00897546,Biomarkers to Predict Response to Interferon Therapy in Patients With Melanoma,Completed,No Results Available,Other: laboratory biomarker analysis,All,"18 Years to 120 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00897546
NCT00060333,Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma,Completed,Has Results,Radiation: radiation therapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00060333
NCT01704287,Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (P08719/KEYNOTE-002),"Active, not recruiting",Has Results,Biological: Pembrolizumab|Drug: Carboplatin|Drug: Paclitaxel|Drug: Dacarbazine|Drug: Temozolomide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01704287
NCT00864253,A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma,Completed,Has Results,Drug: ABI-007|Drug: Dacarbazine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00864253
NCT01137006,"An Open-Label, Dose-Escalation Study of IMC-20D7S In Patients With Malignant Melanoma",Completed,No Results Available,Biological: IMC-20D7S (Cohort 1A)|Biological: IMC-20D7S (Cohort 2A )|Biological: IMC-20D7S (Cohort 3A )|Biological: IMC-20D7S (Cohort 4A )|Biological: IMC-20D7S (Cohort 1B)|Biological: IMC-20D7S (Cohort 2B )|Biological: Biological/Vaccine: IMC-20D7S (Cohort 3B ),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01137006
NCT00952939,Study of Tumor Samples in Patients Undergoing Radiation Therapy or Surgery For Primary Melanoma of the Eye,Completed,No Results Available,Genetic: fluorescence in situ hybridization|Other: laboratory biomarker analysis|Procedure: fine-needle aspiration|Procedure: therapeutic conventional surgery|Other: Questionnaires,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00952939
NCT00059475,Peptide Vaccination for Patients at High Risk for Recurrent Melanoma,Completed,Has Results,Drug: Glycoprotein 100 (GP100): 209-217 (210M)|Drug: Interleukin-2 (IL-2)|Drug: Montanide ISA 51|Drug: Melanoma antigen recognized by T-cells (MART)-1: 27-35|Drug: 27-35 (27L): melanoma antigen recognized by T-cells (MART)-1|Drug: melanoma antigen recognized by T-cells (MART)-1: 26-35(27L),All,"7 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00059475
NCT01543464,Peptide Vaccine and Temozolomide for Metastatic Melanoma Patients,Terminated,No Results Available,Drug: Chemotherapy: Temozolomide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01543464
NCT01200238,STA-9090(Ganetespib) in Metastatic Ocular Melanoma,Completed,Has Results,Drug: STA-9090,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01200238
NCT01910181,A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma,Completed,Has Results,Drug: Vemurafenib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01910181
NCT01701674,Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts,"Active, not recruiting",Has Results,Drug: Ipilimumab|Procedure: Tumor Infiltrating Lymphocytes (TIL)|Drug: Administration of Lymphodepletion|Drug: Cyclophosphamide as Part of Lymphodepletion|Drug: Fludarabine as Part of Lymphodepletion|Drug: High Dose IL-2|Biological: Adoptive Cell Therapy with TIL,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01701674
NCT03166397,"Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients",Recruiting,No Results Available,Drug: Fludarabine|Radiation: Radiation|Biological: TIL|Drug: IL-2,All,"18 Years to 80 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03166397
NCT00006113,Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma,Terminated,No Results Available,Biological: MART-1 antigen|Biological: aldesleukin|Biological: gp100 antigen|Biological: recombinant CD40-ligand|Biological: recombinant interferon gamma|Biological: recombinant interleukin-4|Biological: sargramostim|Biological: therapeutic autologous dendritic cells|Biological: therapeutic tumor infiltrating lymphocytes|Biological: tyrosinase peptide|Radiation: Candida albicans skin test reagent,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00006113
NCT00390338,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma,Completed,No Results Available,Biological: polarized dendritic cells|Biological: non-polarized dendritic cells,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00390338
NCT01721603,Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets,Terminated,Has Results,Drug: Dabrafenib|Procedure: Gamma Knife Radiosurgery|Drug: Trametinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01721603
NCT00559026,Phase I/II Study of Chemo-Immunotherapy Combination in Melanoma Patients,Completed,No Results Available,Biological: Melan-A|Other: Melan-A plus Dacarbazine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00559026
NCT00483301,"A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma",Completed,No Results Available,Drug: Sorafenib (BAY 43-9006)|Drug: ABI-007(Abraxane),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00483301
NCT03493230,Detection of Plasmatic Cell-free BRAF and NRAS Mutations : a New Tool for Monitoring Patients With Metastatic Malignant Melanoma Treated With Targeted Therapies or Immunotherapy ( MALT ),Not yet recruiting,No Results Available,Biological: quantification of BRAF and NRAS mutation,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03493230
NCT00749684,Efficacy and Safety of High-dose Interferon Alfa-2b (Intron A®) for the Adjuvant Treatment of Malignant Melanoma (Study P04083),Completed,Has Results,Biological: Interferon α-2b,All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00749684
NCT01743157,Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma,Completed,No Results Available,Drug: Biochemo + bevacizumab then ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01743157
NCT00003224,Vaccine Therapy in Treating Patients With Metastatic Melanoma,Completed,Has Results,Biological: QS21|Biological: IFA (incomplete Freund's adjuvant)|Biological: p946|Biological: p946/tet-p|Biological: Tet-p,All,"18 Years to 79 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00003224
NCT03712904,Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma,Not yet recruiting,No Results Available,Radiation: Stereotactic Body Radiation Therapy|Biological: Ziv-Aflibercept,Female,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03712904
NCT00623766,Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases,Completed,Has Results,Drug: Ipilimumab|Drug: Corticosteroid: Betamethasone|Drug: Corticosteroid: Dexamethasone|Drug: Corticosteroid: Fludrocortisone|Drug: Corticosteroid: Hydrocortisone|Drug: Corticosteroid: Meprednisone|Drug: Corticosteroid: Methylprednisolone|Drug: Corticosteroid: Prednisolone|Drug: Corticosteroid: Prednisone|Drug: Corticosteroid: Triamcinolone,All,"16 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00623766
NCT01522664,A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma,Completed,No Results Available,Drug: DEDN6526A,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01522664
NCT00527761,Taxotere/Temodar/Cisplatin Study in Melanoma Patients,Completed,No Results Available,Drug: Cisplatin|Drug: Docetaxel|Drug: Temodar,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00527761
NCT00925132,"Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat",Terminated,Has Results,"Drug: Temozolomide, Decitabine, Panobinostat",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00925132
NCT00314093,RFT-5-dgA in Patients With Metastatic Melanoma,Completed,No Results Available,Drug: RFT5pdgA,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00314093
NCT00369395,A Study of Volociximab in Metastatic Melanoma,Terminated,No Results Available,Drug: volociximab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00369395
NCT02676869,Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma,"Active, not recruiting",No Results Available,Drug: IMP321 (eftilagimod alpha)|Drug: Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02676869
NCT00613509,Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma,Terminated,Has Results,"Biological: ALVAC(2) Melanoma multi-antigen therapeutic vaccine|Biological: Intron A, Interferon alpha -2b",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00613509
NCT00323206,Phase I Trial of Intratumoral pIL-12 Electroporation in Malignant Melanoma,Completed,No Results Available,Biological: IL-12p DNA|Procedure: Intratumoral Electroporation,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00323206
NCT01341158,NAM-Trial: Multiferon in Malignant Melanoma,Completed,No Results Available,Drug: human interferon-α,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01341158
NCT02009384,Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox,Terminated,No Results Available,Drug: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02009384
NCT00716495,"Safety and Pharmacodynamic Study of a New Formulation, AGI - 101H Vaccine in the Treatment of Advanced Melanoma",Terminated,No Results Available,Biological: AGI-101H Vaccine,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00716495
NCT01502696,Adjuvant PEG Intron in Ulcerated Melanoma,"Active, not recruiting",No Results Available,Biological: PEG IFN alfa-2b,All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01502696
NCT00365937,Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides,Terminated,No Results Available,Biological: Immunological peptides and immunological adjuvants|Biological: HLA-A2 peptides|Biological: Montanide ISA51|Biological: IMP321,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00365937
NCT00495066,Compassionate Use Trial for Unresectable Melanoma With Ipilimumab,No longer available,No Results Available,Drug: Ipilimumab,All,"16 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00495066
NCT00723710,Effect of Proactive Management of Side Effects on Treatment Compliance in Malignant Melanoma Patients on High-dose Intron A Therapy (Study P04600),Completed,Has Results,Biological: Intron A (interferon alfa-2b; SCH 30500),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00723710
NCT00313235,Combined Modality Treatment for Patients With Stage IV Melanoma,Completed,No Results Available,Biological: DC Vaccine and Cyclophosphamide,All,"21 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00313235
NCT00809588,"Vaccination With Autologous, Lethally Irradiated Melanoma Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-Macrophage Stimulating Factor (GMSF)","Active, not recruiting",No Results Available,"Biological: Autologous, lethally irradiated melanoma cells",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00809588
NCT00197912,Dendritic Cell Based Therapy of Malignant Melanoma,Completed,No Results Available,Biological: tumor antigen loaded autologous dendritic cells,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00197912
NCT00457418,High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831 AM2),Completed,Has Results,Drug: PEG-Intron,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00457418
NCT00145158,Immunization With 8 Peptides Mixed With Adjuvant Montanide ISA 51 in HLA-A2 Patients With Metastatic Cutaneous Melanoma,Suspended,No Results Available,Biological: 8 HLA-A2 restricted peptides and Montanide ISA-51,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00145158
NCT01213732,Phase 1 Dose-finding Study of L19TNFα Plus Melphalan Using Isolated Inferior Limb Perfusion (ILP) in Subjects With Intransit Stage III/IV Melanoma,Completed,No Results Available,Other: Isolated inferior limb perfusion,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01213732
NCT01307397,A Study of Vemurafenib in Participants With Metastatic Melanoma,Completed,Has Results,Drug: Vemurafenib,All,"16 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01307397
NCT00518206,Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma,Completed,Has Results,Biological: NY-ESO-1 ISCOMATRIX® vaccine|Drug: Cyclophosphamide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00518206
NCT00610857,Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma,Completed,Has Results,Drug: Anti-CTLA4 monoclonal antibody and HDI,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00610857
NCT01248936,A Study of RO5185426 in Patients With Metastatic Melanoma,Completed,Has Results,Drug: RO5185426,All,"16 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01248936
NCT02076646,A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma,Unknown status,No Results Available,Drug: L19IL2 - Ph I|Drug: L19IL2 at RD - Ph II|Drug: DTIC,All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02076646
NCT01696045,"Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma",Terminated,Has Results,Biological: Ipilimumab,All,12 Years to 17 Years   (Child),https://ClinicalTrials.gov/show/NCT01696045
NCT00089193,"Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma",Completed,No Results Available,Biological: incomplete Freund's adjuvant|Biological: multi-epitope melanoma peptide vaccine|Biological: sargramostim,All,"12 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00089193
NCT00204581,Intralesional Treatment With Interleukin-2 (Proleukin) in Soft Tissue Melanoma Metastases,Completed,No Results Available,Drug: Interleukin-2 (Proleukin),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00204581
NCT01029873,QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma,Completed,No Results Available,Drug: Cisplatin|Biological: ALT-801,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01029873
NCT00034554,Study of gp75 Vaccine in Patients With Stage III and IV Melanoma,Completed,No Results Available,Biological: gp75 DNA vaccine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00034554
NCT01320085,A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma,"Active, not recruiting",No Results Available,Drug: MEK162,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01320085
NCT01378975,A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases,Completed,Has Results,Drug: Vemurafenib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01378975
NCT02821013,Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP),Recruiting,No Results Available,Other: Intermittent PD-1 inhibitor therapy|Other: Continuous PD-1 inhibitor therapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02821013
NCT01636960,A Study of Pegylated Interferon Alfa-2b (MK-4031) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (MK-4031-370),Terminated,Has Results,Biological: PegIFN alfa-2b,All,"20 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01636960
NCT01927419,"Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma","Active, not recruiting",Has Results,Drug: Nivolumab|Drug: Ipilimumab|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01927419
NCT00383851,Randomized Trial of ATN-224 and Temozolomide in Advanced Melanoma,Unknown status,No Results Available,Drug: ATN-224|Drug: Temozolomide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00383851
NCT00585000,"A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma",Terminated,No Results Available,"Drug: CP-675,206",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00585000
NCT01253564,A Study of RO5185426 in Previously Treated Melanoma Patients With Brain Metastases,Completed,Has Results,Drug: RO5185426,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01253564
NCT01588847,Anesthesia and Cancer Recurrence im Malignant Melanoma,Recruiting,No Results Available,"Procedure: Spinal anesthesia with Bupivacaine hyperbar 0.5 %|Procedure: General anesthesia with Sufentanil, Propofol and Rocuronium and Sevoflurane",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01588847
NCT00412828,A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma,Completed,No Results Available,Drug: CR011-vcMMAE,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00412828
NCT00304525,"A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma",Completed,No Results Available,Drug: RAF265,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00304525
NCT00062933,A Phase II Study of Isolated Hepatic Perfusion (IHP) in Patients With Ocular Melanoma,Completed,No Results Available,Procedure: Laparotomy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00062933
NCT00459849,Tilting of Radioactive Plaques After Initial Accurate Placement for Treatment of Uveal Melanoma,Unknown status,No Results Available,Procedure: Intraoperative ultrasonography,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00459849
NCT00080353,Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma,Completed,No Results Available,Drug: IL-2|Drug: gp100:209-217|Drug: OKT3|Drug: rF-go 100P209|Drug: Montanide ISA 51,All,"7 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00080353
NCT01217398,Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye,Unknown status,No Results Available,Biological: bevacizumab|Drug: temozolomide|Genetic: polymorphism analysis|Other: pharmacogenomic studies,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01217398
NCT02327390,Ex Vivo-Activated Lymph Node Lymphocytes in Treating Patients With Stage IIIC-IV Melanoma,Terminated,No Results Available,Procedure: lymph node|Biological: X-ACT,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02327390
NCT02388906,Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238),"Active, not recruiting",No Results Available,Drug: Ipilimumab|Drug: Nivolumab|Other: Placebo matching Ipilimumab|Other: Placebo matching Nivolumab,All,"15 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02388906
NCT00358319,Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma,Terminated,No Results Available,Drug: Karenitecin|Drug: Valproic Acid,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00358319
NCT01278940,Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant Melanoma,Completed,No Results Available,Biological: Dendritic Cells (DC) malignant melanoma|Procedure: IL-2,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01278940
NCT00533702,A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma,Completed,Has Results,Biological: IMC-1121B (ramucirumab)|Drug: Dacarbazine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00533702
NCT01621490,PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma,"Active, not recruiting",No Results Available,Biological: Nivolumab|Drug: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01621490
NCT01586195,"Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E",Terminated,Has Results,Drug: Vemurafenib,All,"16 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01586195
NCT01460810,Safety and Efficacy of Silicone Oil Tamponade for Surgical Attenuation of Radiation Damage in Choroidal Melanoma,"Active, not recruiting",No Results Available,Other: 1000CsK Silicon Oil Tamponade,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01460810
NCT00512889,Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma,Completed,No Results Available,Biological: therapeutic autologous lymphocytes|Genetic: Use of an artificial antigen presenting cell (aAPC) to generate CTL|Drug: GM-CSF|Radiation: Irradiation of cutaneous tumor lesion,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00512889
NCT03525873,Methylphenidate and Physical Activity in Reducing Cancer-Related Fatigue in Participants With Metastatic Melanoma Who Receive Anti-PD1 Immunotherapy,Recruiting,No Results Available,Other: Laboratory Biomarker Analysis|Drug: Methylphenidate|Other: Physical Activity|Other: Placebo|Other: Quality-of-Life Assessment|Other: Questionnaire Administration,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03525873
NCT00261404,TNFerade™ Biologic Plus Radiation for Metastatic Melanoma,Completed,No Results Available,Drug: TNFerade™,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00261404
NCT00553618,"Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients","Active, not recruiting",No Results Available,Drug: Proleukin and Dacarbazine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00553618
NCT01359956,Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma,Completed,No Results Available,Drug: Dacarbazine|Drug: Fotemustine|Drug: Interferon Alfa-2b,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01359956
NCT03518229,Pilot Study of Intervention to Reduce Sunburns in Melanoma Survivors,Not yet recruiting,No Results Available,Device: Microsoft Band 2 + UV messaging|Device: Microsoft Band 2,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03518229
NCT01189383,"IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma",Completed,No Results Available,Biological: IL15-DC Vaccine,All,"21 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01189383
NCT00700882,"Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery","Active, not recruiting",No Results Available,Drug: dasatinib|Other: laboratory biomarker analysis,All,"18 Years to 120 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00700882
NCT00679289,Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma,Completed,Has Results,Drug: HDI|Drug: KW2871,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00679289
NCT00035165,EPO906 Therapy in Patients With Advanced Melanoma,Completed,No Results Available,Drug: epothilone b,All,"18 Years to 85 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00035165
NCT00028431,Novel Adjuvants for Peptide-Based Melanoma Vaccines,Completed,No Results Available,Biological: MDX-CTLA4 Antibody; Tyrosinase/gp100/MART-1 Peptides Melanoma Vaccine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00028431
NCT00925314,A Study of Transgenic Lymphocyte Immunization (TLI) Against Telomerase in Subjects With Stage III Melanoma,Unknown status,No Results Available,Biological: CB-10-01 (Transgenic Lymphocyte Immunization),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00925314
NCT00145145,Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma,Terminated,No Results Available,Biological: MAGE-3.A1 peptide and CpG 7909,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00145145
NCT01503827,Whole Brain Radiotherapy Following Local Treatment of Intracranial Metastases of Melanoma,"Active, not recruiting",No Results Available,Radiation: WBRT,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01503827
NCT00722098,Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients,Terminated,No Results Available,Biological: DC Vaccine & Cyclophosphamide|Biological: DC Vaccine & Placebo,All,"21 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00722098
NCT01164007,A Study of Bevacizumab (Avastin) in Combination With Dacarbazine in Participants With Unresectable/Metastatic Melanoma,Completed,Has Results,Drug: Bevacizumab|Drug: Dacarbazine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01164007
NCT01970527,Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma,"Active, not recruiting",No Results Available,Biological: Ipilimumab|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Radiation: Stereotactic Body Radiation Therapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01970527
NCT01191034,Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic Melanoma,Unknown status,No Results Available,"Drug: Vaccine MAGE-3.A1 peptide, or the NA17.A2 peptide + IL-2, IFN-α and GMCSF, Imiquimod.",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01191034
NCT00314106,"Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma",Completed,Has Results,Biological: Melanoma Reactive TIL|Drug: Cyclophosphamide|Biological: IL-2|Drug: Fludarabine|Radiation: 1200 total body irradiation (TBI),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00314106
NCT01973322,"Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized ""Proof-of-principle"" Phase II Study",Recruiting,No Results Available,Other: arm 1: DC Vaccine + RT|Other: arm 2: DC Vaccine + IFN-alfa|Other: arm 3: both arm 1 and 2 + RT|Biological: arm 4: DC Vaccine,All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01973322
NCT02936388,Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis,Unknown status,No Results Available,Procedure: SIRT|Procedure: DSM-TACE,All,"18 Years to 99 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02936388
NCT01164891,A Pharmacokinetic and Metabolism Study of 14C-labeled RO5185426 on Patients With Metastatic Melanoma,Completed,Has Results,Drug: RO5185426,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01164891
NCT01005745,Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma,"Active, not recruiting",Has Results,Procedure: Surgery|Drug: Administration of Lymphodepletion|Other: Adoptive Cell Transfer|Drug: High Dose IL-2,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01005745
NCT02366195,Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma,"Active, not recruiting",Has Results,Drug: Talimogene Laherparepvec,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02366195
NCT01328535,Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery,"Active, not recruiting",Has Results,Drug: temozolomide|Other: flow cytometry|Other: staining method|Procedure: biopsy|Other: laboratory biomarker analysis,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01328535
NCT00199901,"Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma",Completed,No Results Available,Biological: NY-ESO-1 ISCOMATRIX®|Biological: ISCOMATRIX® adjuvant,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00199901
NCT00124124,Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma Vaccine,Completed,No Results Available,"Drug: KLH; Peptides; Dendritic Cells|Drug: KLH, peptides plus Montanide",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00124124
NCT01069627,A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma,Completed,Has Results,Drug: bevacizumab [Avastin]|Drug: fotemustine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01069627
NCT01810016,NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma,Terminated,Has Results,Biological: Ipilimumab|Biological: NY-ESO-1 Protein Vaccine|Biological: NY-ESO-1 OLP4 Vaccine with Poly-ICLC and Montanide|Biological: NY-ESO-1 OLP4 Vaccine with Poly-ICLC,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01810016
NCT00395070,A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma,Completed,No Results Available,Biological: Allovectin-7®|Drug: Dacarbazine (DTIC)|Drug: Temozolomide (TMZ),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00395070
NCT00492297,"A Phase II, Multi-Center, Open-Label, Uncontrolled Study to Evaluate the Efficacy and Safety of Sorafenib Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic Melanoma",Completed,Has Results,"Drug: Sorafenib (Nexavar, BAY43-9006) + Dacarbazine (DTIC)",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00492297
NCT01989572,Sargramostim and/or Vaccine Therapy in Preventing Disease Recurrence in Patients With Advanced Melanoma,Completed,Has Results,Biological: sargramostim|Biological: peptide vaccine|Other: GM-CSF placebo|Other: peptide placebo,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01989572
NCT00949702,A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma,Completed,Has Results,Drug: vemurafenib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00949702
NCT00084214,STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma,Completed,No Results Available,Drug: STA-4783|Drug: Paclitaxel,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00084214
NCT01705392,Bevacizumab vs Dacarbazine in Metastatic Melanoma,Terminated,No Results Available,Drug: Bevacizumab|Drug: Propranolol|Drug: Enalapril|Drug: Dacarbazine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01705392
NCT01107418,A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma,Completed,Has Results,Drug: RO5185426,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01107418
NCT00631618,Clinical Trial of Sutent to Treat Metastatic Melanoma,Completed,No Results Available,Drug: Sutent (sunitinib),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00631618
NCT02849145,Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0),"Active, not recruiting",No Results Available,Biological: Blood sampling,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02849145
NCT02223819,Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy,"Active, not recruiting",No Results Available,Drug: Crizotinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02223819
NCT00920907,Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma,Completed,Has Results,Biological: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00920907
NCT01763164,Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma,"Active, not recruiting",No Results Available,Drug: MEK162|Drug: Dacarbazine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01763164
NCT02857569,A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma,Recruiting,No Results Available,Drug: Ipilimumab IT|Drug: Ipilimumab IV|Drug: Nivolumab IV,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02857569
NCT01271803,A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma,Completed,Has Results,Drug: Cobimetinib|Drug: vemurafenib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01271803
NCT00765921,Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma,Completed,No Results Available,Drug: ranibizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00765921
NCT00111007,A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma,Completed,Has Results,"Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Carboplatin/Paclitaxel|Drug: Placebo",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00111007
NCT02854657,Teaching Skin Self -Examination to Melanoma Patients and Their Skin Check Partners,"Active, not recruiting",No Results Available,Behavioral: Skin Self- examination structured training,All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02854657
NCT00093119,Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma,Completed,No Results Available,Drug: ABI-007,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00093119
NCT03518814,Quality of Life in Patients With Multimetastatic Melanoma Currently in Remission (QUALM),Completed,No Results Available,Other: Questionnaires,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03518814
NCT03313206,Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma,Recruiting,No Results Available,Drug: Pembrolizumab|Procedure: Surgery|Radiation: IMRT,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03313206
NCT02073123,Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma,"Active, not recruiting",No Results Available,Drug: Indoximod|Drug: Ipilimumab|Drug: Nivolumab|Drug: Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02073123
NCT00272415,"A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With Melanoma",Terminated,No Results Available,Drug: INO-1001|Drug: temozolomide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00272415
NCT01551459,A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma,Unknown status,No Results Available,Drug: Dacarbazine|Drug: Sunitinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01551459
NCT01519323,BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations,Terminated,Has Results,Drug: vemurafenib,All,12 Years to 17 Years   (Child),https://ClinicalTrials.gov/show/NCT01519323
NCT03553329,Study of the Variations of Albumin Level for Patients With Unresecable Stage IIIc or Stage IV Melanoma Treated by Anti BRAF and Anti MEK,Completed,No Results Available,Drug: dabrafenib,All,"18 Years to 100 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03553329
NCT00068172,Study of PI-88 in Patients With Advanced Melanoma,Completed,No Results Available,Drug: PI-88,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00068172
NCT01264380,A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma,Completed,Has Results,Drug: RO5185426,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01264380
NCT01001299,A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma,Completed,Has Results,Drug: Drug cocktail|Drug: RO5185426,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01001299
NCT00020358,Vaccine Therapy in Treating Patients With Melanoma,Completed,No Results Available,Biological: aldesleukin|Biological: gp100 antigen|Biological: incomplete Freund's adjuvant|Biological: tyrosinase peptide,All,"16 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00020358
NCT00910650,Study of Gene Modified Immune Cells in Patients With Advanced Melanoma,Recruiting,No Results Available,Biological: F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells|Drug: non-myeloablative conditioning chemotherapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00910650
NCT01311466,Liver Transplantation and Uveal Malignant Melanoma,Completed,No Results Available,Procedure: Liver transplantation,All,"18 Years to 65 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01311466
NCT03007823,High-activity Natural Killer Immunotherapy for Small Metastases of Melanoma,Recruiting,No Results Available,Biological: High-activity natural killer,All,30 Years to 60 Years   (Adult),https://ClinicalTrials.gov/show/NCT03007823
NCT01024231,Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma,"Active, not recruiting",No Results Available,Drug: BMS-936558 (MDX1106-04)|Drug: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01024231
NCT02570308,A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma,Recruiting,No Results Available,Drug: IMCgp100,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02570308
NCT00002973,Melphalan and Whole-Body Hyperthermia in Treating Patients With Advanced Melanoma,Completed,No Results Available,Drug: melphalan|Procedure: hyperthermia treatment,All,"16 Years to 120 Years   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00002973
NCT01339663,Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma,Completed,No Results Available,Drug: cyclophosphamide|Biological: aldesleukin|Biological: autologous tumor cell vaccine|Other: laboratory biomarker analysis|Other: immunologic technique|Other: immunohistochemistry staining method|Genetic: polymerase chain reaction|Biological: therapeutic autologous lymphocytes,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01339663
NCT02537600,Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis,"Active, not recruiting",No Results Available,Drug: Cobimetinib + Vemurafenib combination treatment,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02537600
NCT01103635,"Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma","Active, not recruiting",No Results Available,"Biological: CD40 agonist monoclonal antibody CP-870,893|Biological: tremelimumab|Other: laboratory biomarker analysis",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01103635
NCT00729950,Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma,Completed,No Results Available,Biological: MDX-010,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00729950
NCT00273910,Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma,Completed,Has Results,Drug: gp100:209-217 (210M)|Drug: Montanide ISA-51|Drug: Imiquimod,All,"7 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00273910
NCT03625141,A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases,Not yet recruiting,No Results Available,Drug: Cobimetinib|Drug: Atezolizumab|Drug: Vemurafenib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03625141
NCT00734188,Dose Escalation and Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma,Completed,No Results Available,Drug: PTI-6D2,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00734188
NCT03541148,Evaluation of Oncoxin-Viusid® in Cutaneous Melanoma,Completed,No Results Available,Dietary Supplement: Oncoxin-Viusid,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03541148
NCT01307618,Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma,Terminated,Has Results,Biological: NA17.A2 Peptide Vaccine|Biological: Recombinant MAGE-3.1 Antigen|Biological: Recombinant Interleukin-12|Biological: MART-1 Antigen|Other: Laboratory Biomarker Analysis,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01307618
NCT00179608,Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy,Completed,No Results Available,Drug: CC-5013,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00179608
NCT00871481,Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma,Completed,No Results Available,Biological: ipilimumab|Drug: cyclophosphamide|Procedure: biopsy|Biological: aldesleukin|Other: immunohistochemistry staining method|Genetic: polymerase chain reaction|Other: immunoenzyme technique|Biological: therapeutic cytotoxic T lymphocytes,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00871481
NCT00184067,Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma,Terminated,No Results Available,Biological: Montanide ISA 51,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00184067
NCT01693068,Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma,Completed,Has Results,Drug: Pimasertib|Drug: Dacarbazine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01693068
NCT02200562,Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma,Terminated,No Results Available,Drug: ipilimumab and dabrafenib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02200562
NCT03611868,A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors,Recruiting,No Results Available,Drug: APG-115+Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03611868
NCT02077114,Vaccination With Peptides in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Unresectable Stage III or IV Malignant Melanoma,Completed,No Results Available,Biological: Vaccine consisting of a peptide derived from the protein IDO,All,"18 Years to 80 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02077114
NCT00059800,Boron Neutron Capture Therapy in Treating Patients With Melanoma,Completed,No Results Available,Radiation: boron neutron capture therapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00059800
NCT00085306,Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma,Completed,No Results Available,Biological: recombinant interferon beta,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00085306
NCT01482260,Comparative Microarray Analysis in Primary Cutaneous Malignant Melanoma,Completed,No Results Available,Procedure: Biopsy,All,"1 Year and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01482260
NCT03555032,TITAN With Isolated Limb Perfusion With Melphalan and Tumour Necrosis Factor-α in Patients With Advanced Extremity Tumours Including Metastatic Melanoma,Recruiting,No Results Available,Drug: Talimogene laherparepvec (T-VEC),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03555032
NCT00370136,Sentinel Node With Ultrasound Contrast in Melanoma,Completed,No Results Available,Drug: ultrasound contrast,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00370136
NCT00056134,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma,Completed,No Results Available,Biological: Dendritic cell vaccine plus denileukin difitox,All,"18 Years to 120 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00056134
NCT00498836,"Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma",Completed,No Results Available,Drug: CP-4055|Drug: Sorafenib (Nexavar),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00498836
NCT02656706,BrUOG 324: Adjuvant Nivolumab and Low Dose Ipilimumab for Stage III and Resected Stage IV Melanoma: A Phase II Brown University Oncology Research Group Trial,Recruiting,No Results Available,Drug: Ipilumumab|Drug: Nivolumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02656706
NCT00724841,A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma,Terminated,No Results Available,Drug: Obatoclax Mesylate|Drug: Temozolomide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00724841
NCT01610531,COPARIME: Pilot Study of a Target Detection of Malignant Melanoma,Completed,No Results Available,Other: SAMScore questionnaire,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01610531
NCT00498979,"Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers",Completed,No Results Available,Biological: recombinant interferon alfa-2b|Drug: cisplatin|Drug: sodium stibogluconate|Drug: dacarbazine|Drug: vinblastine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00498979
NCT00616564,Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma,Completed,No Results Available,Drug: GM-CSF,All,"16 Years to 90 Years   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00616564
NCT00911443,"Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melanoma",Completed,Has Results,Biological: Dacarbazine + Interferon alpha + Thymosin-alpha-1 1.6 mg|Biological: Dacarbazine + Interferon alpha + Thymosin-alpha-1 3.2 mg|Biological: Dacarbazine + Interferon alpha + Thymosin-alpha-1 6.4 mg|Biological: Dacarbazine + Thymosin-alpha-1 3.2 mg|Drug: Dacarbazine + Interferon alpha,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00911443
NCT02716077,Early FDG PET in Melanoma,Recruiting,No Results Available,Radiation: FDG PET/CT imaging,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02716077
NCT00116597,Active Specific Intranodal Immunotherapy of Recombinant Vaccinia Virus in Locally Advanced to Metastatic Melanoma,Completed,No Results Available,Genetic: Intranodal immunization with a recombinant vaccinia virus expressing 5 transgenes|Biological: Intranodal booster immunizations with synthetic melanoma associated epitopes,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00116597
NCT00738361,Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery,Completed,Has Results,Drug: nab-paclitaxel,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00738361
NCT01789827,Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy,"Active, not recruiting",No Results Available,Other: Laboratory Biomarker Analysis|Procedure: Radionuclide Imaging|Biological: Technetium Tc 99 Hydrazinonicotinamide-Tricine-linked Interleukin-2,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01789827
NCT00005057,Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma,Completed,No Results Available,Biological: adenovirus RSV-TK|Drug: ganciclovir,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00005057
NCT01127451,Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma,"Active, not recruiting",No Results Available,Drug: Denileukin diftitox,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01127451
NCT03057327,Promoting Early Detection of Melanoma During the Mammography Experience,Completed,No Results Available,Behavioral: Improve awareness of checking moles|Other: Comparator,Female,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03057327
NCT01196416,"Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma",Completed,Has Results,Drug: Cisplatin|Drug: Gamma-Secretase Inhibitor RO4929097|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Temozolomide|Drug: Vinblastine Sulfate,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01196416
NCT01497808,RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA,Unknown status,No Results Available,Drug: Ipilimumab|Radiation: Stereotactic Body Radiation Therapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01497808
NCT00402662,A Study of Everolimus in Combination With Imatinib in Metastatic Melanoma,Terminated,No Results Available,Drug: everolimus|Drug: Imatinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00402662
NCT00651703,Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients,Completed,No Results Available,Biological: CYT004-MelQbG10 + Montanide|Biological: CYT004-MelQbG10 + Montanide + Imiquimod|Biological: CYT004-MelQbG10 + Imiquimod|Biological: CYT004-MelQbG10 intra nodal injection,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00651703
NCT03273153,A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma,Recruiting,No Results Available,Drug: Cobimetinib|Drug: Atezolizumab|Drug: Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03273153
NCT00651157,Viral Therapy in Treating Patients With Metastatic Melanoma,Completed,Has Results,Biological: wild-type reovirus,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00651157
NCT01259934,Nordic Adjuvant IFN Melanoma Trial,Completed,No Results Available,Drug: Interferon-alpha2b - 1 year|Drug: Interferon-alpha2b - 2 years,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01259934
NCT03137511,"Optimizing Access to Care Through New Technologies: a Randomized Study Evaluating the Impact of Telephone Contact and the Sending by the General Practitioner of Suspicious Lesions Melanoma Photographs Taken With a Smartphone, on the Time Limit to the Consultation With a Dermatologist",Recruiting,No Results Available,Other: Taking photographs of suspicious lesions with his smartphone and sending them to the dermatologist,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03137511
NCT01106235,"Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma",Terminated,No Results Available,Biological: therapeutic autologous lymphocytes|Biological: aldesleukin|Drug: cyclophosphamide|Procedure: biopsy,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01106235
NCT00438009,A Safety Study of Two Intratumoural Doses of Coxsackievirus Type A21 in Melanoma Patients (PSX-X03),Completed,No Results Available,Drug: Coxsackievirus A21,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00438009
NCT03088176,Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma,Recruiting,No Results Available,"Drug: Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,Vil|Drug: Talimogene Laherparep 100 Mil Pfu/Ml 1Ml|Drug: Dabrafenib|Drug: Trametinib",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03088176
NCT02874040,Phase II Evaluating Endoresection of the Tumor Scar or Transpupillary Thermotherapy When Endoresection is Not Feasible After Proton Beam Therapy for the Treatment of Large Uveal Melanomas (Endoresection-Laser),Unknown status,No Results Available,Procedure: Endoresection|Procedure: Laser diode,Female,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02874040
NCT00153569,Multiepitope Peptide Vaccination in Melanoma,Unknown status,No Results Available,"Biological: Tyrosinase, MAGE-3, GnTV",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00153569
NCT00399113,Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma,Completed,No Results Available,Drug: 188Re-PTI-6D2,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00399113
NCT00627419,"A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma",Terminated,No Results Available,Drug: IPI-504,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00627419
NCT01395121,A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread,Completed,No Results Available,Drug: nilotinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01395121
NCT02202200,Phase I-II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic Melanoma,Unknown status,No Results Available,Drug: PD- 0332991,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02202200
NCT00042497,Immunotherapy With Autologous Dexosomes for Patients With Stage IV Melanoma,Suspended,No Results Available,Biological: autologous dexosomes loaded with tumor-specific peptides,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00042497
NCT01777776,Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.,Terminated,Has Results,Drug: LEE011|Drug: LGX818,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01777776
NCT01133977,E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma,Completed,Has Results,Drug: Lenvatinib|Drug: Dacarbazine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01133977
NCT01006980,A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3),Completed,Has Results,Drug: Vemurafenib|Drug: Dacarbazine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01006980
NCT00861913,Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery,Completed,Has Results,Other: Laboratory Biomarker Analysis|Drug: Pazopanib Hydrochloride|Other: Pharmacological Study,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00861913
NCT01783938,Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064),"Active, not recruiting",Has Results,Biological: Nivolumab|Biological: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01783938
NCT00050102,Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic Melanoma,Completed,No Results Available,Drug: MDX-010 (CTLA-4),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00050102
NCT02680184,Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy,Recruiting,No Results Available,Drug: CMP-001|Drug: Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02680184
NCT00929019,Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients,Terminated,No Results Available,Biological: autologous dendritic cells electroporated with mRNA,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00929019
NCT00249262,Taxoprexin Treatment for Advanced Skin Melanoma,Completed,No Results Available,Drug: Taxoprexin,All,"13 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00249262
NCT00383292,A Study of Tasisulam in Treating Participants With Malignant Melanoma,Completed,Has Results,Drug: tasisulam,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00383292
NCT01974752,Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT),Completed,Has Results,Drug: 75mg selumetinib|Drug: placebo|Drug: Dacarbazine,All,"18 Years to 130 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01974752
NCT00300612,Vaccine Treatment for Advanced Malignant Melanoma,Completed,No Results Available,Biological: HyperAcute-Melanoma Vaccine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00300612
NCT00244816,Taxoprexin® Treatment for Advanced Eye Melanoma,Completed,No Results Available,Drug: Taxoprexin,All,"13 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00244816
NCT03467516,Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma,Recruiting,No Results Available,Biological: Tumor Infiltrating Lymphocytes (TIL),All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03467516
NCT00584493,Treatment Use Study for Advanced Melanoma.,No longer available,No Results Available,"Drug: CP-675,206",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00584493
NCT00306566,Safety and Immunogenicity of a Melan-A VLP Vaccine in Early Stage Melanoma Patients,Completed,No Results Available,Biological: CYT004-MelQbG10,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00306566
NCT02052193,Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study,Terminated,No Results Available,Drug: Dabrafenib|Drug: Vemurafenib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02052193
NCT00139360,Efficacy of Bevacizumab Monotherapy in Treatment of Metastatic Melanoma,Completed,No Results Available,Drug: Bevacizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00139360
NCT01455103,Phase 1 Biomarker Study of Anti-PDL-1 in Advanced Melanoma,Withdrawn,No Results Available,Biological: BMS-936559 (Anti-PD-L1),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01455103
NCT01844505,Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067),"Active, not recruiting",Has Results,Biological: Nivolumab|Biological: Ipilimumab|Biological: Placebo for Nivolumab|Biological: Placebo for Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01844505
NCT00447356,High-Dose Interferon Alfa in Treating Patients With Stage II or StageIII Melanoma,Withdrawn,No Results Available,Drug: recombinant interferon alfa,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00447356
NCT00553306,Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma,Completed,No Results Available,Biological: therapeutic autologous lymphocytes|Biological: aldesleukin|Drug: cyclophosphamide|Procedure: biopsy|Other: immunohistochemistry staining method|Other: flow cytometry|Genetic: polymerase chain reaction,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00553306
NCT02032810,Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma,"Active, not recruiting",No Results Available,Drug: Panobinostat|Drug: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02032810
NCT01099514,Study of Nilotinib in Metastatic Melanoma With KIT Aberrations,Completed,No Results Available,Drug: Nilotinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01099514
NCT00243529,Peptide-pulsed vs. RNA-transfected Dendritic Cell Vaccines in Melanoma Patients,Completed,No Results Available,Biological: autologous dendritic cell vaccine,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00243529
NCT01883323,Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma,Completed,No Results Available,Drug: Cyclophosphamide|Drug: Fludarabine|Biological: Tumor-Infiltrating Lymphocytes|Biological: Low-Dose Interleukin,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01883323
NCT02133222,Circulating Cell-free DNA in Metastatic Melanoma Patient: Mutational Analyses in Consecutive Measurement Before and After Chemotherapy,Completed,No Results Available,Procedure: blood sample,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02133222
NCT00003339,Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma,Completed,No Results Available,Biological: gp100 antigen|Biological: incomplete Freund's adjuvant|Biological: recombinant interleukin-12|Biological: tyrosinase peptide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00003339
NCT00489944,"Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma",Unknown status,No Results Available,Drug: cisplatin|Drug: sunitinib malate|Drug: tamoxifen citrate|Procedure: adjuvant therapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00489944
NCT01377025,A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma,Unknown status,No Results Available,Drug: Placebo|Drug: Sorafenib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01377025
NCT00961844,Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma,Terminated,No Results Available,"Biological: Dendritic cells - transfected with hTERT-, survivin- and tumor cell derived mRNA + ex vivo T cell expansion and reinfusion|Drug: Temozolomide",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00961844
NCT00204607,Intradermal Vaccination With Stabilized Tumor mRNA - a Clinical Phase I/II Trial in Melanoma Patients,Completed,No Results Available,Biological: mRNA|Drug: GM-CSF s.c.,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00204607
NCT03003676,"A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade",Recruiting,No Results Available,Biological: ONCOS-102|Drug: Cyclophosphamide|Drug: Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03003676
NCT02743819,Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma,Recruiting,No Results Available,Drug: Pembrolizumab and Ipilimumab combination,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02743819
NCT00438984,"Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV Melanoma",Completed,No Results Available,Drug: cyclophosphamide|Biological: therapeutic autologous lymphocytes|Biological: aldesleukin|Other: immunohistochemistry staining method|Procedure: biopsy|Other: laboratory biomarker analysis|Other: immunologic technique|Genetic: polymerase chain reaction,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00438984
NCT01978236,"Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites",Terminated,Has Results,Drug: Dabrafenib 150 mg|Drug: Trametinib 2.0 mg,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01978236
NCT00145041,Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic Dysfunction,Completed,Has Results,Drug: Vincristine Sulfate Liposomes Injection,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00145041
NCT01721746,A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037),"Active, not recruiting",Has Results,Biological: BMS-936558|Drug: Dacarbazine|Drug: Carboplatin|Drug: Paclitaxel,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01721746
NCT01082887,A Study of Immunotherapy With TIL (Tumor Infiltrating Lymphocytes) in Combination With Intra-tumoral Injections of Interferon Gamma-adenovirus (Ad-IFNg) in Patients With Stage IIIc or Stage IV Metastatic Melanoma (AJCC)(Protocol TIL-Ad-INFg),Terminated,No Results Available,Other: TIL-Ad-INFg,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01082887
NCT00204516,Vaccination With Tumor mRNA in Metastatic Melanoma - Fixed Combination Versus Individual Selection of Targeted Antigens,Completed,No Results Available,Biological: mRNA coding for melanoma associated antigens|Drug: GM-CSF,All,"18 Years to 80 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00204516
NCT01252251,RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma,Completed,Has Results,Drug: RAD001 (Everolimus) and Pasireotide (SOM230) LAR,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01252251
NCT02413827,A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma,Terminated,No Results Available,"Drug: Combination of varlilumab and ipilimumab|Drug: Cohort A: varlilumab & ipilimumab; Cohort B: varlilumab, ipilimumab, CDX-1401 & poly-ICLC",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02413827
NCT00256230,Disulfiram in Patients With Metastatic Melanoma,Completed,No Results Available,Drug: Disulfiram (DSF),All,"18 Years to 80 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00256230
NCT00087776,Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma,Completed,No Results Available,Drug: Chemotherapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00087776
NCT00099970,Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy,Completed,No Results Available,Drug: M200 (volociximab) in Combination with Dacarbazine (DTIC),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00099970
NCT03618641,CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease,Recruiting,No Results Available,Drug: CMP-001|Biological: Nivolumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03618641
NCT02613325,fPAM for the in Vivo Depth Measurement of Pigmented Lesions and Melanoma Depth,Completed,No Results Available,Device: Functional photoacoustic microscopy|Procedure: Standard of care surgical excision|Device: Single cell photoacoustic microscopy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02613325
NCT00072189,A Phase II Study of UCN-01 in Metastatic Melanoma,Terminated,Has Results,Drug: 7-hydroxystaurosporine|Other: laboratory biomarker analysis|Other: pharmacological study,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00072189
NCT00243594,Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph Node Dissection,Completed,No Results Available,Biological: Peptide-pulsed dendritic cells,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00243594
NCT02907086,Circulating Tumor Material in Colorectal Cancer and Melanoma,Recruiting,No Results Available,Other: blood collection,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02907086
NCT01840007,Pilot Study Evaluating the Efficacy and Safety of Metformin in Melanoma,Unknown status,No Results Available,Drug: Metformin Group,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01840007
NCT01107665,Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma,"Active, not recruiting",No Results Available,Drug: Pazopanib and Paclitaxel,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01107665
NCT00111696,Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma,Completed,No Results Available,Biological: MEDI-522,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00111696
NCT00255762,"Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery",Completed,No Results Available,Drug: carboplatin|Drug: paclitaxel|Biological: bevacizumab|Other: laboratory biomarker analysis,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00255762
NCT01034787,Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma,Completed,No Results Available,"Drug: CP-675,206",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01034787
NCT01605162,Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma,Terminated,No Results Available,Drug: TMZ|Drug: E7016,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01605162
NCT02816021,Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma,Recruiting,No Results Available,Drug: Azacitidine|Drug: Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02816021
NCT00334776,Vaccine Therapy in Treating Patients With Metastatic Melanoma,Completed,No Results Available,Biological: MART-1 antigen|Biological: gp100:209-217(210M) peptide vaccine|Biological: therapeutic autologous dendritic cells|Biological: tyrosinase peptide,All,"16 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00334776
NCT00066196,Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma,Completed,No Results Available,Biological: MEDI--522|Biological: Integrin + Dacarbazine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00066196
NCT00024011,PS-341 in Treating Patients With Metastatic Malignant Melanoma,Completed,No Results Available,Drug: bortezomib|Other: laboratory biomarker analysis,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00024011
NCT00121680,"A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma",Completed,No Results Available,Drug: E7080,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00121680
NCT02259231,RTA 408 Capsules in Patients With Melanoma - REVEAL,Completed,No Results Available,Drug: Omaveloxolone Capsules (2.5 mg/capsule)|Drug: Ipilimumab (3 mg/kg)|Drug: Nivolumab (240 mg),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02259231
NCT01473004,SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver,"Active, not recruiting",No Results Available,Device: Sir-Spheres®,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01473004
NCT00281957,Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery,Completed,Has Results,Drug: sorafenib tosylate|Drug: tipifarnib|Drug: temsirolimus,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00281957
NCT02363283,Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma,Completed,No Results Available,Drug: Glembatumumab Vedotin|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02363283
NCT03131908,Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss,Recruiting,No Results Available,Drug: GSK2636771|Drug: Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03131908
NCT00733798,A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma,Terminated,No Results Available,Drug: 131I-TM601,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00733798
NCT02039947,Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain,Completed,No Results Available,Drug: Dabrafenib|Drug: Trametinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02039947
NCT02142218,Expanded Access Program With Nivolumab to Treat Melanoma,No longer available,No Results Available,Drug: Nivolumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02142218
NCT00087373,Vaccine Therapy in Treating Patients With Metastatic Melanoma,Terminated,No Results Available,Biological: recombinant fowlpox-TRICOM vaccine|Other: laboratory biomarker analysis,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00087373
NCT00006243,Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma,Completed,No Results Available,Biological: tyrosinase peptide|Biological: MART-1:27-35 peptide vaccine|Biological: gp100 antigen|Biological: incomplete Freund's adjuvant|Biological: sargramostim|Other: laboratory biomarker analysis,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00006243
NCT00303836,Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma,Terminated,No Results Available,Drug: cyclophosphamide|Drug: fludarabine phosphate|Biological: therapeutic autologous lymphocytes|Procedure: in vitro-treated peripheral blood stem cell transplantation|Biological: gp100 antigen|Biological: MART-1 antigen|Biological: incomplete Freund's adjuvant|Biological: filgrastim|Biological: aldesleukin,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00303836
NCT00238329,PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma,Completed,No Results Available,Biological: PEG-interferon alfa-2b|Drug: thalidomide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00238329
NCT03278665,4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy,Recruiting,No Results Available,Drug: 4SC-202 in combination with Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03278665
NCT03724968,Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression,Recruiting,No Results Available,Drug: Nivolumab|Drug: Relatlimab|Drug: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03724968
NCT00094653,"MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma",Completed,Has Results,Drug: MDX-010 (anti-CTLA4) monoclonal antibody|Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00094653
NCT03783325,Assessing Gene-Environment Interactions in Clinical Presentation of Nevi and Melanoma,Recruiting,No Results Available,Behavioral: UV Counseling|Other: UV Photo|Other: Biological Sample,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03783325
NCT01676649,Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma,"Active, not recruiting",No Results Available,Biological: Ipilimumab|Drug: Carboplatin|Drug: Paclitaxel,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01676649
NCT00052156,Vaccine Therapy for Patients With Stage IV Melanoma,Unknown status,No Results Available,Biological: CancerVax vaccine (CANVAXIN),All,"18 Years to 80 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00052156
NCT03161756,Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma,Recruiting,No Results Available,Drug: Denosumab|Drug: Nivolumab|Drug: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03161756
NCT00872391,Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Uveal Melanoma,Recruiting,No Results Available,Radiation: Hypofractionated linear accelerator radiotherapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00872391
NCT00052130,Vaccine Therapy for Patients With Stage III Melanoma,Unknown status,No Results Available,Biological: CancerVax vaccine (CANVAXIN),All,"18 Years to 80 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00052130
NCT00060125,Tipifarnib in Treating Patients With Metastatic Malignant Melanoma,Completed,No Results Available,Drug: tipifarnib|Other: laboratory biomarker analysis,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00060125
NCT02211131,Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma,"Active, not recruiting",No Results Available,Drug: Talimogene Laherparepvec|Procedure: Immediate surgical resection of melanoma lesion(s),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02211131
NCT02889861,IMCgp100-401 Rollover Study,"Active, not recruiting",No Results Available,Drug: IMCgp100,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02889861
NCT00226473,Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma,Unknown status,No Results Available,"Drug: Cisplatin, Vindesine, Dacarbazine (drugs)",All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00226473
NCT01781572,A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma,Completed,No Results Available,Drug: LEE011 and MEK162,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01781572
NCT00398073,"Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma",Completed,Has Results,Biological: mouse gp100 plasmid DNA vaccine|Device: The Dermal PowderMed® devices|Other: intramuscularly (IM injection),All,"1 Year to 120 Years   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00398073
NCT02574533,Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma,Completed,No Results Available,Biological: Vigil|Drug: Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02574533
NCT00036764,BMS-247550 in Treating Patients With Stage IV Melanoma,Completed,No Results Available,Drug: ixabepilone|Other: pharmacogenomic studies|Other: laboratory biomarker analysis,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00036764
NCT00119249,Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery,Completed,No Results Available,Drug: sorafenib tosylate|Other: laboratory biomarker analysis,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00119249
NCT00070642,CPG 7909 Injection in Melanoma,Completed,No Results Available,Drug: CPG 7909 Injection|Drug: dacarbazine|Drug: Chemotherapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00070642
NCT03172299,Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated With Proton Therapy for a Large Choroidal Melanoma,Not yet recruiting,No Results Available,Drug: Aflibercept Injection|Drug: False injection,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03172299
NCT02759536,In-hospital Neutron Irradiator (IHNI)-Based Boron Neutron Capture Therapy (BNCT) in the Treatment of Malignant Melanoma,Unknown status,No Results Available,Radiation: Boronophenylalanine and IHNI-based BNCT,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02759536
NCT01066390,A Study on the Safety and Immunogenicity of Combined Intradermal and Intravenous Administration of an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Previously Treated Unresectable Stage III or IV Melanoma,Completed,No Results Available,Biological: TriMix-DC,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01066390
NCT00006003,SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously Treated,Terminated,No Results Available,Drug: semaxanib|Other: laboratory biomarker analysis,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00006003
NCT02027961,Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone,Completed,No Results Available,Biological: MEDI4736|Drug: Dabrafenib|Drug: Trametinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02027961
NCT03177941,Teaching Skin Self-Examination to First-degree Relatives of Melanoma Patients Using Mobile App Technology,Withdrawn,No Results Available,Other: Eviderma Smart Phone Teledermatology Application (Eviderma),All,"16 Years to 70 Years   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03177941
NCT00005949,Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma,Completed,No Results Available,Biological: aldesleukin|Biological: gp100:209-217(210M) peptide vaccine|Other: laboratory biomarker analysis,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00005949
NCT02223884,A Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Failed First-Line Dacabazine or Temozolomide Contained Therapy,Completed,No Results Available,Drug: docetaxel 35mg/m2|Drug: Carboplatin AUC3,All,"20 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02223884
NCT00813449,Safety Study of Combined Chemotherapy and Endostar to Untreated Patients With Advanced Melanoma,Unknown status,No Results Available,Drug: dacarbazine plus Endostar (Experimental group)|Drug: dacarbazine plus placebo (control group),All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00813449
NCT02142244,Fluorescence Surgery for Sentinel Node Identification in Melanoma,Recruiting,No Results Available,Procedure: Near infra red sentinel node biopsy|Drug: Indocyanine green|Device: Intraoperative Near-Infrared Imaging System,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02142244
NCT01064713,Phase II Study of Tesetaxel in Metastatic Melanoma,Completed,Has Results,Drug: Tesetaxel,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01064713
NCT03200847,Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma,Recruiting,No Results Available,Drug: Pembrolizumab with All-Trans Retinoic Acid,All,"18 Years to 100 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03200847
NCT00082875,Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma,Terminated,No Results Available,Drug: cilengitide|Other: pharmacological study|Other: laboratory biomarker analysis,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00082875
NCT01039844,Study of Weekly LOC-paclitaxel Injection for Melanoma,Terminated,No Results Available,Drug: LOC-paclitaxel,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01039844
NCT01436656,A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma,"Active, not recruiting",No Results Available,Drug: LGX818,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01436656
NCT01979523,Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma,Completed,No Results Available,Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Trametinib|Drug: Uprosertib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01979523
NCT01266967,A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain,Completed,Has Results,Drug: GSK2118436,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01266967
NCT00026143,Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma,Completed,No Results Available,Biological: recombinant interleukin-12|Biological: recombinant interferon alfa|Other: laboratory biomarker analysis,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00026143
NCT02917473,Comparison of Two Strategies for Counseling Skin Examination and Sun Protection in First-degree Relatives of Patients With Melanoma,Recruiting,No Results Available,Behavioral: In-person counseling|Behavioral: Written advice|Behavioral: Medical skin screening,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02917473
NCT00026221,Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma,Completed,Has Results,Biological: Recombinant Interferon Alfa|Biological: Bevacizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00026221
NCT01864759,Phase I Endovenous Administration of Oncolytic Adenovirus ICOVIR-5 in Patients With Advanced or Metastatic Melanoma,Completed,No Results Available,Biological: ICOVIR-5,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01864759
NCT02407171,Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC,Recruiting,No Results Available,Drug: MK-3475|Radiation: Stereotactic Body Radiation Therapy (SBRT),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02407171
NCT00089219,"Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma",Completed,No Results Available,Biological: IFA|Biological: 6MHP|Biological: GM-CSF,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00089219
NCT00089206,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery,Completed,No Results Available,Biological: incomplete Freund's adjuvant|Biological: multi-epitope melanoma peptide vaccine|Biological: sargramostim,All,"12 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00089206
NCT01585194,Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma,"Active, not recruiting",No Results Available,Biological: Ipilimumab|Other: Laboratory Biomarker Analysis|Biological: Nivolumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01585194
NCT02357732,Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib,Withdrawn,No Results Available,Drug: Nivolumab|Drug: Trametinib|Drug: Dabrafenib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02357732
NCT00005841,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma,Terminated,No Results Available,Biological: MART-1 antigen|Biological: gp100 antigen|Biological: incomplete Freund's adjuvant|Biological: progenipoietin|Biological: tyrosinase peptide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00005841
NCT00027742,Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma,Completed,No Results Available,Biological: pegylated interferon alfa|Drug: temozolomide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00027742
NCT00058279,Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma,Completed,No Results Available,Biological: aldesleukin|Biological: ipilimumab,All,"16 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00058279
NCT00003802,Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma,Completed,No Results Available,Drug: pyrazoloacridine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00003802
NCT00072345,"Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma",Completed,No Results Available,Drug: lomustine|Drug: temozolomide|Drug: thalidomide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00072345
NCT02721459,XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma,"Active, not recruiting",No Results Available,Drug: XL888|Drug: Vemurafenib|Drug: Cobimetinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02721459
NCT00005815,Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma,Completed,No Results Available,Drug: temozolomide|Drug: thalidomide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00005815
NCT02913417,"Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases",Recruiting,No Results Available,Device: SIR-Spheres® Yttrium 90|Drug: ipilimumab|Drug: nivolumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02913417
NCT00636168,Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma,"Active, not recruiting",Has Results,Drug: ipilimumab|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00636168
NCT02130466,A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022),Recruiting,No Results Available,Biological: Pembrolizumab|Drug: Dabrafenib|Drug: Trametinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02130466
NCT00924001,Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma,Terminated,Has Results,Drug: DMF5 Melanoma Reactive TIL|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Aldesleukin,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00924001
NCT00084656,Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma,Completed,No Results Available,Biological: ipilimumab|Biological: Tyrosinase/gp100/MART-1 Peptides,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00084656
NCT02581930,Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma,"Active, not recruiting",No Results Available,Drug: Ibrutinib|Other: Laboratory Biomarker Analysis|Other: Pharmacogenomic Study|Other: Pharmacological Study,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02581930
NCT00094107,Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma,Completed,Has Results,Drug: Axitinib [AG-013736],All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00094107
NCT02935790,Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab,Completed,No Results Available,Drug: ACY-241|Drug: nivolumab|Drug: ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02935790
NCT00672542,Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells,Completed,No Results Available,Biological: Proteasome siRNA and tumor antigen RNA-transfected dendritic cells,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00672542
NCT02652455,"Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma","Active, not recruiting",No Results Available,Drug: Nivolumab|Procedure: Surgery to Remove Tumor for Growth of TIL|Drug: CD137|Drug: Cyclophosphamide|Drug: Fludarabine|Biological: TIL Infusion|Drug: Interleukin-2,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02652455
NCT00073892,PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma,Completed,No Results Available,Drug: PI-88,All,"18 Years to 120 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00073892
NCT00032045,Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma,Completed,No Results Available,Biological: gp100 antigen|Biological: incomplete Freund's adjuvant|Biological: ipilimumab,All,"16 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00032045
NCT01209676,IMCgp100 in Advanced Unresectable Melanoma,Completed,No Results Available,Drug: IMCgp100 injection,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01209676
NCT03728842,Spontaneous Regression in Metastatic Melanoma and Renal Cell Carcinoma,Recruiting,No Results Available,Other: Blood collection for laboratory studies|Other: Data collection from medical record,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03728842
NCT00002882,Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma,Completed,No Results Available,Biological: Aldesleukin (IL-2)|Biological: Recombinant Interferon Alfa (IFN-A)|Drug: Cisplatin|Drug: Dacarbazine|Drug: Vinblastine|Procedure: Adjuvant Therapy,All,"10 Years to 70 Years   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00002882
NCT01003626,Interstitial Fluid Pressure (IFP) Pilot Study in Melanoma Patients,Withdrawn,No Results Available,Procedure: Tumor Interstitial Fluid Pressure (IFP) assessments|Device: Transducer-catheter SPC-320 + Amplifier,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01003626
NCT00235482,Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma (PXS-X02),Completed,No Results Available,Drug: Coxsackievirus A21,All,"21 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00235482
NCT00091689,Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin Lesions,Completed,No Results Available,Drug: 852A,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00091689
NCT03325257,Post-ATU Study of Nivolumab,Recruiting,No Results Available,Other: Routine care,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03325257
NCT00031733,Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma,Completed,No Results Available,Biological: MART-1 antigen|Biological: gp100 antigen|Biological: incomplete Freund's adjuvant|Biological: recombinant interleukin-12|Biological: sargramostim|Biological: tyrosinase peptide|Drug: alum adjuvant|Procedure: adjuvant therapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00031733
NCT03605771,Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain,Recruiting,No Results Available,Other: Daily Clinical Practice,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03605771
NCT03282188,REO13 Melanoma With of Without GM-CSF,Withdrawn,No Results Available,Biological: Reolysin|Drug: GM-CSF,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03282188
NCT01480323,A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2,Completed,No Results Available,Drug: Interleukin-2|Drug: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01480323
NCT03584334,18FDG PET for Early Identification of Tumor Exhaust for Immunotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Bronchopulmonary Carcinoma or Melanoma,Not yet recruiting,No Results Available,Radiation: 18FDG PET,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03584334
NCT01988831,Efficacy of Propranolol Treatment to Prevent Melanoma Progression,Suspended,No Results Available,Drug: Propranolol hydrochloride|Drug: Placebo pill,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01988831
NCT02111863,Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma,Terminated,Has Results,Drug: Aldesleukin|Drug: Fludarabine|Drug: Cyclophosphamide|Biological: 4-1BB Selected Tumor Infiltrating Lymphocytes (TIL),All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02111863
NCT01468818,Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma,Terminated,Has Results,Drug: Cyclophosphamide|Drug: Fludarabine|Biological: Young Tumor Infiltrating Lymphocytes (TIL),All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01468818
NCT02331134,Tissue and Hematopoietic/Mesenchymal Stem Cell for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer,Recruiting,No Results Available,Drug: Filgrastim,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02331134
NCT02631447,Sequential Combo Immuno and Target Therapy (SECOMBIT) Study,Recruiting,No Results Available,Drug: LGX818|Drug: MEK162|Drug: Nivolumab|Drug: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02631447
NCT00416988,Educational Program in Skin Self-Examination To Detect Melanoma in Healthy Participants,Completed,No Results Available,Other: educational intervention,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00416988
NCT00004016,Interferon Gamma in Treating Patients With Recurrent or Metastatic Melanoma or Other Solid Tumors,Completed,No Results Available,Biological: recombinant interferon gamma,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00004016
NCT02094391,"Trial of Ipilimumab After Isolated Limb Perfusion, in Patients With Metastases Melanoma",Completed,No Results Available,Drug: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02094391
NCT03769155,VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma,Recruiting,No Results Available,Biological: Ipilimumab|Biological: Nivolumab|Biological: VX15/2503|Procedure: Surgery,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03769155
NCT01239134,Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors,Recruiting,No Results Available,Biological: TRX518,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01239134
NCT02902042,"Open Label, Multicentre Study of Encorafenib + Binimetinib + PD (Programmed Cell Death Protein) -1 Antibody Pembrolizumab",Recruiting,No Results Available,Drug: Encorafenib|Drug: Binimetinib|Drug: Pembrolizumab|Drug: Pembrolizumab alone,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02902042
NCT01106040,Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes,Completed,Has Results,Drug: Lymphoseek,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01106040
NCT00621439,Investigative Trial of Interferon Alpha-2b To Shrink Cancer of the Eye,Withdrawn,No Results Available,Drug: Pegylated Interfon Alpha 2B|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00621439
NCT01665183,Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma,Completed,No Results Available,Drug: ADI-PEG 20,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01665183
NCT00568451,Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma,Terminated,Has Results,Drug: carboplatin|Drug: paclitaxel|Drug: temozolomide,All,"18 Years to 120 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00568451
NCT01489423,Tissue and Blood Biomarkers From Patients With Stage III or Stage IV Melanoma Treated With Ipilimumab With or Without Sargramostim,Completed,No Results Available,Genetic: RNA analysis|Genetic: in situ hybridization|Genetic: polymerase chain reaction|Other: enzyme-linked immunosorbent assay|Other: flow cytometry|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis,All,"18 Years to 120 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01489423
NCT03638492,Trial of Surgical Excision Margins in Thick Primary Melanoma - 2,Completed,No Results Available,Procedure: 2-cm margin|Procedure: 4-cm margin,All,"up to 75 Years   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03638492
NCT01950390,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,"Active, not recruiting",No Results Available,Biological: Bevacizumab|Biological: Ipilimumab|Other: Laboratory Biomarker Analysis,All,"18 Years and older   (Adult, Older Adult)",
NCT02230306,Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases,Terminated,Has Results,Drug: Cobimetinib|Drug: Vemurafenib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02230306
NCT01316692,Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma,Terminated,Has Results,Other: laboratory biomarker identification and analysis|Procedure: biopsy|Other: immunohistochemistry/tissue microarrays|Genetic: TdT-mediated dUTP nick end labeling assay|Other: mass spectrometry,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01316692
NCT01191294,Evaluation of a Simulation Training Tool to Identify Lesions Requiring Further Screening for Melanoma,Completed,No Results Available,Other: Simulation teaching session,All,"18 Years to 89 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01191294
NCT00923195,"Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma",Completed,Has Results,Drug: MART-1: 26-35(27L) Peptide|Drug: Montanide ISA 51 VG|Drug: gp100:154-162 Peptide|Procedure: Radiation|Drug: Aldesleukin|Drug: Fludarabine|Drug: Cyclophosphamide|Genetic: Anti-gp 100:154 TCR PBL|Genetic: Anti-MART-1 F5 TCR PBL,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00923195
NCT00506142,Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma,Completed,No Results Available,Drug: Marqibo® (vincristine sulfate liposomes injection),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00506142
NCT01026324,Dinaciclib in Treating Patients With Stage III-IV Melanoma,Terminated,Has Results,Drug: dinaciclib|Other: pharmacological study|Other: laboratory biomarker analysis,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01026324
NCT00597272,"Determine Toxicity and Antibody Responses With a KLH Conjugated Bivalent Vaccine Containing GD2 Lactone, GD3 Lactone With Immunological Adjuvant QS-DG or OPT-821 in Patients With Disease Free AJCC Stage III or IV Cutaneous Melanoma",Completed,Has Results,Biological: KLH conjugates with GD2L and GD3L,All,"21 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00597272
NCT00125749,Vaccination of Patients With Stage IV Melanoma With Dendritic Cells,Completed,No Results Available,Biological: Dendritic cell vaccination,All,"21 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00125749
NCT03329846,"An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma","Active, not recruiting",No Results Available,Drug: BMS-986205|Biological: Nivolumab|Drug: Placebo,All,"12 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03329846
NCT01356771,Melanoma Risk Assessment & Tailored Intervention,Completed,No Results Available,Other: Surveys & Mailed Materials,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01356771
NCT00796991,"Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine",Completed,Has Results,Drug: Ipilimumab|Drug: Carboplatin|Drug: Paclitaxel|Drug: Dacarbazine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00796991
NCT00788775,"Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma",Completed,Has Results,Drug: Nilotinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00788775
NCT00453050,Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the Skin,Completed,No Results Available,Drug: imiquimod|Drug: indocyanine green solution|Other: flow cytometry|Other: immunologic technique|Other: laboratory biomarker analysis,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00453050
NCT00698100,"Vaccination of AJCC Stage IIB, IIC, III and IV Melanoma Patients With Human and Mouse Tyrosinase DNA Vaccines",Completed,No Results Available,Biological: human tyrosinase|Biological: mouse tyrosinase,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00698100
NCT00295958,LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery,Completed,No Results Available,Biological: LMB-2 immunotoxin|Biological: MART-1 antigen|Biological: gp100 antigen|Biological: incomplete Freund's adjuvant,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00295958
NCT00866177,MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma,Completed,Has Results,Other: Laboratory Biomarker Analysis|Drug: Selumetinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00866177
NCT00003789,Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg,Completed,No Results Available,Drug: isolated limb perfusion|Drug: melphalan|Biological: recombinant tumor necrosis factor family protein|Other: pharmacological study|Other: laboratory biomarker analysis,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00003789
NCT03715205,Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593),Not yet recruiting,No Results Available,Drug: Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03715205
NCT00707161,Radiation Therapy and Concurrent Cisplatin Chemotherapy for Locally Advanced or Metastatic Malignant Melanoma,Terminated,Has Results,Radiation: Radiation Therapy|Drug: Cisplatin|Procedure: Surgical resection,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00707161
NCT00897520,Biomarkers in Patients With High-Risk Melanoma Receiving High-Dose Interferon Therapy,Completed,No Results Available,Biological: recombinant interferon alfa|Genetic: proteomic profiling|Other: immunoenzyme technique|Other: laboratory biomarker analysis,All,"up to 120 Years   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00897520
NCT03175432,Study of BEvacizumab in Combination With ATezolizumab in Patients With Untreated Melanoma Brain Metastases,Recruiting,No Results Available,Behavioral: Neurocognitive Exam|Behavioral: Questionnaires|Drug: Bevacizumab|Drug: Atezolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03175432
NCT01216787,"RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery",Withdrawn,No Results Available,Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097|Other: pharmacological study|Procedure: therapeutic conventional surgery|Other: laboratory biomarker analysis,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01216787
NCT01495572,Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells,Terminated,Has Results,Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Aldesleukin|Drug: MART-1 Reactive CD8+ PBL,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01495572
NCT02062359,T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma,Terminated,Has Results,Biological: Anti-NY ESO-1 T cell receptor (TCR) cluster of differentiation 62L (CD62L)+ cells|Drug: Aldesleukin|Drug: Cyclophosphamide|Drug: Fludarabine,All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02062359
NCT00945269,"Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma",Terminated,No Results Available,Biological: therapeutic autologous lymphocytes|Biological: aldesleukin|Biological: denileukin diftitox|Procedure: biopsy|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Genetic: polymerase chain reaction,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00945269
NCT01425008,Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Patients With Metastatic Melanoma,Completed,No Results Available,Drug: MLN2480,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01425008
NCT00671918,Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma,Completed,Has Results,Drug: Lymphoseek,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00671918
NCT02145910,Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases,Withdrawn,No Results Available,Drug: Vemurafenib|Radiation: Whole-brain radiation therapy (WBRT)|Radiation: Radiosurgery (SRS),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02145910
NCT03235245,Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib,Recruiting,No Results Available,Drug: Nivolumab + Ipilimumab|Drug: Encorafenib + Binimetinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03235245
NCT00833807,Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver,Completed,No Results Available,Drug: Nab-Paclitaxel (Abraxane),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00833807
NCT03408587,CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER),"Active, not recruiting",No Results Available,Biological: CVA21|Biological: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03408587
NCT00391300,Bioelectric Field Imaging in Diagnosing Melanoma and Other Skin Cancers in Patients With Skin Lesions,Unknown status,No Results Available,Procedure: bioelectric field imaging|Procedure: biopsy|Procedure: histopathologic examination,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00391300
NCT01236573,Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes,Terminated,Has Results,Drug: Fludarabine|Drug: Cyclophosphamide|Biological: IL-12 transduced TIL,All,"18 Years to 66 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01236573
NCT00005610,Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung,Completed,No Results Available,Biological: sargramostim,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00005610
NCT01369875,Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma,Completed,Has Results,Drug: Cyclophosphamide|Drug: Fludarabine|Biological: Aldesleukin|Biological: Tumor Infiltrating Lymphocytes,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01369875
NCT01703507,Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma,"Active, not recruiting",No Results Available,Drug: Ipilimumab|Radiation: Whole-Brain Radiation Therapy (WBRT)|Radiation: Stereotactic Radiosurgery (SRS),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01703507
NCT00496223,A Phase I/II Study of Sunitinib and Dacarbazine,Terminated,No Results Available,Drug: Sunitinib|Drug: Dacarbazine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00496223
NCT01369888,Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma,Terminated,Has Results,Drug: Cyclophosphamide|Drug: Fludarabine|Biological: Tumor Infiltrating Lymphocytes|Drug: IL-15,All,"18 Years to 66 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01369888
NCT02442466,Proof of Concept Study With an Endothelin Receptor B Inhibitor (BQ-788) for Human Melanoma,Terminated,No Results Available,Drug: Endothelin Receptor B inhibitor BQ788|Drug: PBS,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02442466
NCT00062491,Study of Karenitecin (BNP1350) to Treat Malignant Melanoma,Completed,No Results Available,Drug: Karenitecin (BNP1350),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00062491
NCT00424515,Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma,Completed,Has Results,Drug: Imatinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00424515
NCT00017121,Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung,Completed,No Results Available,Biological: sargramostim,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00017121
NCT01785316,The Scandinavian Randomized Controlled Trial of Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases,Recruiting,No Results Available,Procedure: IHP,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01785316
NCT00057616,Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.,Completed,No Results Available,Drug: CC-5013,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00057616
NCT00386906,Sentinel Lymph Node (SLN) Biopsy for Conjunctival/Eyelid Melanoma,"Active, not recruiting",No Results Available,Procedure: Sentinel Lymph Node Mapping and Biopsy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00386906
NCT02382549,A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib,Recruiting,No Results Available,Drug: dabrafenib|Biological: 6MHP|Drug: Trametinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02382549
NCT01149343,Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer,Completed,Has Results,"Biological: Immunotherapeutic GSK2302025A, different formulations",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01149343
NCT01021059,A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer,Completed,No Results Available,Biological: rh IL-15,All,"18 Years to 85 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01021059
NCT00068666,Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System,Terminated,No Results Available,Drug: temozolomide|Radiation: radiation therapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00068666
NCT00527657,"Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients",Completed,No Results Available,Drug: Lomustine|Drug: Temozolomide|Drug: Thalidomide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00527657
NCT01960829,Everolimus in Selected Patients With Metastatic Melanoma: Efficacy and Safety Study,Unknown status,No Results Available,Drug: Everolimus,All,"18 Years to 80 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01960829
NCT02509598,"A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping",Recruiting,No Results Available,Drug: Tc99m tilmanocept|Drug: Vital Blue Dye (optional),All,up to 17 Years   (Child),https://ClinicalTrials.gov/show/NCT02509598
NCT00110994,Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma,Completed,Has Results,"Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Placebo|Drug: Dacarbazine",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00110994
NCT00509288,Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes,Completed,Has Results,Biological: autologous anti-MART-1 F5 T-cell receptor|Drug: Cyclophosphamide|Drug: Fludarabine|Biological: Aldesleukin|Biological: autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00509288
NCT02452294,Buparlisib in Melanoma Patients Suffering From Brain Metastases (BUMPER),Recruiting,No Results Available,Drug: Buparlisib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02452294
NCT01338389,Influence of Oral Treatment With Citicoline for the Prevention of Radiation Optic Neuropathy in Patients Treated for Uveal Melanomas With Proton Beam Therapy,"Active, not recruiting",No Results Available,Dietary Supplement: CITICOLINE|Dietary Supplement: PLACEBO,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01338389
NCT00470379,"Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery",Completed,No Results Available,Drug: resiquimod,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00470379
NCT02553642,Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260),Recruiting,No Results Available,Drug: Nivolumab|Drug: Nivolumab plus Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02553642
NCT03332589,E6201 for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS),Recruiting,No Results Available,Drug: E6201,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03332589
NCT00055562,Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma,Completed,No Results Available,Drug: CC 5013,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00055562
NCT01603212,"Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor",Completed,No Results Available,Drug: Vemurafenib|Drug: IL-2|Drug: Interferon Alpha-2b,All,"18 Years to 65 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01603212
NCT01585415,Vemurafenib and White Blood Cell Therapy for Advanced Melanoma,Terminated,No Results Available,Drug: Vemurafenib|Biological: Young TIL|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Aldesleukin,All,"18 Years to 66 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01585415
NCT03086174,Tolerability and Pharmacokinetics of JS001 in Combination With Axitinib in Patients With Kidney Cancer and Melanoma,Recruiting,No Results Available,Biological: humanized anti-PD-1 monoclonal antibody,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03086174
NCT01826448,"A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma",Terminated,No Results Available,Drug: PLX3397|Drug: vemurafenib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01826448
NCT00020839,Temozolomide With or Without Radiation Therapy to the Brain in Treating Patients With Stage IV Melanoma That Is Metastatic to the Brain,Terminated,No Results Available,Drug: temozolomide|Radiation: radiation therapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00020839
NCT03514901,To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.,Not yet recruiting,No Results Available,Other: Experimental combination beyond Focal Progression|Drug: Pembrolizumab or Nivolumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03514901
NCT02314143,Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib,Completed,No Results Available,Drug: Dabrafenib|Drug: Trametinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02314143
NCT00509496,Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes,Terminated,Has Results,Drug: fludarabine phosphate|Drug: cyclophosphamide|Biological: aldesleukin|Biological: autologous anti-gp 100:154-162 T-cell receptor gene-engineered tumor infiltrating lymphocytes|Biological: autologous anti-gp 100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00509496
NCT03808441,CAcTUS - Circulating Tumour DNA Guided Switch,Not yet recruiting,No Results Available,Other: ctDNA analysis,All,"16 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03808441
NCT02306512,Mohs and Immunofluorescence for Malignant Melanoma In Situ,Withdrawn,No Results Available,Procedure: H&E|Procedure: IHC MART-1|Procedure: IF MART-1|Procedure: IF cocktail,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02306512
NCT01136967,"An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma",Completed,Has Results,Drug: Lenvatinib,All,"18 Years to 99 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01136967
NCT02027935,Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4,"Active, not recruiting",No Results Available,Drug: Cyclophosphamide|Procedure: CD8+ T Cells|Drug: Interleukin-2|Drug: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02027935
NCT00387751,Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma,Completed,Has Results,Biological: Bevacizumab|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Sorafenib Tosylate,All,"18 Years to 120 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00387751
NCT00087386,Tanespimycin in Treating Patients With Stage III-IV Melanoma,Terminated,No Results Available,Drug: tanespimycin|Other: laboratory biomarker analysis,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00087386
NCT00601861,Effect of rIL-21 on Metastases in Lymph Nodes in Melanoma Skin Cancer,Terminated,No Results Available,Drug: recombinant interleukin-21,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00601861
NCT03538314,Phase I of UV1 Vaccine With Pembrolizumab,Recruiting,No Results Available,Drug: UV1/GM-CSF,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03538314
NCT00668512,Intratumoral Injection Of Alpha-Gal Glycosphingolipids,Completed,No Results Available,Biological: Antimelanoma injection of GSL alpha-Gal,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00668512
NCT03165409,Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread,Completed,No Results Available,Biological: Nivolumab|Biological: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03165409
NCT02974725,A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma,Recruiting,No Results Available,Drug: LXH254|Drug: LTT462|Drug: Trametinib|Drug: Ribociclib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02974725
NCT00287196,Immediate Radiotherapy or Observation After Surgery for Melanoma Involving Lymph Nodes,Completed,No Results Available,Radiation: Radiotherapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00287196
NCT00116363,Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma,Unknown status,No Results Available,Genetic: investigational drug INGN 241,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00116363
NCT00039234,Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver,Unknown status,No Results Available,Biological: aldesleukin|Drug: histamine dihydrochloride,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00039234
NCT01319565,Prospective Randomized Study of Cell Therapy for Metastatic Melanoma Using Short-Term Cultured Tumor Infiltrating Lymphocytes Plus IL-2 Following Either a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Alone or in Conjunction w/1200 TBI,"Active, not recruiting",No Results Available,Drug: Aldesleukin|Drug: Cyclophosphamide|Drug: Fludarabine|Biological: Young Tumor Infiltrating Lymphocytes|Radiation: Total Body Irradiation (TBI),All,"18 Years to 66 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01319565
NCT00336986,Efficacy Study of IL-21 to Treat Metastatic Melanoma,Completed,No Results Available,Drug: recombinant interleukin-21,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00336986
NCT02879474,Study of Risk Factors and Clinical Characterization of Rapidly Growing Melanoma,Unknown status,No Results Available,Behavioral: Melanoma scale questionnair,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02879474
NCT00610311,Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma,Terminated,Has Results,Drug: cyclophosphamide|Drug: fludarabine phosphate|Biological: Aldesleukin|Biological: ALVAC gp100 Vaccine|Biological: anti-gp100:154-162 Tcell receptor (TCR) peripheral blood lymphocyte (PBL),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00610311
NCT00135408,A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide,Completed,No Results Available,Drug: Ipilimumab+ Placebo|Drug: Ipilimumab+ Budesonide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00135408
NCT00612222,Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma,Terminated,Has Results,Biological: autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes|Biological: ALVAC MART-1 Vaccine|Biological: aldesleukin|Drug: cyclophosphamide|Drug: fludarabine phosphate,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00612222
NCT00978913,Transfected Dendritic Cell Based Therapy for Patients With Breast Cancer or Malignant Melanoma,Completed,No Results Available,Biological: DC vaccine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00978913
NCT00804908,A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma,Completed,Has Results,Drug: temozolomide|Drug: ABT-888|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00804908
NCT00794235,Monocentric Pilot Study Investigating the Metabolic Activity of Melanoma in Vivo During Sorafenib and Dacarbazine,Completed,No Results Available,"Drug: Sorafenib (Nexavar), Dacarbazine (DTIC)",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00794235
NCT01455259,Phase I/IIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors,Completed,No Results Available,Biological: AdCD40L,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01455259
NCT02379000,TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy,"Active, not recruiting",No Results Available,Drug: Triamcinolone Acetonide|Procedure: Transpupillary thermotherapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02379000
NCT01851408,"Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma",Withdrawn,No Results Available,Drug: sorafenib tosylate|Drug: temsirolimus,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01851408
NCT00747825,Phase I Safety and Dosimetry Study in Patients With Confirmed Metastatic Melanoma,Terminated,No Results Available,Drug: 131-I-MIP-1145,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00747825
NCT00750399,Effect of Intravitreal Ranibizumab on Radiation Retinopathy Following Plaque Brachytherapy for Choroidal Melanoma,Completed,No Results Available,Drug: Ranibizumab|Drug: ranibizumab,All,"21 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00750399
NCT00979693,Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma,Withdrawn,No Results Available,Drug: psilocybin,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00979693
NCT00005615,Post-Operative Adjuvant Radiotherapy With Concurrent Interferon-Alfa,Completed,No Results Available,Biological: Interferon alfa|Radiation: Radiation therapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00005615
NCT01677975,"The Value of Preoperative Dynamic Lymphscintigraphy and Ultrasoundscanning, Eventually With FNA, for Identification of Malignant Sentinel Node(s) in Patients With Melanoma",Unknown status,No Results Available,Procedure: FNA (fine needle aspiration),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01677975
NCT01684241,RBL001/RBL002 Phase I Clinical Trial,Completed,No Results Available,Biological: RBL001/RBL002,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01684241
NCT01266603,"High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI",Completed,No Results Available,Drug: HDIL-2|Biological: recMAGE-A3 + AS15,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01266603
NCT00665470,Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma,Completed,Has Results,Drug: Aldesleukin,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00665470
NCT01666418,Pilot Study Investigating the Metabolic Activity and Transcriptional Profiling in Vivo in Tumor Biopsies in Melanoma Patients During Treatment With Pazopanib Alone and in Combination With Paclitaxel,Completed,No Results Available,Drug: Pazopanib/Paclitaxel,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01666418
NCT00885534,"Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma",Completed,Has Results,"Drug: Cisplatin, Vinblastine, Temozolomide",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00885534
NCT00948480,Vaccine Biotherapy of Cancer: Autologous Tumor Cells and Dendritic Cells,Completed,No Results Available,Biological: Autologous tumor cells plus dendritic cells|Drug: GM-CSF,All,"16 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00948480
NCT02736123,Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone,Withdrawn,No Results Available,Drug: Nivolumab - Arm A|Drug: Nivolumab + Ipilimumab - Arm B,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02736123
NCT01168050,Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.,Unknown status,No Results Available,Drug: Nilotinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01168050
NCT02115139,GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases,Completed,No Results Available,Drug: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02115139
NCT02058953,"CNS and Extracranial Tumor Tissues, CSF, and Blood From Patients With Melanoma Brain Metastases",Recruiting,No Results Available,Procedure: Craniotomy scheduled|Procedure: Collection for non-craniotomy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02058953
NCT01409733,TACE With Drug Eluting Beads Loaded With Doxorubicin in Liver Metastases From Melanoma Patients,Unknown status,No Results Available,Device: TACE using Drug Eluting Beads loaded with Doxorubicin,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01409733
NCT00338130,Randomised Study to Compare the Efficacy of AZD6244 vs TMZ,Completed,No Results Available,Drug: AZD6244|Drug: Temozolomide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00338130
NCT00232726,Clinical Study of Previously Untreated Patients With Malignant Melanoma,Completed,No Results Available,Drug: CP-4055 (ELACYT),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00232726
NCT01587352,Vorinostat in Treating Patients With Metastatic Melanoma of the Eye,Terminated,No Results Available,Other: Laboratory Biomarker Analysis|Drug: Vorinostat,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01587352
NCT01183936,Trial of Surgical Excision Margins in Thick Primary Melanoma,Completed,No Results Available,Procedure: 2-cm margin|Procedure: 4-cm margin,All,"up to 75 Years   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01183936
NCT02035956,IVAC MUTANOME Phase I Clinical Trial,"Active, not recruiting",No Results Available,"Biological: IVAC MUTANOME, RBL001/RBL002",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02035956
NCT03111901,Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer,Recruiting,No Results Available,Drug: Pembrolizumab|Drug: Interleukin-2,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03111901
NCT01205815,Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment,Recruiting,No Results Available,Other: Tissue and blood collection,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01205815
NCT02061007,Biomarker Correlates of Hypoxia in Metastatic Melanoma,Withdrawn,No Results Available,Drug: Pimonidazole hydrochloride (Hypoxyprobe™-1)|Drug: Optional 18F-FMISO PET scan (18F-fluoromisonidazole)|Procedure: Surgical Resection of Melanoma Metastases,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02061007
NCT02574260,An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016),Completed,Has Results,Biological: Talimogene Laherparepvec,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02574260
NCT00304460,Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer,Completed,No Results Available,Biological: aldesleukin,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00304460
NCT03130569,Skin Health Online for Melanoma: Better Risk Assessment,Completed,No Results Available,Behavioral: Web-based Module Group,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03130569
NCT01863108,Safety Study of a Dendritic Cell-based Cancer Vaccine in Melanoma,Completed,No Results Available,Biological: GeniusVac-Mel4,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01863108
NCT02339324,Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b,"Active, not recruiting",No Results Available,Drug: Pembrolizumab and high dose interferon alfa-2b (HDI),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02339324
NCT00275496,Multicenter Selective Lymphadenectomy Trial (MSLT),Completed,No Results Available,Procedure: Sentinel Lymph Node Dissection|Procedure: Complete Lymph Node Dissection|Procedure: Wide Excision,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00275496
NCT02625337,Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients,Recruiting,No Results Available,Drug: Pembrolizumab|Drug: Dabrafenib|Drug: Trametinib|Procedure: Biopsy|Procedure: Blood taking,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02625337
NCT03276832,Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma,Recruiting,No Results Available,Drug: Imiquimod|Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03276832
NCT01563614,"A Clinical Trial to Assess the Safety & Efficacy of the Treatment of Patients With Metastasis From Malignant Melanoma - Treatment Consists of the Substances Lomustine (Capsules) & Cytarabine (Injected Into an Area Near the Spinal Cord), Accompanied by Radiotherapy of the Brain",Terminated,No Results Available,"Radiation: Brain radiotherapy (WBRT alone, SRT/SRS alone or WBRT plus SRT/SRS)|Drug: Lomustine|Drug: Liposomal cytarabine",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01563614
NCT02974803,Concurrent Dabrafenib and Trametinib With Sterotactic Radiation in Patients With BRAF Mutation-Positive Malignant Melanoma and Brain Metastases,Recruiting,No Results Available,Drug: Dabrafenib|Drug: Trametinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02974803
NCT02014441,Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec,Completed,Has Results,Drug: Talimogene laherparepvec,All,"18 Years to 100 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02014441
NCT00798629,Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured,Completed,No Results Available,Biological: Autologous dendritic cell-adenovirus CCL21 vaccine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00798629
NCT02718391,Complementary Vaccination With Dendritic Cells Pulsed With Autologous Tumor Lysate in Resected Stage III and IV Melanoma Patients.,Recruiting,No Results Available,Biological: Autologous Dendritic Cell vaccine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02718391
NCT02385253,Training Primary Care Physicians to Perform Melanoma Opportunistic Surveillance,Completed,No Results Available,Behavioral: Educational training program,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02385253
NCT02591654,MRI and PET to Assess Pembrolizumab Response,Recruiting,No Results Available,Drug: Pembrolizumab|Drug: FLT PET,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02591654
NCT01783431,Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells,Terminated,No Results Available,Drug: Poly ICLC|Procedure: leukapheresis,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01783431
NCT01593579,Autonomic Phenotype Before and After Akt Inhibition,Withdrawn,No Results Available,Behavioral: Autonomic Function Tests|Other: supine and standing catecholamines,All,"18 Years to 80 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01593579
NCT00072163,Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma,Completed,No Results Available,Drug: temozolomide|Drug: thalidomide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00072163
NCT01559818,A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001,"Active, not recruiting",No Results Available,Biological: IMM-101,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01559818
NCT02406183,Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma,Completed,No Results Available,Radiation: Stereotactic body radiotherapy (SBRT)|Drug: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02406183
NCT00543205,"Pharmacokinetics of G3139 in Subjects With Advanced Melanoma, Including Those With Normal Hepatic Function and Those With Moderate Hepatic Impairment",Terminated,No Results Available,"Drug: Genasense® (G3139, oblimersen sodium)",Female,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00543205
NCT02662725,Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain Metastases,Completed,No Results Available,Drug: IPILIMUMAB|Radiation: Stereotactic radiosurgery,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02662725
NCT01400451,Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF),Terminated,Has Results,Drug: Ipilimumab (BMS-734016)|Drug: Vemurafenib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01400451
NCT02296112,Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations,"Active, not recruiting",No Results Available,Drug: trametinib|Other: laboratory biomarker analysis|Other: pharmacological study,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02296112
NCT03526185,A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes,Recruiting,No Results Available,Drug: Tumor Infiltrating Lymphocytes,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03526185
NCT03620019,Denosumab + Pembrolizumab in Patients With Stage IV Melanoma,Recruiting,No Results Available,Drug: Denosumab|Drug: Pembrolizumab,All,"18 Years to 99 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03620019
NCT03728465,Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma,Recruiting,No Results Available,Biological: Nivolumab|Biological: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03728465
NCT01176461,Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558,"Active, not recruiting",No Results Available,Biological: MART-1|Biological: NY-ESO-1|Biological: gp100:209-217(210M)|Biological: gp100:280-288(288V)|Drug: Montanide ISA 51 VG|Biological: BMS-936558,All,"16 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01176461
NCT02097732,Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery,"Active, not recruiting",Has Results,Drug: Ipilimumab|Procedure: Stereotactic Radiosurgery,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02097732
NCT01437605,Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC,"Active, not recruiting",No Results Available,Drug: MAGE-A3 ASCI injections without Poly IC:LC|Drug: MAGE-A3 ASCI injections with Poly IC:LC,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01437605
NCT01728051,Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver,No longer available,No Results Available,Drug: Melphalan|Device: Percutaneous Hepatic Perfusion,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01728051
NCT00966173,International Melanoma Algorithm Training Study - IMATS,Completed,No Results Available,Device: SciBase III Electrical Impedance Spectrometer,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00966173
NCT02158520,Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery,"Active, not recruiting",No Results Available,Biological: Bevacizumab|Biological: Ipilimumab|Other: Laboratory Biomarker Analysis|Drug: Nab-paclitaxel|Other: Pharmacological Study,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02158520
NCT01266096,PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study,"Active, not recruiting",No Results Available,Drug: PET scan with 124I-cRGDY-PEG-dots,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01266096
NCT01744171,Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma,Recruiting,No Results Available,Biological: Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine|Other: Laboratory Biomarker Analysis,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01744171
NCT02812693,Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification,Withdrawn,No Results Available,Drug: Imatinib Mesylate|Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02812693
NCT01160445,Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer,Terminated,Has Results,Drug: Zanolimumab|Drug: Aldesleukin,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01160445
NCT00004250,Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery,Completed,No Results Available,Biological: dactinomycin|Drug: isolated limb perfusion|Drug: melphalan,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00004250
NCT00513604,Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma,Completed,Has Results,Biological: aldesleukin|Biological: therapeutic autologous lymphocytes|Drug: Cyclophosphamide|Drug: Fludarabine phosphate|Radiation: Total body irradiation,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00513604
NCT01321437,Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma,"Active, not recruiting",No Results Available,Procedure: therapeutic conventional surgery|Other: laboratory biomarker analysis|Drug: Axitinib|Other: pharmacological study,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01321437
NCT03773744,Trial of MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma,Not yet recruiting,No Results Available,Drug: Ad-MAGEA3|Drug: MG1-MAGEA3|Drug: Pembrolizumab|Drug: Cyclophosphamide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03773744
NCT01355562,Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer,Withdrawn,No Results Available,Drug: Interleukin-2 (IL-2),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01355562
NCT01884961,Radiotherapy as an Immunological Booster in Patients With Metastatic Melanoma or Renal Cell Carcinoma Treated With High-dose Interleukin-2,Recruiting,No Results Available,Other: Boost of radiotherapy + high dose IL-2 treatment,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01884961
NCT02755233,Ipilimumab-induced Lung Toxicity: Observational Study,Completed,No Results Available,Other: Pulmonary Function,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02755233
NCT02508909,Videoscopic Ilioinguinal Lymphadenectomy for Melanoma,Completed,No Results Available,Procedure: Videoscopic ilioinguinal dissection,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02508909
NCT03340129,Anti-PD 1 Brain Collaboration + Radiotherapy (ABC-X Study),Not yet recruiting,No Results Available,Drug: Ipilimumab|Drug: Nivolumab|Radiation: Stereotactic Radiotherapy|Radiation: Salvage Radiotherapy,All,"18 Years to 120 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03340129
NCT02938299,Neoadjuvant L19IL2/L19TNF- Pivotal Study,Recruiting,No Results Available,Drug: L19IL2 + L19TNF|Procedure: Surgery,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02938299
NCT02981303,Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer,Recruiting,No Results Available,Biological: Imprime PGG|Drug: Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02981303
NCT02771340,Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma,Completed,No Results Available,Biological: ICON-1,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02771340
NCT00095108,Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer,Completed,No Results Available,Drug: Recombinant Human Interleukin-21,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00095108
NCT02700971,RATIO: Rational Approach To Immuno-Oncology,Recruiting,No Results Available,Procedure: Molecular Microscope Diagnostic system,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02700971
NCT01008527,Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100,Completed,No Results Available,"Drug: CP 870,893|Biological: Peptides|Biological: Oncovir poly IC:LC",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01008527
NCT00700167,Immune Responses To Antigen-Bearing Dendritic Cells in Patients With Malignancy,Completed,No Results Available,Biological: dendritic cell vaccine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00700167
NCT01212276,A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma,Terminated,No Results Available,Drug: MORAb-028,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01212276
NCT01826864,Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma,Withdrawn,No Results Available,Biological: sargramostim|Procedure: sentinel lymph node biopsy|Other: laboratory biomarker analysis|Other: hypertonic saline,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01826864
NCT02668887,Employment and Quality of Life in Patients With Malignant Melanoma,"Active, not recruiting",No Results Available,"Behavioral: Quality of Life, status of employment",All,"18 Years to 65 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02668887
NCT02089685,Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29),"Active, not recruiting",No Results Available,Biological: Pembrolizumab|Biological: PegIFN-2b|Biological: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02089685
NCT02296996,Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients,Completed,No Results Available,Drug: Dabrafenib + Trametinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02296996
NCT00779714,Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC,Unknown status,No Results Available,Drug: DTIC (dacarbazine)|Drug: paclitaxel + cisplatin|Drug: treosulfan + cytarabine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00779714
NCT00680589,Patients With Mouse Tyrp2 DNA: A Phase I Trial to Assess Safety and Immune Response,Completed,No Results Available,Biological: injection of mouse TYRP2 DNA,All,"7 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00680589
NCT00414765,Aldesleukin in Patients With Metastatic Renal Cell Carcinoma and Metastatic Melanoma,Completed,No Results Available,Drug: Aldesleukin,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00414765
NCT00482911,"Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma",Terminated,Has Results,Drug: cyclophosphamide|Drug: lenalidomide|Drug: sunitinib malate,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00482911
NCT02236546,FDG-PET in Advanced Melanoma,Terminated,Has Results,Diagnostic Test: [18F]fluorodeoxyglucose|Other: Molecular assays on biopsied tissue|Device: positron emission tomography|Device: computed tomography,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02236546
NCT02065466,"Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases",Withdrawn,No Results Available,Drug: nab-paclitaxel|Drug: Temozolomide|Drug: Bevacizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02065466
NCT00020540,Biological Therapy in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer,Completed,No Results Available,Biological: recombinant CD40-ligand|Biological: recombinant flt3 ligand,All,"16 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00020540
NCT00082914,Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer,Completed,No Results Available,Biological: denileukin diftitox,All,"16 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00082914
NCT02909348,Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab,Recruiting,No Results Available,Drug: Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02909348
NCT00001832,Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma,Completed,Has Results,Drug: gp100:209-217 (210M)|Drug: Montanide ISA-51|Drug: IL-2|Drug: MART-1:26-35(27L)|Biological: Abl cells|Drug: Fludarabine|Drug: Cyclophosphamide|Biological: GCSF (Growth colony stimulating factor)|Procedure: Apheresis,All,"7 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00001832
NCT00492440,Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or Metastatic Kidney Cancer,Terminated,No Results Available,Biological: recombinant interleukin-7|Genetic: gene expression analysis|Genetic: polymerase chain reaction|Genetic: protein expression analysis|Other: flow cytometry|Other: immunoenzyme technique|Other: immunologic technique|Other: laboratory biomarker analysis|Other: pharmacological study,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00492440
NCT00006200,Thalidomide and Dacarbazine for Metastatic Melanoma,Unknown status,No Results Available,Drug: thalidomide|Drug: dacarbazine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00006200
NCT02374242,Anti‐PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases,"Active, not recruiting",No Results Available,Drug: Nivolumab|Drug: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02374242
NCT00003091,High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma,Completed,No Results Available,Biological: aldesleukin|Biological: recombinant interferon alfa,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00003091
NCT01271907,Drosophila-generated CTL,Terminated,Has Results,Drug: fludarabine|Drug: cyclophosphamide|Drug: Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ PBL|Drug: Aldesleukin,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01271907
NCT00705640,Vaccine Therapy in Treating Patients With Advanced Melanoma,Completed,No Results Available,Biological: incomplete Freund's adjuvant|Biological: multi-epitope melanoma peptide vaccine|Biological: tetanus toxoid helper peptide|Procedure: biopsy,All,"18 Years to 120 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00705640
NCT03048253,A Phase I-c Study of Recombinant GM-CSF Herpes Simplex Virus to TreatⅣ M1c,Recruiting,No Results Available,Biological: OrienX010,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03048253
NCT02107755,Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma,"Active, not recruiting",No Results Available,Biological: ipilimumab|Radiation: stereotactic radiosurgery|Other: laboratory biomarker analysis,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02107755
NCT00004244,Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Kidney Cancer or Malignant Melanoma,Completed,No Results Available,Biological: recombinant interferon alfa|Biological: recombinant interleukin-12,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00004244
NCT00004135,Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Metastatic Kidney Cancer,Completed,No Results Available,Biological: filgrastim|Biological: therapeutic allogeneic lymphocytes|Drug: cyclophosphamide|Drug: fludarabine phosphate|Procedure: peripheral blood stem cell transplantation,All,"18 Years to 65 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00004135
NCT02076633,Intratumoral Administration of L19IL2/L19TNF,Completed,No Results Available,Drug: L19IL2+L19TNF,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02076633
NCT01726738,LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations,Completed,No Results Available,Drug: BRAF inhibitor dabrafenib and MEK inhibitor trametinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01726738
NCT00257205,"CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy",Completed,No Results Available,"Drug: dacarbazine|Drug: CP-675,206|Drug: temozolomide",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00257205
NCT00349206,"Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma",Completed,No Results Available,Drug: sorafenib tosylate|Drug: temsirolimus,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00349206
NCT00110123,Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma,Terminated,No Results Available,Drug: fotemustine|Drug: isolated perfusion,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00110123
NCT00276835,Genistein and Interleukin-2 in Treating Patients With Metastatic Melanoma or Kidney Cancer,Completed,No Results Available,Biological: High-dose interleukin-2|Dietary Supplement: genistein,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00276835
NCT00328861,Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer,Completed,Has Results,Drug: Natural Killer (NK) Lymphocytes|Biological: IL-2|Drug: Cyclophosphamide|Drug: Fludarabine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00328861
NCT00264056,Efficacy of Chemotherapy Combined With Regional Hypothermia in Advanced Malignant Melanoma Patients With Progressive Soft Tissue Metastases,Unknown status,No Results Available,Device: hyperthermia,All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00264056
NCT00297895,Multicenter Selective Lymphadenectomy Trial II (MSLT-II),"Active, not recruiting",No Results Available,Procedure: Completion Lymphadenectomy|Procedure: Monitoring with nodal ultrasound,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00297895
NCT00306553,Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients,Completed,No Results Available,Biological: CYT004-MelQbG10,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00306553
NCT01765569,A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma,Completed,Has Results,Drug: Digoxin|Drug: Vemurafenib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01765569
NCT01765556,A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma,Withdrawn,No Results Available,Drug: ketoconazole|Drug: vemurafenib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01765556
NCT00397982,Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma,Completed,Has Results,Biological: Bevacizumab|Other: Laboratory Biomarker Analysis|Drug: Temsirolimus|Procedure: Therapeutic Conventional Surgery,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00397982
NCT02517736,Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination,Completed,No Results Available,Drug: Sorafenib at a dose of 800 mg / day,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02517736
NCT02257424,"The BAMM Trial: BRAF, Autophagy and MEK Inhibition in Metastatic Melanoma: A Phase I/2 Trial of Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma",Recruiting,No Results Available,Drug: Trametinib 2mg daily|Drug: hydroxychloroquine (HCQ),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02257424
NCT00495950,Prospective Measurement of Post-Treatment Lymphedema,Completed,No Results Available,Behavioral: Questionnaire,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00495950
NCT01013623,Stage IV Surgery Versus Best Medical Therapy,Terminated,No Results Available,Procedure: Surgery|Procedure: Surgery plus 2 adjuvant doses of BCG|Other: best medical therapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01013623
NCT00418496,Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma,Completed,No Results Available,Drug: Aldesleukin|Drug: Sorafenib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00418496
NCT00356460,Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma,Completed,No Results Available,Biological: GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|Biological: GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ ) Monoclonal Antibody,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00356460
NCT01701037,Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery,Terminated,Has Results,Drug: dabrafenib|Drug: trametinib|Other: laboratory biomarker analysis,All,"18 Years to 90 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01701037
NCT00597038,A Phase I/II Study of Dasatinib and Dacarbazine,Completed,Has Results,Drug: Dasatinib and Dacarbazine (DTIC),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00597038
NCT00441662,Sub-Tenon Triamcinolone in the Prevention of Radiation-Induced Macular Edema,Completed,No Results Available,Drug: Sub-Tenon triamcinolone 40mg,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00441662
NCT00471471,Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery,Completed,No Results Available,Biological: Peptide vaccine|Biological: GM-CSF|Biological: PF3512676,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00471471
NCT00625768,Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma,Completed,No Results Available,Drug: AS1409,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00625768
NCT00542893,"A Phase I, Randomized, Open-label, Cross-over, Pharmacokinetic Study of Genasense With and Without Dacarbazine",Completed,No Results Available,"Drug: Genasense® (G3139, oblimersen sodium)|Drug: Genasense followed by DTIC; then DTIC alone|Drug: DTIC alone; then Genasense followed by DTIC",Female,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00542893
NCT00588341,Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection,Completed,Has Results,Drug: Temozolomide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00588341
NCT01715077,Study of Ipilimumab in the Immune System,Completed,No Results Available,Drug: Ipilimumab at 3 mg/kg dose,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01715077
NCT00324727,Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma,Completed,No Results Available,Drug: melphalan|Drug: regional chemotherapy|Drug: systemic chemotherapy|Procedure: hepatic artery embolization,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00324727
NCT00003989,"ISIS 3521 in Treating Patients With Advanced, Unresectable, or Metastatic Non-small Cell Lung Cancer or Unresectable or Metastatic Melanoma",Completed,No Results Available,Biological: ISIS 3521,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00003989
NCT02231775,Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation,Recruiting,No Results Available,Drug: Dabrafenib|Other: Laboratory Biomarker Analysis|Procedure: Therapeutic Conventional Surgery|Drug: Trametinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02231775
NCT03543969,Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma,Recruiting,No Results Available,Drug: Vemurafenib|Drug: Cobimetinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03543969
NCT02359851,Pembrolizumab in Treating Patients With Advanced Uveal Melanoma,"Active, not recruiting",Has Results,Biological: Pembrolizumab|Other: Laboratory Biomarker Analysis,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02359851
NCT03396952,Prostaglandin Inhibition and PD-1/CTLA4 Blockade in Melanoma,Recruiting,No Results Available,Drug: Aspirin|Biological: Ipilimumab|Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab,All,"19 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03396952
NCT00279058,The Role of Peptide-loaded Dendritic Cells to Augment the Therapeutic Effect of Interleukin-2,Completed,No Results Available,Procedure: Immunotherapy treatment for melanoma,All,"18 Years to 65 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00279058
NCT00074308,Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers,Completed,Has Results,Drug: imatinib mesylate|Biological: bevacizumab|Other: pharmacological study|Other: laboratory biomarker analysis,All,"21 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00074308
NCT00044356,Phase II Trial of Allovectin-7® for Metastatic Melanoma,Completed,No Results Available,Genetic: Allovectin-7®,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00044356
NCT00811200,Treatment Of Radiation Retinopathy Trial,Unknown status,No Results Available,Drug: ranibizumab|Drug: triamcinolone acetonide|Other: sham,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00811200
NCT02521870,A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma,Recruiting,No Results Available,Drug: SD-101(1)|Biological: Pembrolizumab|Drug: SD-101(2),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02521870
NCT00520299,Study of ADI-PEG 20 in Patients With Advanced Melanoma,Completed,Has Results,Drug: ADI PEG 20,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00520299
NCT02203604,High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery,"Active, not recruiting",No Results Available,Biological: aldesleukin|Biological: ipilimumab|Other: laboratory biomarker analysis,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02203604
NCT02094872,Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic,"Active, not recruiting",No Results Available,Other: cytology specimen collection procedure|Drug: MEK 162 therapy or molecularly targeted therapy|Procedure: therapeutic procedure|Other: laboratory biomarker analysis|Other: quality-of-life assessment,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02094872
NCT01650350,"Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer",Terminated,Has Results,Drug: Naltrexone,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01650350
NCT02425475,FLuorescence Identification of Melanoma by a Multicenter Based Algorithm (FLIMMA),Completed,No Results Available,Device: LIMES,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02425475
NCT02699918,Impact of Obstructive SAS on Metastatic Potential of Cutaneous Melanoma,Withdrawn,No Results Available,Procedure: nocturnal oximetry,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02699918
NCT03325101,Dendritic Cell Therapy After Cryosurgery in Combination With Pembrolizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Remove by Surgery,Recruiting,No Results Available,Procedure: Cryosurgery|Biological: Pembrolizumab|Procedure: Pheresis|Biological: Therapeutic Autologous Dendritic Cells,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03325101
NCT03033576,Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery,Recruiting,No Results Available,Biological: Ipilimumab|Other: Laboratory Biomarker Analysis|Biological: Nivolumab,All,"18 Years and older   (Adult, Older Adult)",
NCT01708941,Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Advanced Melanoma,"Active, not recruiting",Has Results,Biological: Ipilimumab|Biological: Recombinant Interferon Alfa-2b,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01708941
NCT02126579,Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists,Recruiting,No Results Available,Biological: Peptide Vaccine (LPV7) + Tetanus peptide|Other: PolyICLC|Other: Resiquimod|Other: IFA,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02126579
NCT03512457,Skin Self-Examination Education During Mammography,Recruiting,No Results Available,Behavioral: Minimal Intervention|Behavioral: Intensive Intervention,Female,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03512457
NCT00313508,Dendritic Cell Vaccination During Lymphoid Reconstruction,Completed,No Results Available,Biological: Autologous Dendritic Cells (DC)|Drug: Fludarabine|Biological: Autologous Lymphocyte Infusion (ALI),All,"16 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00313508
NCT03329755,Optimization of the Patient Care Pathway in Immuno-oncology,Recruiting,No Results Available,Other: Dedicated and coordinated e-follow-up during the treatment period|Other: Standard follow-up during the treatment period,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03329755
NCT01807182,Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma,"Active, not recruiting",No Results Available,Biological: Aldesleukin|Drug: Cyclophosphamide|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Biological: Therapeutic Tumor Infiltrating Lymphocytes,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01807182
NCT00669019,Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery,Completed,Has Results,Drug: saracatinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00669019
NCT01274338,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,"Active, not recruiting",No Results Available,Biological: Ipilimumab|Other: Quality-of-Life Assessment|Biological: Recombinant Interferon Alfa-2b,All,"12 Years and older   (Child, Adult, Older Adult)",
NCT03068624,"Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Participants With Metastatic Uveal Melanoma",Recruiting,No Results Available,Biological: Aldesleukin|Biological: Autologous CD8+ SLC45A2-specific T Lymphocytes|Drug: Cyclophosphamide|Biological: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03068624
NCT01519427,Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib,Terminated,Has Results,Drug: Akt inhibitor MK2206|Drug: selumetinib|Other: laboratory biomarker analysis,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01519427
NCT00462280,Lovastatin in Treating Patients At High Risk of Melanoma,Completed,Has Results,Drug: lovastatin|Other: placebo|Procedure: biopsy|Procedure: laboratory biomarker analysis,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00462280
NCT00412425,Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting,Completed,Has Results,Drug: Palonosetron,All,"18 Years to 65 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00412425
NCT00436605,Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma,Completed,Has Results,Drug: dasatinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00436605
NCT01328106,"Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma",Withdrawn,No Results Available,Drug: GSK1120212,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01328106
NCT03294330,SPY-X: A Study to Assess the Feasibility of Using SPY Alone for Sentinel Node Localization for Melanoma or Breast Cancer,Enrolling by invitation,No Results Available,Drug: IC-Green KIT,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03294330
NCT02989064,"MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers",Recruiting,No Results Available,Genetic: Autologous genetically modified MAGE A10ᶜ⁷⁹⁶T cells,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02989064
NCT02819843,"A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors",Recruiting,No Results Available,Drug: TALIMOGENE LAHERPAREPVEC (TVEC)|Radiation: Hypofractionated Radiotherapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02819843
NCT01918930,Tissue Procurement Substudy for Participants in Study CP-MGA271-01,Terminated,No Results Available,Biological: MGA271,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01918930
NCT02968303,Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy,Recruiting,No Results Available,Drug: Vemurafenib and Cobimetinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02968303
NCT02110355,A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma,Completed,No Results Available,Drug: AMG 232|Drug: Trametinib|Drug: Dabrafenib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02110355
NCT03021460,Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recruiting,No Results Available,Drug: Ibrutinib|Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03021460
NCT01950195,SRS (Stereotactic Radiosurgery) Plus Ipilimumab,Terminated,No Results Available,Procedure: Stereotactic Radiosurgery (SRS)|Biological: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01950195
NCT03425461,Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma,Recruiting,No Results Available,Biological: Anti-SEMA4D Monoclonal Antibody VX15/2503|Biological: Ipilimumab|Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Other: Pharmacological Study,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03425461
NCT03554083,Neoadjuvant Combination Targeted and Immunotherapy for Patients With High-Risk Stage III Melanoma,Recruiting,No Results Available,Drug: Atezolizumab|Drug: Cobimetinib|Drug: Vemurafenib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03554083
NCT02306850,Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma,Recruiting,No Results Available,Drug: Pembrolizumab,All,"18 Years to 90 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02306850
NCT02846714,Family Lifestyle Actions and Risk Education Study,"Active, not recruiting",No Results Available,Behavioral: FLARE,All,"8 Years to 110 Years   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02846714
NCT02965716,Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma,Recruiting,No Results Available,Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab|Biological: Talimogene Laherparepvec,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02965716
NCT03725449,Internet-based Intervention for Skin Self-Examination in Participants With Increased Risk for Melanoma,Not yet recruiting,No Results Available,Other: Best Practice|Behavioral: mySmartCheck|Other: Survey Administration,All,"18 Years to 89 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03725449
NCT02437227,"A Phase I, First in Man Study to Evaluate the Safety and Tolerability of a panRAF Inhibitor (CCT3833/BAL3833)in Patients With Solid Tumours","Active, not recruiting",No Results Available,Drug: CCT3833,All,"18 Years to 100 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02437227
NCT03430947,Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases,Recruiting,No Results Available,Drug: Vemurafenib|Drug: Cobimetinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03430947
NCT01013844,Partner Assistance in Learning and Performing Skin Self-Examination,Completed,Has Results,Behavioral: Skin Self Examination Information and ABCDE Rule,All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01013844
NCT03060356,Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET),Recruiting,No Results Available,Biological: T cells modified with RNA anti -cMET CAR,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03060356
NCT03677739,Young Melanoma Family Facebook Intervention or Healthy Lifestyle Facebook Intervention in Improving Skin Examination in Participants With Melanoma and Their Families,Not yet recruiting,No Results Available,Other: Informational Intervention|Other: Survey Administration,All,"18 Years to 80 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03677739
NCT02718066,"Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer",Recruiting,No Results Available,Drug: HBI-8000 in combination with nivolumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02718066
NCT00019682,Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma,Completed,Has Results,Biological: Aldesleukin|Biological: gp100 Antigen|Drug: Montanide ISA 51 VG|Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Other: Laboratory Biomarker Analysis,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00019682
NCT03698019,Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery,Recruiting,No Results Available,Biological: Pembrolizumab|Procedure: Therapeutic Conventional Surgery,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03698019
NCT02012751,Nevus Doctor Clinical Decision Support,Completed,No Results Available,Device: Nevus doctor program,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02012751
NCT03627026,Evaluation of Sphingolipids as Predictive Biomarkers of Immune Checkpoint Inhibitors Response,Not yet recruiting,No Results Available,Other: Blood samples will be collected at different time points:,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03627026
NCT02339571,Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Suspended,No Results Available,Biological: Ipilimumab|Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Other: Questionnaire Administration|Biological: Sargramostim,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02339571
NCT00261365,Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010),Completed,No Results Available,Drug: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00261365
NCT03719131,Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy,Not yet recruiting,No Results Available,Drug: Nivolumab|Biological: Rituximab and Hyaluronidase Human|Drug: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03719131
NCT02748564,Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma,Recruiting,No Results Available,Biological: Aldesleukin|Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab,All,"15 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02748564
NCT02857374,Intravital Microscopy in Identifying Tumor Vessels in Patients With Stage IB-IIIC Melanoma Undergoing Sentinel Lymph Node Biopsy,"Active, not recruiting",No Results Available,Procedure: Diagnostic Microscopy|Drug: Fluorescein Sodium Injection|Other: Laboratory Biomarker Analysis|Procedure: Sentinel Lymph Node Biopsy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02857374
NCT01166126,Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV,Terminated,Has Results,Drug: temsirolimus|Drug: selumetinib|Other: laboratory biomarker analysis,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01166126
NCT00512798,Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma,Terminated,Has Results,Drug: PS-341 (VELCADE)|Drug: temozolomide|Other: immunoenzyme technique|Drug: Temozolomide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00512798
NCT00237965,The Use of Mole Mapping Diagrams to Increase Skin Self Examination Accuracy,Completed,No Results Available,Behavioral: Mole Mapping Diagram,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00237965
NCT02738489,A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Melanoma Subjects,Unknown status,No Results Available,Biological: SHR-1210,All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02738489
NCT02316795,Fluorescence Imaging in Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma,Completed,No Results Available,Procedure: Sentinel lymph node biopsy|Device: Goggle-based device with light-emitting diodes (LED)|Drug: Indocynanine Green,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02316795
NCT00462982,Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma,Completed,Has Results,Drug: sunitinib malate,All,"18 Years to 120 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00462982
NCT00710515,Study to Assess the Effect of Dosing AZD6244 HydSulfate in the Presence and Absence of Food in Patients With Advanced Solid Malignancies,Completed,No Results Available,Drug: AZD6244,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00710515
NCT01886235,Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery,"Active, not recruiting",Has Results,Procedure: Diagnostic Microscopy|Drug: Fluorescein Sodium Injection|Other: Laboratory Biomarker Analysis|Procedure: Therapeutic Conventional Surgery,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01886235
NCT02587650,"Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma",Recruiting,No Results Available,Drug: Capmatinib|Drug: Ceritinib|Drug: Entrectinib|Other: Laboratory Biomarker Analysis|Drug: Regorafenib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02587650
NCT02224781,Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma,Recruiting,No Results Available,Drug: Dabrafenib|Biological: Ipilimumab|Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Other: Quality-of-Life Assessment|Drug: Trametinib,All,"18 Years and older   (Adult, Older Adult)",
NCT01748747,Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery,Completed,No Results Available,Drug: Montanide ISA 51 VG|Biological: MART-1 antigen|Other: laboratory biomarker analysis|Biological: Gag:267-274 peptide vaccine|Drug: resiquimod,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01748747
NCT02129075,CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301 in Treating Patients With Stage IIB-IV Melanoma,Suspended,No Results Available,Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Other: Laboratory Biomarker Analysis|Biological: Neoantigen-based Melanoma-Poly-ICLC Vaccine|Other: Pharmacological Study|Biological: Recombinant Flt3 Ligand,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02129075
NCT02320305,MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery,"Active, not recruiting",No Results Available,Biological: MART-1 Antigen|Drug: TLR4 Agonist GLA-SE|Other: Laboratory Biomarker Analysis,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02320305
NCT03673332,"Elderly Cancer PatIents, Safety and qualiTy of Life Under immunOtheraPies",Not yet recruiting,No Results Available,Drug: immune-checkpoint inhibitors therapies,All,70 Years and older   (Older Adult),https://ClinicalTrials.gov/show/NCT03673332
NCT02506153,"High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery","Active, not recruiting",No Results Available,Biological: Ipilimumab|Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab|Other: Pharmacological Study|Other: Quality-of-Life Assessment|Biological: Recombinant Interferon Alfa-2b,All,"18 Years and older   (Adult, Older Adult)",
NCT00288041,"Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma",Completed,No Results Available,Drug: carboplatin|Drug: paclitaxel|Drug: bortezomib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00288041
NCT03685890,Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion,Not yet recruiting,No Results Available,Drug: Nivolumab|Procedure: Isolated limb perfusion (ILP),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03685890
NCT02910700,Nivolumab and Trametinib With or Without Dabrafenib in Treating Patients With BRAF Mutated or Wild Type Metastatic Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recruiting,No Results Available,Drug: Dabrafenib|Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Other: Pharmacological Study|Drug: Trametinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02910700
NCT00470470,Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery,Completed,Has Results,Drug: imatinib mesylate|Other: laboratory biomarker analysis,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00470470
NCT02196181,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,Recruiting,No Results Available,Drug: Dabrafenib|Other: Laboratory Biomarker Analysis|Drug: Trametinib,All,"18 Years and older   (Adult, Older Adult)",
NCT02437136,"Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer","Active, not recruiting",No Results Available,Drug: entinostat|Drug: pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02437136
NCT03699995,"MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma","Active, not recruiting",No Results Available,Other: Confocal Microscopy|Procedure: Imaging Technique|Drug: Lidocaine|Procedure: Punch Biopsy|Procedure: Shave Biopsy,All,"18 Years to 80 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03699995
NCT02760225,Pembrolizumab-PET Imaging,Recruiting,No Results Available,Drug: 89Zr-Pembrolizumab|Device: 89Zr-Pembrolizumab PET,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02760225
NCT01989585,"Dabrafenib, Trametinib, and Navitoclax in Treating Patients With BRAF Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery",Recruiting,No Results Available,Drug: Dabrafenib|Other: Laboratory Biomarker Analysis|Biological: Navitoclax|Other: Pharmacological Study|Drug: Trametinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01989585
NCT02986867,"SAbR Induced Innate Immunity in Urothelial Carcinoma, Melanoma, and Cervical Carcinoma",Completed,No Results Available,Radiation: SAbR Treatment of Lesions,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02986867
NCT01777802,"Immune Responses in Prostate, Lung, Melanoma and Breast Cancer Patients Following Stereotactic Body Radiotherapy (SBRT), Intensity Modulated Radiotherapy (IMRT) or Brachytherapy",Recruiting,No Results Available,Radiation: SBRT|Radiation: IMRT|Radiation: Brachytherapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01777802
NCT01134614,Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery,"Active, not recruiting",Has Results,Biological: Ipilimumab|Other: Laboratory Biomarker Analysis|Biological: Sargramostim,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01134614
NCT01843738,Radiation Use During Vemurafenib Treatment,Withdrawn,No Results Available,Radiation: Radiation therapy|Drug: Vemurafenib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01843738
NCT01940809,"Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery","Active, not recruiting",No Results Available,Drug: Dabrafenib|Biological: Ipilimumab|Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Drug: Trametinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01940809
NCT00329641,"Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye",Completed,Has Results,Drug: carboplatin|Drug: paclitaxel|Drug: sorafenib tosylate,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00329641
NCT02085070,MK-3475 in Melanoma and NSCLC Patients With Brain Metastases,"Active, not recruiting",No Results Available,Drug: MK-3475,All,"18 Years to 99 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02085070
NCT03780608,This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO),Not yet recruiting,No Results Available,Drug: AZD6738|Drug: Durvalumab,All,"19 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03780608
NCT00617799,Biomarkers That Predict Response to High-Dose Aldesleukin in Patients With Metastatic Kidney Cancer or Metastatic Melanoma,Completed,No Results Available,Biological: aldesleukin|Genetic: gene expression analysis|Genetic: mutation analysis|Other: flow cytometry,All,"19 Years to 120 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00617799
NCT00111046,Pain Relief - Tramadol Versus Ibuprofen,Unknown status,No Results Available,Drug: Ibuprofen|Drug: Tramadol,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00111046
NCT01258855,Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Completed,No Results Available,Biological: Aldesleukin|Other: Laboratory Biomarker Analysis|Biological: Ziv-Aflibercept,All,"17 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01258855
NCT02743611,Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma,Recruiting,No Results Available,Biological: BPX-701|Drug: Rimiducid,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02743611
NCT00110019,Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery,Completed,Has Results,Drug: Carboplatin|Other: Laboratory Biomarker Analysis|Drug: Paclitaxel|Other: Pharmacological Study|Other: Placebo|Drug: Sorafenib Tosylate,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00110019
NCT02681549,Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer,Recruiting,No Results Available,Drug: Pembrolizumab plus Bevacizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02681549
NCT01644591,Stereotactic Radiosurgery in Treating Participants With Greater Than 3 Melanoma Brain Metastases,Recruiting,No Results Available,Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Radiation: Stereotactic Radiosurgery,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01644591
NCT00121225,Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma,Completed,Has Results,Drug: vorinostat,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00121225
NCT00083239,Study of Talabostat in Advanced Melanoma,Completed,No Results Available,Drug: talabostat (PT-100) tablets,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00083239
NCT02771626,"Study CB-839 in Combination With Nivolumab in Patients With Melanoma, ccRCC and NSCLC",Recruiting,No Results Available,Drug: CB-839|Drug: Nivolumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02771626
NCT01413191,Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye,Completed,Has Results,Biological: Cixutumumab|Other: Laboratory biomarker analysis,All,"17 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01413191
NCT00217542,Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery,Completed,No Results Available,Biological: recombinant interferon alfa-2b|Drug: amifostine/azacitidine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00217542
NCT01876641,Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib,Terminated,No Results Available,"Drug: Vemurafenib + Cobimetinib, Decitabine",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01876641
NCT00083252,Study of Talabostat and Cisplatin in Advanced Melanoma,Completed,No Results Available,Drug: talabostat (PT-100) tablets|Drug: cisplatin,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00083252
NCT02716948,SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine,Recruiting,No Results Available,Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Radiation: Stereotactic Radiosurgery,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02716948
NCT02621515,Nivo/Ipi Combination Therapy in Symptomatic Brain Metastases,Terminated,No Results Available,Drug: Nivolumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02621515
NCT03502330,"APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma",Recruiting,No Results Available,Drug: APX005M|Drug: Cabiralizumab|Drug: Nivolumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03502330
NCT03297463,Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma,Withdrawn,No Results Available,Drug: Interleukin-2 & Ipilimumab (P-Ib)|Drug: Interleukin-2 & Ipilimumab (P-II),All,"18 Years to 85 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03297463
NCT02977052,Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab,Recruiting,No Results Available,Drug: Ipilimumab|Drug: Nivolumab|Procedure: Surgery|Procedure: Blood for PBMCs|Procedure: Biopsies,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02977052
NCT00221702,PegIntron Versus IntronA in CMAJCC Stage II (EADO 2001/CMII Trial),Completed,No Results Available,Drug: PegIntron|Drug: intron A,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00221702
NCT01118091,Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M...,Completed,Has Results,Biological: Aldesleukin|Biological: CD8 enriched Young TIL,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01118091
NCT00003895,Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma,Completed,Has Results,Biological: HPV 16 E7:12-20|Biological: gp100:209-217(210M)|Other: laboratory biomarker analysis,All,"17 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00003895
NCT00661622,Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF,Completed,Has Results,Drug: GM-CSF|Procedure: Embolization,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00661622
NCT00003601,Tretinoin With or Without Fenretinide in Treating Patients With Dysplastic Nevus Syndrome,Completed,No Results Available,Drug: fenretinide|Drug: tretinoin,All,"18 Years to 120 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00003601
NCT01143402,Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye,Completed,Has Results,Drug: Dacarbazine|Other: Laboratory Biomarker Analysis|Other: Quality-of-Life Assessment|Drug: Selumetinib|Drug: Temozolomide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01143402
NCT02575404,"GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients",Recruiting,No Results Available,Drug: GR-MD-02|Drug: Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02575404
NCT01835145,Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery,Completed,No Results Available,Drug: Cabozantinib S-malate|Drug: Dacarbazine|Other: Laboratory Biomarker Analysis|Drug: Temozolomide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01835145
NCT00089063,Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma,Completed,No Results Available,Biological: tyrosinase peptide|Biological: gp100 antigen|Biological: MART-1 antigen|Biological: incomplete Freund's adjuvant|Drug: Montanide ISA 51 VG|Biological: sargramostim|Other: laboratory biomarker analysis,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00089063
NCT02083354,Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma,"Active, not recruiting",No Results Available,Drug: Dabrafenib|Drug: Trametinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02083354
NCT01925118,Irradiated Donor Lymphocyte Infusion Plus High-dose IL-2,Terminated,No Results Available,Biological: Irradiated donor lymphocyte infusion,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01925118
NCT02336763,Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases,Terminated,Has Results,Radiation: External Beam Radiation Therapy|Other: Laboratory Biomarker Analysis,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02336763
NCT03727789,CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma,Not yet recruiting,No Results Available,Drug: FACT Complex-targeting Curaxin CBL0137,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03727789
NCT02519322,Nivolumab With or Without Ipilimumab or Relatlimab Before Surgery in Treating Patients With Stage IIIB-IV Melanoma That Can Be Removed by Surgery,Recruiting,No Results Available,Biological: Ipilimumab|Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Biological: Relatlimab|Procedure: Therapeutic Conventional Surgery,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02519322
NCT02068586,Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma,Recruiting,No Results Available,Drug: Sunitinib|Drug: Valproic Acid,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02068586
NCT01961115,Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma,Completed,Has Results,Drug: Epacadostat|Biological: MELITAC 12.1 Peptide Vaccine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01961115
NCT03628417,Confirmatory Trial in the Evaluation of Ca Electroporation for the Treatment of Cutaneous Metastases,Enrolling by invitation,No Results Available,Procedure: Calcium Electroporation|Procedure: Bleomycin based electrochemotherapy,All,"18 Years to 100 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03628417
NCT00039572,Boron Neutron Capture Therapy in Treating Patients With Glioblastoma Multiforme or Melanoma Metastatic to the Brain,Completed,No Results Available,Drug: boronophenylalanine-fructose complex,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00039572
NCT00316901,Positron Emission Tomography and CT Scan in Predicting Response in Patients With Metastatic Melanoma or Kidney Cancer Who Are Undergoing Cellular Adoptive Immunotherapy on a Surgery Branch Clinical Trial,Completed,No Results Available,Procedure: computed tomography|Procedure: positron emission tomography|Radiation: fludeoxyglucose F 18,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00316901
NCT03409419,PET Imaging of the Immune System Using Analog Probes,Not yet recruiting,No Results Available,Drug: [18F] CFA,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03409419
NCT01928940,Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part),Completed,Has Results,Drug: dabrafenib|Drug: trametinib,All,"20 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01928940
NCT01533948,Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery,Terminated,Has Results,Drug: axitinib|Other: laboratory biomarker analysis,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01533948
NCT02831933,Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma,Recruiting,No Results Available,Biological: ADV/HSV-tk|Drug: Valacyclovir|Radiation: SBRT|Drug: nivolumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02831933
NCT03052205,A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors,Recruiting,No Results Available,Drug: IMO-2125,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03052205
NCT01227889,A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma,Completed,Has Results,Drug: GSK2118436|Drug: Dacarbazine (DTIC),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01227889
NCT02097225,"Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery","Active, not recruiting",No Results Available,Drug: Dabrafenib|Other: Laboratory Biomarker Analysis|Drug: Onalespib|Other: Pharmacological Study|Drug: Trametinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02097225
NCT01568996,Pilot Study Evaluating Sulforaphane in Atypical Nevi-Precursor Lesions,Completed,No Results Available,Drug: broccoli sprout extract - sulforaphane (BSE-SFN),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01568996
NCT01303341,Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma,"Active, not recruiting",No Results Available,Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Riluzole|Drug: Sorafenib Tosylate,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01303341
NCT03534635,Analysis of the Modulation of the Tumor Microenvironment by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS),Recruiting,No Results Available,Drug: Pembrolizumab|Drug: Pembrolizumab - additional treatment,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03534635
NCT00002754,Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Melanoma or Brain Tumors,Completed,No Results Available,Biological: monoclonal antibody Me1-14 F(ab')2,All,"3 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00002754
NCT01313429,"Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum",Completed,No Results Available,Drug: Cyclophosphamide|Biological: Allogenic tumor Cell Vaccine (K562)|Drug: Celecoxib,All,"18 Years to 99 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01313429
NCT03109327,Investigating the Clinical Utility of the MDS,Not yet recruiting,No Results Available,Diagnostic Test: Melanoma Detection System -MDS,All,"18 Years to 99 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03109327
NCT02381314,Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer,"Active, not recruiting",No Results Available,Biological: enoblituzumab plus ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02381314
NCT02029729,RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER,Completed,No Results Available,Drug: omaveloxolone,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02029729
NCT00450255,VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery,Completed,Has Results,Biological: ziv-aflibercept|Other: pharmacological study,All,"18 Years to 120 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00450255
NCT00108875,"Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer",Unknown status,No Results Available,Biological: Survivin peptide vaccine,All,"19 Years to 90 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00108875
NCT00006022,Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer,Completed,No Results Available,Biological: aldesleukin|Drug: bryostatin 1,All,"18 Years to 120 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00006022
NCT02668536,A Sunscreen Based on Bioadhesive Nanoparticles,Completed,No Results Available,Drug: Standard Sunscreen|Device: BNP,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02668536
NCT01037127,Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor,Completed,Has Results,Drug: GSK1120212,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01037127
NCT03508297,Reflectance Confocal Microscopy to Diagnose MM & LM,Recruiting,No Results Available,Diagnostic Test: In-vivo imaging,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03508297
NCT00085189,Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma,Completed,No Results Available,Biological: gp100 antigen|Biological: tyrosinase peptide|Biological: recombinant MAGE-3.1 antigen|Biological: multi-epitope melanoma peptide vaccine|Biological: incomplete Freund's adjuvant|Drug: Montanide ISA 51 VG|Drug: agatolimod sodium|Other: laboratory biomarker analysis,All,"16 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00085189
NCT03300843,Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer,Recruiting,No Results Available,Biological: Peptide loaded dendritic cell vaccine,All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03300843
NCT02831634,A Feasibility Study to Identify T-cell Responses to Neo-epitopes in Tumor Invaded Lymph Nodes (NeoEpitope),Completed,No Results Available,Procedure: Blood sampling,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02831634
NCT00518050,"Health Behaviors, Surveillance, Psychosocial Factors, and Family Concerns",Completed,No Results Available,Behavioral: Focus group|Behavioral: Survey,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00518050
NCT00720031,Treatment of Metastatic Melanoma With Autologous Melan-A/MART-1 Specific CTL Clones,Completed,No Results Available,Biological: autologous Melan-A/MART-1 specific CTL clones,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00720031
NCT00631072,In Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer,Completed,No Results Available,Biological: INKT|Drug: GM-CSF,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00631072
NCT01767454,Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma,Completed,No Results Available,Drug: Dabrafenib|Drug: Trametinib|Drug: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01767454
NCT00847522,Fluorescein for Lymphatic Mapping and Sentinel Lymph Node (SLN) Biopsy in Patients With Stage I and II Malignant Melanoma,Completed,Has Results,Drug: Fluorescein,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00847522
NCT01616199,Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma,Terminated,No Results Available,Drug: PX-866|Drug: vemurafenib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01616199
NCT02441465,Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies,Completed,No Results Available,Drug: Vemurafenib|Drug: 14C-Labeled Vemurafenib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02441465
NCT02639026,"Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers",Recruiting,No Results Available,Radiation: Radiotherapy|Drug: MEDI4736|Drug: Tremelimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02639026
NCT02439411,Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain,Completed,No Results Available,Drug: Trametinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02439411
NCT02193581,Non-invasive Melanoma Assessment Using a Topical Fluorescence Reagent and Optical Imaging,Completed,No Results Available,Device: MDS,All,"21 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02193581
NCT00831545,"Study to Evaluate the Efficacy and Safety of Temozolomide in Subjects With Brain Metastases of Either Malignant Melanoma, Breast, or Non-small Cell Lung Cancer (P02064)",Completed,No Results Available,Drug: Temozolomide,All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00831545
NCT01851824,A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy,Completed,No Results Available,Drug: acenocoumarol|Drug: vemurafenib,All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01851824
NCT01849666,A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy,Completed,No Results Available,Drug: phenprocoumon|Drug: vemurafenib,All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01849666
NCT01844674,A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies,Completed,No Results Available,Drug: Tizanidine|Drug: Vemurafenib,All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01844674
NCT01765543,A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf),Completed,Has Results,Drug: Rifampin|Drug: Vemurafenib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01765543
NCT00937937,Dinaciclib in Treating Patients With Stage IV Melanoma,"Active, not recruiting",Has Results,Drug: Dinaciclib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00937937
NCT01460875,Recombinant Interferon Alfa-2b in Treating Patients With Melanoma,Completed,Has Results,Biological: recombinant interferon alfa-2b|Other: laboratory biomarker analysis,All,"12 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01460875
NCT03347617,Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Brain Tumors From Melanoma and Glioblastoma,Recruiting,No Results Available,Drug: Ferumoxytol|Other: Laboratory Biomarker Analysis|Procedure: Magnetic Resonance Imaging|Biological: Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03347617
NCT02057393,Infrared Lymphangiography as a Method of Sentinel Node Identification,Completed,Has Results,Drug: Indocyanine green|Drug: Technetium99|Drug: Methylene blue,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02057393
NCT01120275,Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma,Terminated,Has Results,Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097|Other: laboratory biomarker analysis,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01120275
NCT03638375,TIL and Anti-PD1 in Metastatic Melanoma,Recruiting,No Results Available,Drug: Nivolumab & Tumor Infiltrating Lymphocytes with/without Interferon-Alpha,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03638375
NCT00540930,Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy,Unknown status,No Results Available,Drug: Ranibizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00540930
NCT01823172,Second Echelon Node Study With Methylene Blue,Completed,No Results Available,Procedure: Methylene blue dye injection of sentinel lymph node,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01823172
NCT00226408,Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon,Unknown status,No Results Available,Drug: Interferon-alpha-2b,All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00226408
NCT00294476,"IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma",Unknown status,No Results Available,Drug: IVIG|Procedure: Biological Therapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00294476
NCT01720407,Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face,Recruiting,No Results Available,Drug: Imiquimod cream + surgery|Drug: Placebo + surgery,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01720407
NCT02352623,Quality of Life and Surgical Late Effects of Melanoma Treatment,Completed,No Results Available,Radiation: DXA scan|Procedure: Clinical examination,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02352623
NCT00743496,"A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma",Completed,No Results Available,Biological: Anti-GD2 antibody,All,"up to 21 Years   (Child, Adult)",https://ClinicalTrials.gov/show/NCT00743496
NCT03336606,Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma,Recruiting,No Results Available,Drug: MEDI0562,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03336606
NCT03233828,Pre-Treatment of Highly Suspicious Pigmented Skin Lesions With Interleukin-2,Enrolling by invitation,No Results Available,Biological: Aldesleukin|Other: Saline,All,"18 Years to 80 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03233828
NCT02308020,"A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain","Active, not recruiting",No Results Available,Drug: Abemaciclib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02308020
NCT01730157,Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases,Terminated,No Results Available,Biological: ipilimumab|Radiation: yttrium Y 90 glass microspheres|Other: laboratory biomarker analysis,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01730157
NCT01471054,Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma,Terminated,Has Results,Drug: Ozurdex|Drug: Bevacizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01471054
NCT03545334,Lymph Node Identification in Skin Malignancy Using ICG Transcutaneously Study,Recruiting,No Results Available,Diagnostic Test: VS3 - 3DHD camera,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03545334
NCT01652547,"A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel Cell Carcinoma",Completed,No Results Available,Drug: Pasireotide sub-cutaneous formulation|Drug: Pasireotide lon acting release formulation,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01652547
NCT02452424,A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors,Completed,No Results Available,Drug: PLX3397|Biological: Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02452424
NCT02858869,Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases,Recruiting,No Results Available,Biological: Pembrolizumab|Radiation: Stereotactic Radiosurgery,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02858869
NCT01480154,"Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer","Active, not recruiting",No Results Available,Drug: Akt Inhibitor MK2206|Drug: Hydroxychloroquine|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01480154
NCT00243061,AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma,Completed,Has Results,Drug: cediranib maleate,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00243061
NCT03158935,The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial,Recruiting,No Results Available,Drug: Cyclophosphamide|Drug: Fludarabine|Procedure: Pembrolizumab|Biological: Tumor-Infiltrating Lymphocytes (TILs)|Biological: Interleukin-2 (IL-2),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03158935
NCT00580320,Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma,Completed,No Results Available,Drug: Dacarbazine and bortezomib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00580320
NCT00667082,"NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma",Completed,No Results Available,Drug: NPI-0052 (marizomib) + vorinostat,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00667082
NCT03454282,Impact of Dietary Intervention on Tumor Immunity: the DigesT Trial,Recruiting,No Results Available,Other: FMD,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03454282
NCT00295906,Computer-Based Continuing Education for Doctors in Examination and Counseling of Patients on Skin Cancer or Weight Control,Unknown status,No Results Available,Other: educational intervention|Other: internet-based intervention,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00295906
NCT00841204,Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma,Completed,Has Results,Drug: sulindac|Other: placebo|Other: laboratory biomarker analysis,All,"18 Years to 65 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00841204
NCT01711684,Treatment of Cutaneous Metastases With Diphenylcyclopropenone (DPCP),Completed,No Results Available,Drug: Diphenylcyclopropenone (DPCP),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01711684
NCT00003308,"Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma",Completed,No Results Available,Radiation: stereotactic radiosurgery,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00003308
NCT01835184,Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery,Terminated,No Results Available,Drug: cabozantinib-s-malate|Drug: vemurafenib|Other: laboratory biomarker analysis|Other: pharmacological study,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01835184
NCT01904123,JAK2 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain,Recruiting,No Results Available,Drug: JAK2 Inhibitor WP1066|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01904123
NCT02507076,Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma,Withdrawn,No Results Available,Drug: isolated limb perfusion|Drug: melphalan|Procedure: quality-of-life assessment,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02507076
NCT02460068,A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis,Recruiting,No Results Available,Drug: Fotemustine|Drug: Fotemustine and Ipilimumab|Drug: Ipilimumab and nivolumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02460068
NCT01874119,Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma,Terminated,Has Results,Drug: Fosaprepitant,All,"18 Years to 90 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01874119
NCT02668770,Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies,Recruiting,No Results Available,Drug: MGN1703|Drug: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02668770
NCT00021164,Vaccine Therapy in Treating Patients With Metastatic Cancer,Completed,No Results Available,Biological: aldesleukin|Biological: incomplete Freund's adjuvant|Biological: telomerase: 540-548 peptide vaccine,All,"16 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00021164
NCT03050060,"Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer",Recruiting,No Results Available,Drug: Atezolizumab|Radiation: Hypofractionated Radiation Therapy|Other: Laboratory Biomarker Analysis|Drug: Nelfinavir Mesylate|Biological: Nivolumab|Biological: Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03050060
NCT03220009,"Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma",Withdrawn,No Results Available,Procedure: Conventional Surgery|Biological: Ipilimumab|Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Other: Patient Observation|Radiation: Radiation Therapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03220009
NCT02210104,Adoptive Therapy Using Antigen-Specific CD4 T-Cells,Withdrawn,No Results Available,Drug: Ipilimumab|Drug: Cyclophosphamide|Biological: CD4+ T cells,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02210104
NCT00403377,Investigation of a Behavioral Substitute for Sunbathing,Completed,No Results Available,Behavioral: Intervention,All,"18 Years to 120 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00403377
NCT03509467,Using MC1R Genotype to Impact Melanoma Risk Behavior,"Active, not recruiting",No Results Available,Behavioral: Personalized Information|Behavioral: Standard Information|Other: DNA Extraction Determination of MC1R Genotypes,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03509467
NCT03028948,Interactive Tailored Website to Promote Sun Protection and Skin Self-Check Behaviors in Patients With Stage 0-III Melanoma,"Active, not recruiting",No Results Available,Other: Internet-Based Intervention|Other: Questionnaire Administration|Other: Survey Administration,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03028948
NCT00923169,Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma),Completed,No Results Available,Drug: Anti-Transforming Growth Factor-beta (GC 1008),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00923169
NCT00948467,Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies,Completed,No Results Available,Drug: TAK-733,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00948467
NCT02897765,"A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer","Active, not recruiting",No Results Available,Biological: NEO-PV-01|Biological: Nivolumab|Other: Adjuvant,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02897765
NCT02475213,Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab in Refractory Cancer,"Active, not recruiting",No Results Available,Biological: Enoblituzumab|Biological: Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02475213
NCT00147550,"MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.",Terminated,No Results Available,Drug: PD-0325901,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00147550
NCT00002455,"Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma",Unknown status,No Results Available,Biological: Corynebacterium granulosum P40|Procedure: adjuvant therapy,All,"20 Years to 80 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00002455
NCT02020707,Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers,Recruiting,No Results Available,Biological: Bevacizumab|Other: Laboratory Biomarker Analysis|Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Other: Pharmacological Study,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02020707
NCT01727076,"Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer",Completed,No Results Available,Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Biological: Recombinant Human Interleukin-15,All,"19 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01727076
NCT02105168,Identification of Marker of Primary or Acquired Resistance to Anti Tumorous Treatment,Recruiting,No Results Available,Procedure: Blood sample|Procedure: Tumorous biopsy|Procedure: Healthy material sample,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02105168
NCT02573259,"A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors",Recruiting,No Results Available,Drug: PF-06801591,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02573259
NCT03246412,Nevus Doctor Clinical Decision Support for GPs,Recruiting,No Results Available,Diagnostic Test: Nevus doctor clinical decision support,All,"18 Years to 120 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03246412
NCT03535077,Assessing Tissue Remodeling in the Skin Using SFI (Skin Fluorescence Imaging),Recruiting,No Results Available,Other: Diagnostic Test,All,"21 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03535077
NCT00324272,Post-Operative Drainage Following Lymph Node Dissection,Completed,Has Results,Drug: Fibrin Sealant (Tisseel) used in the Experimental Arm.,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00324272
NCT01295827,"Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)",Completed,No Results Available,Drug: Pembrolizumab 1 mg/kg|Drug: Pembrolizumab 3 mg/kg|Drug: Pembrolizumab 10 mg/kg|Drug: Pembrolizumab MEL|Drug: Pembrolizumab NSCLC|Drug: Pembrolizumab MEL Low Dose|Drug: Pembrolizumab MEL High Dose|Drug: Pembrolizumab NSCLC Low Dose|Drug: Pembrolizumab NSCLC High Dose|Drug: Pembrolizumab NSCLC Medium Dose|Drug: Pembrolizumab NSCLC 200 mg,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01295827
NCT02318771,"Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer","Active, not recruiting",No Results Available,Radiation: Radiation Therapy (RT)|Drug: MK-3475,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02318771
NCT01562899,A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors,Terminated,No Results Available,Drug: MEK162|Drug: AMG 479,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01562899
NCT01364051,Cediranib Maleate and Selumetinib in Treating Patients With Solid Malignancies,"Active, not recruiting",No Results Available,Drug: Cediranib Maleate|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Selumetinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01364051
NCT01769222,"Ipilimumab and Local Radiation Therapy in Treating Patients With Recurrent Melanoma, Non-Hodgkin Lymphoma, Colon, or Rectal Cancer",Terminated,Has Results,Biological: Ipilimumab|Radiation: Radiation therapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01769222
NCT01341496,Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal,Terminated,No Results Available,Biological: Epigenetically Modified Autologous Tumor|Drug: Cyclophosphamide|Drug: Celecoxib,All,"18 Years to 99 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01341496
NCT03171064,Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment,Recruiting,No Results Available,Behavioral: Resistance and Endurance Exercise,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03171064
NCT00405587,Safety Study of PLX4032 in Patients With Solid Tumors,Completed,Has Results,Drug: PLX4032,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00405587
NCT03311542,Expanded Access for Pembrolizumab (MK-3475),No longer available,No Results Available,Biological: pembrolizumab,All,"18 Years to 80 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03311542
NCT02122861,"Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1","Active, not recruiting",No Results Available,Biological: ID-LV305,All,"18 Years to 100 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02122861
NCT03123783,CD40 Agonistic Antibody APX005M in Combination With Nivolumab,Recruiting,No Results Available,Drug: APX005M|Drug: Nivolumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03123783
NCT03698162,Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain Metastases,Not yet recruiting,No Results Available,Device: Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Drug: Bevacizumab Injection,All,"21 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03698162
NCT02829775,A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies,Completed,Has Results,Drug: Pegylated Interferon Alfa-2a|Drug: Recombinant Interferon Alfa 2a,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02829775
NCT00025012,Isotretinoin in Preventing Skin Cancer,Completed,No Results Available,Drug: isotretinoin,All,"2 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00025012
NCT03747744,Intratumoral Injection of Autologous CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Talimogene Laherparepvec (T-VEC),Recruiting,No Results Available,Other: CD1c (BDCA-1)+ myDC,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03747744
NCT03745872,SunSmart Intervention in Schools,Recruiting,No Results Available,Behavioral: Knowledge Assessment,All,9 Years to 15 Years   (Child),https://ClinicalTrials.gov/show/NCT03745872
NCT03438279,Survival Study for Participants Treated With Ipilimumab-Nivolumab Combination Therapy,Completed,No Results Available,Other: Non-Interventional,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03438279
NCT03267381,Circulating Blood Profile to Predict Recurrence and Response to Systemic Therapy,Recruiting,No Results Available,Other: Blood draw (before surgery)|Other: Blood draw (every 3 months)|Other: Blood draw (at diagnosis),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03267381
NCT02520622,Digital vs. Printed Photographs: Impact on Skin Self-Examinations,Completed,No Results Available,Behavioral: Digital photographs loaded onto a mobile device|Behavioral: Skin exam reminders|Behavioral: Social support network,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02520622
NCT02516527,"A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors",Recruiting,No Results Available,Drug: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02516527
NCT02515227,Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab,Recruiting,No Results Available,Biological: 6MHP|Drug: Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02515227
NCT02101008,Disulfiram and Chelated Zinc for the Rx of Disseminated Mets Mel That Has Failed First Line Therapy,Completed,Has Results,Drug: disulfiram and chelated zinc,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02101008
NCT02050594,Ipilimumab 12-month Intensive Pharmacovigilance Protocol,Completed,No Results Available,Drug: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02050594
NCT01846143,Evaluation of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With High Risk and Advanced Malignancies,Completed,No Results Available,Biological: pBCAR3-phosphopeptide|Biological: pIRS2-phosphopeptide|Biological: 2-MpP (pBCAR3-phosphopeptide + pIRS2-phosphopeptide),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01846143
NCT01272609,Treatment of Port Wine Stains in Children With Pulsed Dye Laser and Timolol Gel,Unknown status,No Results Available,Drug: Timolol + LCP|Device: LCP,All,"6 Months to 18 Years   (Child, Adult)",https://ClinicalTrials.gov/show/NCT01272609
NCT02166255,"APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery",Completed,No Results Available,Biological: siRNA-transfected peripheral blood mononuclear cells APN401|Other: laboratory biomarker analysis,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02166255
NCT01004952,Measuring Real Time Decision-Making About Ultraviolet Radiation (UVR) Protection,"Active, not recruiting",No Results Available,Behavioral: screening questionnaire,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01004952
NCT00960752,Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist,"Active, not recruiting",No Results Available,Drug: gp100|Drug: R848 gel|Drug: MAGE-3,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00960752
NCT02431572,A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy,Recruiting,No Results Available,Other: PBR PET|Biological: Cancer Immunotherapy|Radiation: Radiation and chemotherapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02431572
NCT00431275,"Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody",Completed,No Results Available,"Drug: CP-675,206",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00431275
NCT00162123,A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies,Completed,Has Results,Drug: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00162123
NCT03362138,Artificial Intelligence-assisted Evaluation of Pigmented Skin Lesions,Recruiting,No Results Available,Device: dermoscopy,All,"18 Years to 90 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03362138
NCT02909517,The Role of Inflammation in Ocular Tumours,Unknown status,No Results Available,Other: cSLO imaging,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02909517
NCT02723721,Prospective Study of Ingenol Mebutate for Non-invasive Lentigo Melanoma of the Face,Recruiting,No Results Available,Drug: Picato gel,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02723721
NCT03122522,A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy,Recruiting,No Results Available,Drug: ipilimumab|Drug: nivolumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03122522
NCT02224768,YERVOY® Risk Minimization Tool Effectiveness Evaluation Survey,Completed,No Results Available,Drug: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02224768
NCT02106598,Targeted Silica Nanoparticles for Real-Time Image-Guided Intraoperative Mapping of Nodal Metastases,Recruiting,No Results Available,Drug: fluorescent cRGDY-PEG-Cy5.5-C dots,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02106598
NCT00636558,Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers (PSX-X04),Completed,No Results Available,Drug: CVA21,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00636558
NCT00516802,A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine,Completed,No Results Available,Drug: KU-0059436 (AZD2281)(PARP inhibitor)|Drug: dacarbazine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00516802
NCT01294735,Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1),Completed,No Results Available,Drug: MK-4827|Drug: Temozolomide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01294735
NCT01477463,Pilot Trial to Evaluate the Effect of Vitamin D on Melanocyte Biomarkers,Completed,Has Results,Drug: Vitamin D3|Drug: placebo and vitamin D,Female,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01477463
NCT00818480,An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155,Completed,No Results Available,Drug: YM155,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00818480
NCT00188370,Ultrasound Biomicroscopy - Apoptosis,Completed,No Results Available,Procedure: high frequency ultrasound imaging,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00188370
NCT01134250,Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients,Unknown status,No Results Available,Drug: F16IL2 in combination with paclitaxel,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01134250
NCT01053819,Can We Miss Pigmented Lesions in Psoriasis Patients?,Completed,Has Results,Drug: etanercept,All,"19 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01053819
NCT00002733,Biological Therapy in Treating Patients With Metastatic Cancer,Completed,No Results Available,Biological: aldesleukin|Biological: recombinant interferon alfa|Biological: therapeutic tumor infiltrating lymphocytes|Drug: cimetidine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00002733
NCT03291002,"Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC",Recruiting,No Results Available,Biological: CV8102|Biological: CV8102 + anti-PD-1 therapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03291002
NCT03315975,Flu Vaccine Responses in the Setting of Melanoma Treatment,Enrolling by invitation,No Results Available,Biological: Inactivated influenza vaccine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03315975
NCT03069846,"Diagnosing Melanoma, Squamous Cell Carcinoma and Basal Cell Carcinoma Using the Spectra-Scope",Recruiting,No Results Available,Device: Spectra-Scope,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03069846
NCT03073031,The Use of PatientReportedOutcomes (PRO)- CTCAE by Melanoma Patients Receiving Immunotherapy,Recruiting,No Results Available,Device: Tablet: Samsung Galaxy Tab A,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03073031
NCT03472586,Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver,Suspended,No Results Available,Biological: Ipilimumab|Biological: Nivolumab|Drug: Embolization Therapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03472586
NCT02332642,Immuno-monitoring of Patients With Metastatic Melanoma (AJCC Stadium IV) Under Chemotherapy,Completed,No Results Available,Other: Immuno-monitoring,All,"18 Years to 80 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02332642
NCT00785369,In Vivo Confocal Microscopy for Pigmented Lesion Diagnosis,Completed,No Results Available,Device: Reflectance confocal microscopy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00785369
NCT03313492,Modifying Young Adult Skin Cancer Risk and Protective Behaviors,Recruiting,No Results Available,Behavioral: UV4.me2|Behavioral: UV4.me|Behavioral: E-Pamphlet,All,18 Years to 25 Years   (Adult),https://ClinicalTrials.gov/show/NCT03313492
NCT01988077,Clinical Evaluation of Yervoy in Combination With Adoptive T Cell Transfer for Metastatic Melanoma Patients,Terminated,No Results Available,Biological: Adoptive cell transfer|Drug: Ipilimumab 5 MG/ML Injection [Yervoy],All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01988077
NCT02332668,A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051),Recruiting,No Results Available,Biological: Pembrolizumab,All,6 Months to 17 Years   (Child),https://ClinicalTrials.gov/show/NCT02332668
NCT00685750,Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma,Terminated,No Results Available,Procedure: Collection of tumor and blood samples,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00685750
NCT00006126,"Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery",Withdrawn,No Results Available,Drug: busulfan|Drug: cyclophosphamide|Drug: etoposide|Drug: fludarabine phosphate|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy,All,"up to 59 Years   (Child, Adult)",https://ClinicalTrials.gov/show/NCT00006126
NCT02608034,A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State,"Active, not recruiting",No Results Available,Drug: Itraconazole|Drug: Rifampin|Drug: Vemurafenib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02608034
NCT01612221,Oral N-acetylcysteine for Protection of Human Nevi Against UV-induced Oxidative Stress/Damage in Vivo,Completed,Has Results,Drug: N-acetylcysteine|Other: Placebo arm,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01612221
NCT03161613,"Study to Assess the Safety of Nivolumab in the Treatment of Metastatic Melanoma, Lung Cancer, Renal Cancer, Squamous Cell Carcinoma of the Head and Neck, and Chronic Hodgkin Lymphoma in Adults in Mexico",Recruiting,No Results Available,Other: Non-Interventional,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03161613
NCT01584115,Clinical Trial of a Therapeutic Vaccine With NY-ESO-1 in Combination With the Adjuvant Monophosphoryl Lipid A (MPLA),Unknown status,No Results Available,Biological: NY-ESO-1 combined with MPLA|Biological: NY-ESO-1 combined with MPLA vaccine,All,18 Years to 60 Years   (Adult),https://ClinicalTrials.gov/show/NCT01584115
NCT01290536,Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases,Completed,Has Results,Device: Selective internal radiation therapy to the liver using Yttrium-90 glass microspheres (TheraSphere),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01290536
NCT02459067,ImmuniCell® in Patients With Advanced Cancers,Terminated,No Results Available,Biological: ImmuniCell®,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02459067
NCT01433991,E7050 in Combination With E7080 in Subjects With Advanced Solid Tumors (Dose Escalation) and in Subjects With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2),Unknown status,No Results Available,Drug: E7050 plus lenvatinib|Drug: lenvatinib plus E7050|Drug: E7050 plus lenvatinib or lenvatinib alone plus E7050 add-on therapy|Drug: E7050,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01433991
NCT01980264,Harmonics-based in Vivo Optical Virtual Biopsy,Recruiting,No Results Available,Device: Harmonic Generation Microscopy,All,"18 Years to 90 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01980264
NCT00704938,"Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer",Terminated,Has Results,Biological: aldesleukin|Biological: anti-p53 T-cell receptor-transduced peripheral blood lymphocytes|Biological: autologous dendritic cell-adenovirus p53 vaccine|Biological: filgrastim|Drug: cyclophosphamide|Drug: fludarabine phosphate,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00704938
NCT01336985,Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting Beads,Terminated,No Results Available,Drug: Irinotecan|Procedure: Chemoembolization|Device: Drug-Eluting Beads|Procedure: Biopsy,All,"18 Years to 84 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01336985
NCT02387307,A Study of rSIFN-co in Subjects With Advanced Solid Tumors,Unknown status,No Results Available,Drug: rSIFN-co,All,"21 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02387307
NCT00844064,"Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2",Completed,No Results Available,Drug: AP 12009,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00844064
NCT02464007,Study of rSIFN-co for Patients With Advanced Solid Tumors,"Active, not recruiting",No Results Available,Biological: rSIFN-co,All,"18 Years to 80 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02464007
NCT00526617,A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients,Completed,No Results Available,Drug: ABT-888|Drug: Temozolomide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00526617
NCT03797053,Ex Vivo Expansion of Circulating Tumor Cells as a Model for Cancer Predictive Pharmacology,Recruiting,No Results Available,Procedure: Biological sample,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03797053
NCT02457793,"A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors",Completed,Has Results,Drug: Cobimetinib|Drug: GDC-0994,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02457793
NCT03163433,Feedback in the Consultation - a Dialogue-based Tool in Personalised Care Planning Using Systematic Patient Involvement,Recruiting,No Results Available,Behavioral: Feedback in the consultation,All,"18 Years to 100 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03163433
NCT03073304,A Randomized Controlled Study Comparing Priming Solution Containing Crystalloid or Packed Red Blood Cells in Patients Treated With Isolated Limb Perfusion.,Completed,No Results Available,Drug: Crystalloid based prime solution|Drug: Erythrocyte based prime solution,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03073304
NCT02836795,Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors,"Active, not recruiting",No Results Available,Biological: humanized anti-PD-1 monoclonal antibody,All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02836795
NCT02285101,Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors,Recruiting,No Results Available,Biological: PEG-BCT-100,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02285101
NCT02893774,"Longitudinal Study of Behavioral Changes, Economic and Sociological After CAncer","Active, not recruiting",No Results Available,Other: quality of life assessment,All,"18 Years to 65 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02893774
NCT00039091,"Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer",Terminated,No Results Available,Biological: ipilimumab,All,"19 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00039091
NCT01993654,In Vivo Confocal Microscopy Study of Pigmented Conjunctival Lesions,Terminated,No Results Available,Procedure: HRT III with Non-Contact Cornea Rostock Module,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01993654
NCT02439008,Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response,"Active, not recruiting",No Results Available,Procedure: Blood samples collection before radiotherapy|Procedure: Blood samples collection during radiotherapy|Procedure: Blood samples collection after radiotherapy|Radiation: Radiotherapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02439008
NCT00112476,Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors,Completed,No Results Available,Drug: bryostatin 1|Drug: temsirolimus,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00112476
NCT00670748,Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer,Terminated,Has Results,Biological: Anti-NY ESO-1 T-cell receptor PBL|Drug: aldesleukin|Drug: Cyclophosphamide|Drug: fludarabine phosphate|Biological: ALVAC NY ESO-1 vaccine,All,"18 Years to 66 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00670748
NCT01457131,Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer,Terminated,No Results Available,Drug: Fludarabine|Drug: Cyclophosphamide|Other: IL-12 &amp; Anti-NY ESO1 TCR PBL,All,"18 Years to 99 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01457131
NCT03236935,Phase Ib of L-NMMA and Pembrolizumab,Recruiting,No Results Available,Drug: L-NMMA|Drug: Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03236935
NCT01218867,CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer,Completed,Has Results,Biological: Anti-VEGFR2 CAR CD8 plus PBL|Drug: Cyclophosphamide|Biological: Aldesleukin|Drug: Fludarabine,All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01218867
NCT02417948,Improving Sun-Protective Behaviors and Skin Self-Examinations Among African Americans,Completed,No Results Available,Other: Written Educational Brochure|Other: Online educational video,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02417948
NCT00000124,Collaborative Ocular Melanoma Study (COMS),Unknown status,No Results Available,Procedure: Brachytherapy|Procedure: Eye Removal,All,"21 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00000124
NCT03515551,Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers,Recruiting,No Results Available,Drug: IMCnyeso,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03515551
NCT01273181,MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes,Terminated,Has Results,Biological: PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes|Drug: Aldesleukin|Drug: Cyclophosphamide|Drug: Fludarabine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01273181
NCT00003690,Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors,Completed,No Results Available,Drug: alvocidib|Drug: carboplatin|Drug: cisplatin,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00003690
NCT00003750,Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors,Completed,No Results Available,Biological: hu14.18-IL2 fusion protein,All,"up to 21 Years   (Child, Adult)",https://ClinicalTrials.gov/show/NCT00003750
NCT03715985,Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac),Not yet recruiting,No Results Available,Drug: EVAX-01-CAF09b,All,"18 Years to 120 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03715985
NCT03025256,Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease,Recruiting,No Results Available,Biological: Nivolumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03025256
NCT00855452,Activated Allogeneic Lymphocytes for Induction Graft Versus Tumor Effect in Metastatic Solid Tumors,Completed,No Results Available,Procedure: one - three cycles of cell therapy during 4-6 weeks (3-5x10^7 cells/kg will be given through IV systemically,All,"12 Years to 70 Years   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00855452
NCT02807844,Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies,Recruiting,No Results Available,Drug: MCS110|Drug: PDR001,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02807844
NCT00965861,SCRI Tissue Testing Registry,Terminated,No Results Available,Other: Tissue Registry Study,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00965861
NCT03138889,A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 (Pembrolizumab) and of NKTR-214 in Combination With Anti-PD-L1 (Atezolizumab) in Patients With Select Advanced or Metastatic Solid Tumors,Recruiting,No Results Available,Drug: NKTR-214|Drug: Pembrolizumab|Drug: Atezolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03138889
NCT03207347,A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001),Recruiting,No Results Available,Drug: Niraparib,All,"18 Years to 80 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03207347
NCT00625456,Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors,Completed,No Results Available,Drug: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00625456
NCT00540969,Cryoablation or External-Beam Radiation Therapy in Treating Patients With Painful Bone Metastases,Terminated,Has Results,Procedure: cryosurgery|Radiation: radiation therapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00540969
NCT01738139,Ipilimumab and Imatinib Mesylate in Treating Participants With Metastatic or Unresectable Solid Tumors,Recruiting,No Results Available,Drug: Imatinib Mesylate|Biological: Ipilimumab,All,"15 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01738139
NCT01902173,"Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer",Suspended,No Results Available,Drug: Akt Inhibitor GSK2141795|Drug: Dabrafenib|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Trametinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01902173
NCT00405405,Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer,Completed,No Results Available,Drug: Cisplatin|Drug: Docetaxel|Drug: Bevacizumab|Drug: Erlotinib|Radiation: Radiotherapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00405405
NCT03412058,Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists,Recruiting,No Results Available,Procedure: Biopsy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03412058
NCT03313544,Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1,Not yet recruiting,No Results Available,Drug: Nivolumab|Device: MRI|Biological: BLOOD SAMPLES|Device: trans-thoracic echocardiography,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03313544
NCT03050047,A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of BCD-100 in Patients With Advanced Solid Tumors,"Active, not recruiting",No Results Available,Biological: BCD-100,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03050047
NCT01967823,T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer,Recruiting,No Results Available,Biological: Anti-NY ESO-1 mTCR PBL|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Aldesleukin,All,"15 Years to 70 Years   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01967823
NCT03679767,A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203),Not yet recruiting,No Results Available,Drug: INCMGA00012,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03679767
NCT02307630,PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study,"Active, not recruiting",No Results Available,Biological: 124I-Humanized 3F8,All,"3 Years to 90 Years   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02307630
NCT01666353,PET Quantitative Assessments of Solid Tumor Response to Immune Checkpoint Blockade Therapy,Unknown status,No Results Available,Radiation: PET/CT imaging with [18F] 2-deoxy-2-(18F)fluoro-D-glucose (FDG),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01666353
NCT02763761,An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo,Withdrawn,No Results Available,Drug: Infliximab + Prednisone|Drug: Methylprednisolone + Prednisone,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02763761
NCT02658890,An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread,Recruiting,No Results Available,Drug: BMS-986205|Drug: Nivolumab|Drug: Ipilimumab,All,"18 Years to 100 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02658890
NCT01017185,Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions,Completed,No Results Available,Drug: HF10,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01017185
NCT02015416,A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer,Completed,No Results Available,Biological: IDC-G305,All,"18 Years to 80 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02015416
NCT01773447,Set-back Suture Versus Traditional Vertical Mattress Suture,Completed,No Results Available,Procedure: Set-back suture|Procedure: Vertical mattress suture,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01773447
NCT01770002,Eversion in Dermatologic Surgery: Is Cosmetic Appearance Improved?,Completed,No Results Available,Procedure: Everted suture technique|Procedure: Non-everted suture technique,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01770002
NCT03607578,Test of Interventions to Prevent Skin Cancer Among Danes on Vacation in High UV Index Sunny Destinations,"Active, not recruiting",No Results Available,Behavioral: Other: Control Group - Minimal Intervention|Behavioral: Experimental: Protection Routine 1|Behavioral: Experimental: Protection Routine 2,All,"18 Years to 99 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03607578
NCT00610389,Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors,Unknown status,No Results Available,Biological: immunotherapy with dendritic cells,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00610389
NCT01618136,"An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors",Completed,No Results Available,Drug: E7449 alone|Drug: E7449 plus TMZ|Drug: E7449 plus carboplatin and paclitaxel,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01618136
NCT03645928,Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors,Recruiting,No Results Available,Biological: Lifileucel|Biological: LN-145|Drug: Pembrolizumab,All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03645928
NCT03548467,"A Study to Evaluate Safety, Feasibility, Efficacy of Multiple Dosing With VB10.NEO Immunotherapy in Patients With Locally Advanced or Metastatic Cancer",Recruiting,No Results Available,Drug: VB10.NEO,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03548467
NCT00835133,"Collecting Blood and Tissue Samples From Family Members of Patients With Pancreatic Diseases, Pancreatic Cancer, and Melanoma",Recruiting,No Results Available,Other: biologic sample preservation procedure|Other: medical chart review|Other: survey administration,All,"18 Years to 120 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00835133
NCT00862901,Safety Study Using Photodynamic Therapy Light Therapy for Patients With Chest Wall Progression of Breast Cancer and Satellite Metastases of Melanoma,Completed,No Results Available,Device: CLIPT patch,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00862901
NCT02685592,Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream,Completed,No Results Available,Drug: 5-aminolevulinic acid nanoemulsion,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02685592
NCT03708328,"A Dose Escalation and Expansion Study of RO7121661, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors",Recruiting,No Results Available,Drug: RO7121661,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03708328
NCT00276536,"Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma",Completed,No Results Available,Biological: recombinant interferon alpha-1b|Drug: IFN,All,"18 Years to 120 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00276536
NCT02153905,T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive,Terminated,No Results Available,Drug: Aldesleukin|Drug: Fludarabine|Drug: Cyclophosphamide|Biological: Anti-MAGE-A3 HLAA* 01-restricted TCR,All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02153905
NCT03621462,Elucid Labs AIDA™ - Labelled Image Acquisition Protocol,Not yet recruiting,No Results Available,Device: Artificial Intelligence Dermatology Assistant (AIDA™),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03621462
NCT01433302,Inflammatory Response and Tissue Fibrosis/ Lymphatico-venous Bypass,Completed,No Results Available,Procedure: Punch Biopsy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01433302
NCT02013492,Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery,Recruiting,No Results Available,Drug: propranolol hydrochloride|Other: Correlative Studies,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02013492
NCT02791334,A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors,Recruiting,No Results Available,Drug: LY3300054|Drug: Ramucirumab|Drug: Abemaciclib|Drug: Merestinib|Drug: LY3321367,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02791334
NCT01932489,The Jules Bordet Institute Molecular Profiling Program Feasibility Trial,Completed,No Results Available,Procedure: Biopsy of a metastatic lesion.,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01932489
NCT03108131,Cobimetinib and Atezolizumab in Advanced Rare Tumors,Recruiting,No Results Available,Drug: Cobimetinib|Drug: Atezolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03108131
NCT02729298,First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors,Recruiting,No Results Available,Drug: TP-0903,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02729298
NCT00179764,Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC]),Unknown status,No Results Available,Procedure: Immunoablative Hematopoietic PBSC Transplant|Procedure: Busulfan pharmacokinetics|Radiation: Central Nervous System (CNS) prophylaxis radiation,All,"up to 21 Years   (Child, Adult)",https://ClinicalTrials.gov/show/NCT00179764
NCT00003266,Methylphenidate in Treating Patients With Melanoma,Completed,No Results Available,Drug: methylphenidate hydrochloride|Procedure: quality-of-life assessment,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00003266
NCT02069769,Ensuring Communication in Hospice by Oncology Study (ECHO),Completed,No Results Available,Behavioral: communication with oncology team,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02069769
NCT00033956,Evaluation of M40403 for the Prevention of Dose Limiting Toxicities of High Dose IL-2,Suspended,No Results Available,Drug: M40403,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00033956
NCT00002980,Decitabine in Treating Patients With Melanoma or Other Advanced Cancer,Completed,No Results Available,Drug: decitabine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00002980
NCT00030615,Decitabine in Treating Patients With Advanced Solid Tumors,Completed,No Results Available,Drug: decitabine|Other: pharmacological study|Other: laboratory biomarker analysis,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00030615
NCT00132704,An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation,Completed,No Results Available,Radiation: Ionizing radiation (IR) therapy|Radiation: Ionizing radiation (IR),All,"19 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00132704
NCT01072175,"Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212",Completed,Has Results,Drug: GSK2118436|Drug: GSK1120212,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01072175
NCT01946789,A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors,"Active, not recruiting",No Results Available,Biological: ALT-803,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01946789
NCT03633110,"Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine",Recruiting,No Results Available,Biological: GEN-009 Adjuvanted Vaccine|Drug: Nivolumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03633110
NCT01853878,"A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor",Completed,No Results Available,Biological: Recombinant PRAME protein combined with the AS15 Adjuvant System GSK2302032A|Biological: Placebo,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01853878
NCT00441337,A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies,Completed,Has Results,Biological: MDX-1106,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00441337
NCT03080948,Risk Stratification Among Individuals Who Have Many Moles on Their Skin,Enrolling by invitation,No Results Available,Behavioral: survey|Other: Saliva samples,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03080948
NCT00421811,A Study of ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan,Completed,No Results Available,Drug: ADH-1|Drug: melphalan,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00421811
NCT03326258,"Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery",Withdrawn,No Results Available,Drug: Glembatumumab Vedotin|Biological: Ipilimumab|Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Other: Pharmacological Study,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03326258
NCT00526149,BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors,Completed,No Results Available,Drug: BI 2536|Other: high performance liquid chromatography|Other: mass spectrometry|Other: pharmacological study,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00526149
NCT01773655,Clinical and Histopathologic Characteristics of BAP1 Mutations,"Active, not recruiting",No Results Available,Other: tumor specimens,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01773655
NCT02941900,Interest and Impact of Skin Cancer Genetic Testing,Enrolling by invitation,No Results Available,Genetic: MC1R genotyping|Behavioral: MC1R Testing Website|Behavioral: Baseline Survey,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02941900
NCT02651246,Optional Sub-study to Intraoperative Imaging With ICG Registry,Recruiting,No Results Available,Other: data collection,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02651246
NCT03176485,"Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors",Completed,No Results Available,Other: Solar Simulator,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03176485
NCT03246633,Perceptual Expertise Training for Triage of Moles,Completed,No Results Available,Other: Perceptual Training,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03246633
NCT00003022,Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer,Completed,No Results Available,Radiation: iodine I 131 monoclonal antibody 3F8,All,"3 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00003022
NCT03140137,Immune Checkpoint Inhibitors and Pre-existing Autoimmune Diseases,Recruiting,No Results Available,Drug: Checkpoint inhibitor therapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03140137
NCT00757614,"Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United Kingdom",Unknown status,No Results Available,Genetic: DNA analysis|Genetic: polymorphism analysis|Other: laboratory biomarker analysis|Other: questionnaire administration,All,"18 Years to 69 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00757614
NCT00002947,Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer,Terminated,No Results Available,Radiation: indium In 111 pentetreotide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00002947
NCT00093678,"Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced Cancer",Withdrawn,No Results Available,Drug: celecoxib|Procedure: anticachectic therapy|Procedure: nutritional support|Procedure: pain therapy|Procedure: supportive care/therapy,All,"18 Years to 120 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00093678
NCT00311272,Dendritic Cell Vaccination in Patients With Advanced Colorectal Cancer,Completed,No Results Available,Biological: MelCancerVac,All,"25 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00311272
NCT01673737,A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer,Completed,No Results Available,Drug: SAR260301|Drug: Vemurafenib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01673737
NCT03107663,⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma,Completed,No Results Available,Drug: ⁸⁹Zr-Df-IAB22M2C Infusion,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03107663
NCT02298959,Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors,Recruiting,No Results Available,Biological: Pembrolizumab|Biological: Ziv-Aflibercept,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02298959
NCT02644369,Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors,"Active, not recruiting",No Results Available,Biological: Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02644369
NCT02304458,Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas,Recruiting,No Results Available,Biological: Ipilimumab|Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Other: Pharmacological Study,All,"12 Months to 30 Years   (Child, Adult)",https://ClinicalTrials.gov/show/NCT02304458
NCT02902822,Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo,"Active, not recruiting",No Results Available,Procedure: Screening|Device: Tele-dermatology,All,"18 Years to 99 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02902822
NCT00574977,Safety Study of Modified Vaccinia Virus to Cancer,Completed,No Results Available,Biological: Vaccinia virus (vvDD-CDSR),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00574977
NCT00550654,Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain,Terminated,Has Results,Other: questionnaire administration|Radiation: 3-dimensional conformal radiation therapy|Radiation: hypofractionated radiation therapy|Radiation: image-guided radiation therapy|Radiation: tomotherapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00550654
NCT03464032,A Study of BCD-135 in Patients With Advanced Solid Tumors,Recruiting,No Results Available,Drug: BCD-135,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03464032
NCT03229278,Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma,Recruiting,No Results Available,Drug: Enzyme Inhibitor Therapy|Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Biological: Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03229278
NCT00753415,A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002),Completed,Has Results,Biological: V935|Biological: V934-EP,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00753415
NCT03767348,Study of RP1 Monotherapy and RP1 in Combination With Nivolumab,Recruiting,No Results Available,Biological: RP1|Biological: nivolumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03767348
NCT03590054,A Phase 1b Dose Escalation/Expansion Study of Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies,Recruiting,No Results Available,Drug: Abexinostat|Biological: Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03590054
NCT01794793,Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.,Recruiting,No Results Available,Drug: Pasireotide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01794793
NCT02423863,"In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®",Recruiting,No Results Available,Biological: Hiltonol,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02423863
NCT01935453,A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus to Treat Cancer,Completed,No Results Available,Biological: Recombinant hGM-CSF Herpes Simplex Virus Injection,All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01935453
NCT03399448,NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells),Recruiting,No Results Available,Biological: NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1|Drug: Cyclophosphamide|Drug: Fludarabine|Device: NY-ESO-1 expression testing,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03399448
NCT03098160,Immunotherapy Study of Evofosfamide in Combination With Ipilimumab,Recruiting,No Results Available,Drug: Evofosfamide|Drug: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03098160
NCT02961283,Study of ASN003 in Subjects With Advanced Solid Tumors,"Active, not recruiting",No Results Available,Drug: ASN003 ascending doses|Drug: ASN003 MTD,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02961283
NCT01522820,Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors,Completed,No Results Available,Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Sirolimus,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01522820
NCT02387125,"Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1","Active, not recruiting",No Results Available,Biological: CMB305|Biological: G100|Drug: Metronomic CPA,All,"18 Years to 80 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02387125
NCT02352428,Skin Cancer Screening Education Study,Unknown status,No Results Available,Other: Skin Cancer Screening Training,All,"20 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02352428
NCT02711345,A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.,Recruiting,No Results Available,Drug: LTT462,All,"12 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02711345
NCT03154190,Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer,Recruiting,No Results Available,Other: Best Practice|Other: Laboratory Biomarker Analysis|Procedure: Supportive Care|Other: Survey Administration,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03154190
NCT02607813,Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations,Recruiting,No Results Available,Drug: LXH254|Drug: PDR001,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02607813
NCT01638533,"Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction",Recruiting,No Results Available,Other: Pharmacological Study|Drug: Romidepsin,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01638533
NCT01131234,Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors,Completed,No Results Available,Drug: Gamma-Secretase Inhibitor RO4929097|Drug: Cediranib Maleate|Other: Pharmacological Study|Other: Laboratory Biomarker Analysis,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01131234
NCT02307500,Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy,Recruiting,No Results Available,Drug: Regorafenib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02307500
NCT03112668,Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners,Recruiting,No Results Available,Behavioral: Cognitive Behavior Therapy|Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Other: Survey Administration,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03112668
NCT03425279,CAB-AXL-ADC Safety and Efficacy Study in Patients With Solid Tumors,Recruiting,No Results Available,Biological: CAB-AXL-ADC,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03425279
NCT02839694,Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy,Withdrawn,No Results Available,Drug: decitabine (DAC)|Drug: Tetrahydrouridine (THU)|Drug: Celecoxib,All,"18 Years to 99 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02839694
NCT00601185,Confocal Reflectance Microscopy of Shave-Biopsy Sites on Skin in Vivo.,Completed,No Results Available,Procedure: confocal microscopy in vivo,All,"18 Years to 80 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00601185
NCT00574392,Multi-Wavelength and Coherence Confocal Reflectance Microscopy of Pigmented and Non-Pigmented Lesions on the Skin In-Vivo,Completed,No Results Available,Device: Multiwavelength and coherence confocal reflectance microscopy (Vivascope 1500m multiwavelength),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00574392
NCT01590069,Aerosolized Aldesleukin in Treating Patients With Lung Metastases,"Active, not recruiting",No Results Available,Biological: Aerosolized Aldesleukin|Other: Laboratory Biomarker Analysis,All,"12 Years to 50 Years   (Child, Adult)",https://ClinicalTrials.gov/show/NCT01590069
NCT03517488,A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors,Recruiting,No Results Available,Biological: XmAb20717,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03517488
NCT01065441,Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer,Withdrawn,No Results Available,Biological: AlloStim|Procedure: Cryoablation,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01065441
NCT02107963,A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors,Completed,No Results Available,Biological: Anti-GD2-CAR engineered T cells|Drug: AP1903|Drug: Cyclophosphamide,All,"1 Year to 35 Years   (Child, Adult)",https://ClinicalTrials.gov/show/NCT02107963
NCT00379132,131-I-TM-601 Study in Adults With Solid Tumors,Completed,No Results Available,Drug: 131-I-TM-601 (chlorotoxin),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00379132
NCT02595866,"Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms",Recruiting,No Results Available,Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02595866
NCT02012231,"Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.",Terminated,No Results Available,Drug: PLX8394,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02012231
NCT00600496,"A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)","Active, not recruiting",No Results Available,Drug: AZD6244|Drug: Dacarbazine|Drug: Erlotinib|Drug: Docetaxel|Drug: Temsirolimus,All,"18 Years to 130 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00600496
NCT03132922,MAGE-A4ᶜ¹º³²T for Multi-Tumor,Recruiting,No Results Available,Genetic: Autologous genetically modified MAGE-A4ᶜ¹º³²T cells,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03132922
NCT03652077,A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies,Recruiting,No Results Available,Drug: INCAGN02390,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03652077
NCT01191775,A Study of PNT2258 in Patients With Advanced Solid Tumors,Completed,No Results Available,Drug: PNT2258,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01191775
NCT01526486,Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer,Completed,No Results Available,"Procedure: Videoscopic procedure|Procedure: Open, traditional approach",All,"18 Years to 80 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01526486
NCT00769990,Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases,Withdrawn,No Results Available,Dietary Supplement: genistein|Radiation: radiation therapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00769990
NCT03474497,"Intralesional IL-2, Hypofractionated Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade",Not yet recruiting,No Results Available,Drug: IL-2|Drug: Pembrolizumab|Radiation: Radiotherapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03474497
NCT03716193,Measurement of the Partial Pressure of Oxygen in Cutaneous Tumors Using Electron Paramagnetic Resonance (EPR) Oximetry,Not yet recruiting,No Results Available,Other: Oxygen,All,"18 Years to 90 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03716193
NCT01962103,Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors,Completed,Has Results,Drug: nab-paclitaxel,All,"6 Months to 24 Years   (Child, Adult)",https://ClinicalTrials.gov/show/NCT01962103
NCT02465060,"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",Recruiting,No Results Available,Drug: Adavosertib|Drug: Afatinib|Drug: Binimetinib|Drug: Capivasertib|Drug: Crizotinib|Other: Cytology Specimen Collection Procedure|Drug: Dabrafenib|Drug: Dasatinib|Drug: Defactinib|Drug: FGFR Inhibitor AZD4547|Other: Laboratory Biomarker Analysis|Drug: Larotrectinib|Biological: Nivolumab|Drug: Osimertinib|Drug: Palbociclib|Biological: Pertuzumab|Drug: PI3K-beta Inhibitor GSK2636771|Drug: Sapanisertib|Drug: Sunitinib Malate|Drug: Taselisib|Drug: Trametinib|Biological: Trastuzumab|Biological: Trastuzumab Emtansine|Drug: Vismodegib,All,"18 Years and older   (Adult, Older Adult)",
NCT00089362,Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors,Completed,No Results Available,Drug: alvespimycin hydrochloride|Other: laboratory biomarker analysis|Other: pharmacological study,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00089362
NCT03809624,"Study of INBRX-105 in Patients With Solid Tumors, Hodgkin or Non-Hodgkin Lymphoma",Not yet recruiting,No Results Available,Drug: INBRX-105 - PDL1x41BB antibody,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03809624
NCT00436410,Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer,Completed,No Results Available,Biological: colloidal gold-bound tumor necrosis factor|Other: electron microscopy|Other: pharmacological study|Procedure: conventional surgery,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00436410
NCT01391143,Safety Study of MGA271 in Refractory Cancer,"Active, not recruiting",No Results Available,Biological: MGA271,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01391143
NCT03297424,A Study of PLX2853 in Advanced Malignancies.,Recruiting,No Results Available,Drug: PLX2853,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03297424
NCT01351103,A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands,Recruiting,No Results Available,Drug: LGK974|Biological: PDR001,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01351103
NCT02437916,Safety Study of AMG 228 to Treat Solid Tumors,Terminated,No Results Available,Drug: AMG 228,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02437916
NCT02568267,"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)",Recruiting,No Results Available,Drug: Entrectinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02568267
NCT02643303,"A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers",Recruiting,No Results Available,Drug: Durvalumab|Drug: Tremelimumab|Drug: Poly ICLC,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02643303
NCT00553683,"Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer",Unknown status,No Results Available,Drug: cyclophosphamide|Drug: poly ICLC|Procedure: hepatic artery embolization|Radiation: 3-dimensional conformal radiation therapy,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00553683
NCT02223052,Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies,"Active, not recruiting",No Results Available,Drug: CC-486|Drug: Vidaza,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02223052
NCT03653819,High Intensity Interval Training (HIIT) for Patients With Cancer-related Lymphedema in the Lower Limbs,Completed,No Results Available,Other: First exercise session + compression|Other: First exercise session - compression,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03653819
NCT00667641,Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors,Completed,No Results Available,Drug: bortezomib|Drug: paclitaxel,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00667641
NCT00019019,Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas,Completed,No Results Available,Drug: carboxyamidotriazole|Drug: paclitaxel,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00019019
NCT00004065,Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer,Completed,No Results Available,Drug: tanespimycin,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00004065
NCT03752398,A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3),Not yet recruiting,No Results Available,Biological: XmAb®23104,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03752398
NCT00587964,Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases,Completed,Has Results,Radiation: Stereotactic Radiosurgery,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00587964
NCT03237013,Strategies to Promote Skin Health,Completed,No Results Available,Behavioral: Facial Morphing Intervention|Behavioral: Mindfulness Intervention,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03237013
NCT02637531,"A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549",Recruiting,No Results Available,Drug: IPI-549|Drug: Nivolumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02637531
NCT01037790,PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER,Recruiting,No Results Available,Drug: PD-0332991|Other: pharmacological study,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01037790
NCT00730639,A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies,"Active, not recruiting",Has Results,Biological: BMS-936558 (MDX-1106),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00730639
NCT01217411,RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer,Terminated,Has Results,Drug: Gamma-secretase/Notch signalling pathway inhibitor RO4929097|Radiation: Whole-brain radiation therapy (WBRT)|Radiation: Stereotactic radiosurgery (SRS)|Procedure: Cognitive assessment|Other: Laboratory biomarker analysis,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01217411
NCT00019331,Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors,Completed,No Results Available,Biological: aldesleukin|Biological: ras peptide cancer vaccine|Biological: sargramostim|Drug: DetoxPC,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00019331
NCT00006368,Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer,Completed,No Results Available,Radiation: yttrium Y 90-edotreotide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00006368
NCT02661100,"A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients",Withdrawn,No Results Available,Drug: Pembrolizumab|Biological: CDX-1401|Biological: Poly-ICLC,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02661100
NCT00014456,Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors,Completed,No Results Available,Biological: filgrastim|Drug: docetaxel|Drug: gemcitabine hydrochloride,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00014456
NCT00655655,Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors,Completed,No Results Available,Drug: everolimus|Drug: vatalanib|Other: pharmacological study|Other: laboratory biomarker analysis|Procedure: dynamic contrast-enhanced magnetic resonance imaging|Procedure: ultrasound imaging,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00655655
NCT02650635,"TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors",Terminated,No Results Available,Drug: Cyclophosphamide|Other: Laboratory Biomarker Analysis|Biological: Pegfilgrastim|Other: Pharmacological Study|Drug: TLR8 Agonist VTX-2337,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02650635
NCT00041808,Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver,Completed,No Results Available,Drug: MTC-DOX for Injection|Procedure: Chemotherapy,All,"18 Years to 80 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00041808
NCT03215511,Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers,Recruiting,No Results Available,Drug: LOXO-195,All,"1 Month and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03215511
NCT02206360,Pancreatic Cancer Early Detection Program,Recruiting,No Results Available,Procedure: Endoscopic Ultrasound|Procedure: Magnetic Resonance Imaging (MRI),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02206360
NCT02576431,Study of LOXO-101 (Larotrectinib) in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE),Recruiting,No Results Available,Drug: Larotrectinib LOXO-101,All,"12 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02576431
NCT01460134,A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers,Completed,No Results Available,Drug: CDX-1127,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01460134
NCT03689192,Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors,Recruiting,No Results Available,"Biological: ARG1-18,19,20",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03689192
NCT02655822,Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers,Recruiting,No Results Available,Drug: CPI-444|Drug: CPI-444 + atezolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02655822
NCT00540566,Optical Biopsy of Human Skin in Conjunction With Laser Treatment,Completed,No Results Available,Device: Optical Biopsy imaging,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00540566
NCT01307267,A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab,"Active, not recruiting",No Results Available,Drug: PF-05082566|Drug: rituximab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01307267
NCT03538028,A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies,Recruiting,No Results Available,Biological: INCAGN02385,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03538028
NCT02378337,"Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image Quality",Completed,No Results Available,Other: Image quantify,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02378337
NCT02309632,Pancreatic Cancer Screening of High-Risk Individuals in Arkansas,"Active, not recruiting",No Results Available,Other: Pancreatic Cancer Screening Pathway 1|Other: Pancreatic Cancer Screening Pathway 2,All,"18 Years to 99 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02309632
NCT03480152,"Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer",Recruiting,No Results Available,"Biological: NCI-4650, a mRNA-based, Personalized Cancer Vaccine",All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03480152
NCT02983045,A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) or in Combination With Nivolumab and Anti-CTLA4 Antibody (Ipilimumab) in Patients With Select Advanced or Metastatic Solid Tumors,Recruiting,No Results Available,Drug: Combination of NKTR-214 + nivolumab|Drug: Combination of NKTR-214 + nivolumab + ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02983045
NCT02527304,Adaptive Staged Stereotactic Body Radiation Therapy in Treating Patients With Spinal Metastases That Cannot Be Removed by Surgery,Unknown status,No Results Available,Radiation: Image-Guided Adaptive Radiation Therapy|Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Radiation: Stereotactic Body Radiation Therapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02527304
NCT02404441,Phase I/II Study of PDR001 in Patients With Advanced Malignancies,"Active, not recruiting",No Results Available,Biological: PDR001,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02404441
NCT03511391,CHEckpoint Inhibition in Combination With an Immunoboost of External Body Radiotherapy in Solid Tumors,Recruiting,No Results Available,Drug: Pembrolizumab or Nivolumab|Radiation: SBRT,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03511391
NCT00765193,The Impact of Total Body Skin Examination on Skin Cancer Detection,Completed,Has Results,Other: Inspection of covered areas,All,"18 Years to 95 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00765193
NCT02014116,A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body,Terminated,No Results Available,Drug: LY3009120 capsule,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02014116
NCT02830724,Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers,Recruiting,No Results Available,Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Aldesleukin|Biological: Anti-hCD70 CAR transduced PBL,All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02830724
NCT00043368,PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909),Completed,No Results Available,Drug: PF-3512676,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00043368
NCT01215500,Dose Escalation of Hypofractionated Radiation Therapy in Patients With Metastatic Cancer,Completed,No Results Available,Radiation: Hypofractionated RT,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01215500
NCT02111850,T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive,Recruiting,No Results Available,Biological: Anti-MAGE-A3-DP4 TCR PBL|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: high dose Aldesleukin,All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02111850
NCT02043184,Improving Adherence to Oral Cancer Agents and Self Care of Symptoms Using an IVR,Completed,No Results Available,Behavioral: Interactive Voice Response (IVR) Reminders,All,"21 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02043184
NCT00739609,IDO Inhibitor Study for Relapsed or Refractory Solid Tumors,Terminated,No Results Available,Drug: 1-methyl-D-tryptophan,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00739609
NCT01386580,"An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.",Completed,No Results Available,Drug: 2B3-101|Drug: Trastuzumab|Drug: 2B3-101 60 mg/m2 every 4 weeks|Drug: 2B3-101 50 mg/m2 every 3 weeks,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01386580
NCT02054104,"Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum",Suspended,No Results Available,Biological: H1299 Lysate Vaccine|Drug: Cyclophosphamide|Drug: Celecoxib,All,"18 Years to 99 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02054104
NCT01916135,"PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative","Active, not recruiting",No Results Available,Radiation: [18F]-SKI-249380|Procedure: PET/CT scan|Other: Blood draws,All,"21 Years to 90 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01916135
NCT02857270,A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer,Recruiting,No Results Available,Drug: LY3214996|Drug: Midazolam|Drug: Abemaciclib|Drug: Nab-paclitaxel|Drug: Gemcitabine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02857270
NCT00207298,18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography in Oncology,Completed,No Results Available,Procedure: Positron Emission Tomography,All,"19 Years to 90 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00207298
NCT00565721,A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis,Completed,Has Results,Drug: Fluciclatide Injection - (AH111585 (F18)),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00565721
NCT00451880,Study of XL281 in Adults With Solid Tumors,Completed,No Results Available,Drug: XL281|Drug: famotidine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00451880
NCT03684785,Intratumoral AST-008 Combined With Pembrolizumab in Patients With Advanced Solid Tumors,Recruiting,No Results Available,Drug: AST-008|Biological: Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03684785
NCT02173171,Registry Study for Talimogene Laherparepvec,Enrolling by invitation,No Results Available,Other: Information collection,All,"18 Years to 99 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02173171
NCT00633516,A Pilot Study to Evaluate Optical Spectroscopy of Pigmented Skin Lesions,Completed,No Results Available,Device: Optical Spectroscopy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00633516
NCT02473874,Comparison Imaging System Between Spatially Modulated Quantitative Spectroscopy and Skin Spect Dermoscopy,Withdrawn,No Results Available,Device: Skin Spect dermoscope|Device: Spatially modulated quantitative,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02473874
NCT01088737,Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna,"Active, not recruiting",No Results Available,Drug: Imiquimod,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01088737
NCT00422448,Study to Test Genetic Alterations Among Different Dermoscopic Types of Melanocytic Nevi.,Completed,Has Results,Genetic: To test the frequency of BRAF and NRAS mutations among nevi,All,"9 Years to 80 Years   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00422448
NCT01984892,Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC),Terminated,Has Results,Drug: Poly-ICLC,All,"14 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01984892
NCT03370861,How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes,Recruiting,No Results Available,Biological: Immunotherapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03370861
NCT03311334,A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Subjects With Advanced Solid Tumors,Recruiting,No Results Available,Drug: DSP-7888 Dosing Emulsion|Drug: Nivolumab|Drug: Atezolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03311334
NCT02346955,Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001),Terminated,No Results Available,Biological: CM-24 (MK-6018)|Biological: Pembrolizumab (MK-3475),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02346955
NCT01986426,LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab,Completed,No Results Available,Drug: LTX-315 consecutive lesions|Drug: LTX-315|Drug: LTX-315 + ipilimumab|Drug: LTX-315 + pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01986426
NCT02482168,Study of the CD40 Agonistic Monoclonal Antibody APX005M,"Active, not recruiting",No Results Available,Drug: APX005M,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02482168
NCT00311558,"Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or Myeloma",Terminated,No Results Available,Biological: recombinant interferon alfa-2b|Drug: sodium stibogluconate|Drug: SSG & interferon,All,"18 Years to 120 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00311558
NCT02861209,Collaborative Network to Take Responsibility for Oral Anticancer Therapy,Unknown status,No Results Available,Other: Implementation of a care pathway,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02861209
NCT03637803,MRx0518 and Pembrolizumab Combination Study,Recruiting,No Results Available,Drug: MRx0518|Drug: Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA],All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03637803
NCT03693014,A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors,Recruiting,No Results Available,"Radiation: Stereotactic Body Radiotherapy|Biological: Ipilimumab, Nivolumab, Pembrolizumab or Atezolizumab",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03693014
NCT01882946,Safety and Efficacy Study of DCVax-Direct in Solid Tumors,Unknown status,No Results Available,Biological: DCVax-Direct,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01882946
NCT01390818,Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors,Completed,Has Results,Drug: MSC1936369B (pimasertib)|Drug: SAR245409 (PI3K and mTOR inhibitor),All,"18 Years to 82 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01390818
NCT00824889,Exploratory Study of Natural Killer Cells in Human Skin,Completed,No Results Available,Other: Biopsy and sample of blood,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00824889
NCT03073473,Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers,Terminated,No Results Available,Diagnostic Test: NantHealth GPS Cancer Test,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03073473
NCT03554434,An Expanded Access Program for AM0010 (Pegilodecakin),Temporarily not available,No Results Available,Biological: AM0010,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03554434
NCT03435640,A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies,Recruiting,No Results Available,Drug: NKTR-262|Drug: NKTR-214|Drug: nivolumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03435640
NCT03329950,A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies,Recruiting,No Results Available,Drug: CDX-1140|Drug: CDX-301,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03329950
NCT03289962,A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors,Recruiting,No Results Available,Drug: RO7198457|Drug: Atezolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03289962
NCT03058289,A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6,Recruiting,No Results Available,Drug: INT230-6|Biological: anti-PD-1|Biological: anti-PD-1 antibody,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03058289
NCT01508013,An Appearance-Based Intervention to Reduce Teen Skin Cancer Risk,Completed,Has Results,Behavioral: Appearance-Focused Website Intervention|Behavioral: Control Website,Female,"12 Years to 18 Years   (Child, Adult)",https://ClinicalTrials.gov/show/NCT01508013
NCT02009449,A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors,"Active, not recruiting",No Results Available,Drug: AM0010|Drug: Paclitaxel or Docetaxel and Carboplatin or Cisplatin|Drug: FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)|Drug: gemcitabine/nab-paclitaxel|Drug: Capecitabine|Drug: Pazopanib|Drug: Pembrolizumab|Drug: Paclitaxel|Drug: nivolumab|Drug: Gemcitabine/carboplatin,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02009449
NCT02005614,A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI and Rational Dose Selection,Suspended,No Results Available,Procedure: Gamma Knife Radiosurgery,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02005614
NCT03756792,Assessing Patient Anxiety During Mohs Micrographic Surgery,Not yet recruiting,No Results Available,Behavioral: Normal Education Material|Behavioral: Vignette,All,"18 Years to 80 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03756792
NCT02586987,"A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours","Active, not recruiting",No Results Available,Drug: Selumetinib|Drug: MEDI4736|Drug: Tremelimumab,All,"18 Years to 99 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02586987
NCT01223248,Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy,"Active, not recruiting",No Results Available,Radiation: IGIMRT using a single dose of 24 Gy|Radiation: IGIMRT 27 Gy in 3 fractions,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01223248
NCT00623831,A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen,Completed,Has Results,Biological: Mixed bacterial vaccine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00623831
NCT02890368,Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides,Recruiting,No Results Available,Drug: TTI-621 Monotherapy|Drug: TTI-621 + PD-1/PD-L1 Inhibitor|Drug: TTI-621 + pegylated interferon-α2a|Other: TTI-621 + T-Vec|Other: TTI-621 + radiation,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02890368
NCT02869217,Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors,Recruiting,No Results Available,Drug: Cyclophosphamide|Biological: TBI-1301,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02869217
NCT02646748,Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors,Recruiting,No Results Available,Drug: Pembrolizumab|Drug: itacitinib|Drug: INCB050465,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02646748
NCT02628535,Safety Study of MGD009 in B7-H3-expressing Tumors,"Active, not recruiting",No Results Available,Biological: MGD009,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02628535
NCT03552718,QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.,Recruiting,No Results Available,Biological: YE-NEO-001,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03552718
NCT03629756,A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies,Recruiting,No Results Available,Drug: AB928|Drug: AB122,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03629756
NCT02498665,A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies,"Active, not recruiting",No Results Available,Drug: DSP-7888 Dosing Emulsion,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02498665
NCT00423254,Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.,Completed,No Results Available,Biological: PSMA/PRAME,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00423254
NCT03321903,EPR Tumor Oximetry With CE India Ink,Recruiting,No Results Available,Device: Carlo Erba Ink Injection|Other: EPR Oximetry Measurement,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03321903
NCT03787056,Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients,Recruiting,No Results Available,Other: Blood draws,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03787056
NCT03707574,Genetic Analysis of Blood and Tissue Samples From Participants With Advanced Cancer,Not yet recruiting,No Results Available,Procedure: Biospecimen Collection,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03707574
NCT03628677,A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies,Recruiting,No Results Available,Drug: AB154|Drug: AB122,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03628677
NCT01829971,"A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection",Terminated,No Results Available,Drug: MRX34,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01829971
NCT03638206,Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies,Recruiting,No Results Available,Biological: CAR-T cell immunotherapy,All,"4 Years to 70 Years   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03638206
NCT03621982,Study of ADCT-301 in Patients With Selected Advanced Solid Tumors,Recruiting,No Results Available,Drug: ADCT-301,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03621982
NCT03212404,Phase 1 Study of CK-301 as a Single Agent in Subjects With Advanced Cancers,Recruiting,No Results Available,Drug: CK-301,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03212404
NCT02457650,T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies,Recruiting,No Results Available,Drug: Cyclophosphamide|Drug: Fludarabine|Biological: Anti-NY ESO-1 TCR-transduced T cells,All,"1 Year and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02457650
NCT03422679,Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies,Recruiting,No Results Available,Drug: CB-103,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03422679
NCT02988817,HuMax-AXL-ADC Safety Study in Patients With Solid Tumors,Recruiting,No Results Available,Biological: HuMax-AXL-ADC,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02988817
NCT02310503,Spanish Registry of Mohs Surgery,Recruiting,No Results Available,Procedure: Mohs surgery,Female,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02310503
NCT03207867,A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma,Recruiting,No Results Available,Drug: NIR178|Drug: PDR001,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03207867
NCT03195699,"Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers",Recruiting,No Results Available,Drug: TTI-101,All,"18 Years to 65 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03195699
NCT02966509,Engagement of Patients With Advanced Cancer,Completed,Has Results,Behavioral: EPAC,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02966509
NCT02900248,"CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice","Active, not recruiting",No Results Available,Other: Provider determined,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02900248
NCT02327078,"A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)","Active, not recruiting",No Results Available,Drug: Nivolumab (Phase 1)|Drug: Epacadostat (Phase 1)|Drug: Chemotherapy (Phase 1)|Drug: Nivolumab (Phase 2)|Drug: Epacadostat (Phase 2),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02327078
NCT02576665,"A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)","Active, not recruiting",No Results Available,Biological: Toca 511|Drug: Toca FC,All,"18 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02576665
NCT02543645,A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer,Terminated,No Results Available,Drug: Combination of Varlilumab and Atezolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02543645
NCT02432963,Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy,"Active, not recruiting",No Results Available,Other: Laboratory Biomarker Analysis|Biological: Modified Vaccinia Virus Ankara Vaccine Expressing p53|Biological: Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02432963
NCT02376699,Safety Study of SEA-CD40 in Cancer Patients,"Active, not recruiting",No Results Available,Drug: IV SEA-CD40 monotherapy regimen|Drug: Pembrolizumab|Drug: SC SEA-CD40 monotherapy regimen,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02376699
NCT02374255,Improving Goals of Care Discussion in Advanced Cancer Patients,Recruiting,No Results Available,Behavioral: GoC intervention,All,"21 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02374255
NCT02355535,Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1,Recruiting,No Results Available,Drug: PAC-1,All,"18 Years to 85 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02355535
NCT02178722,"A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037/ ECHO-202)","Active, not recruiting",No Results Available,Drug: MK-3475|Drug: INCB024360,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02178722
NCT02129049,Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children,Completed,No Results Available,Other: educational intervention|Behavioral: telephone-based intervention|Other: questionnaire administration,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02129049
NCT02045368,Study of IGF-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R,Completed,No Results Available,Drug: IGF-Methotrexate conjugate,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02045368
NCT01896778,Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer,Completed,No Results Available,Procedure: Hyperthermia Treatment|Other: Laboratory Biomarker Analysis,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01896778
NCT01639911,Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors,Completed,No Results Available,Drug: Alisertib|Drug: Pazopanib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01639911
NCT01625351,A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas,"Active, not recruiting",No Results Available,Drug: alemtuzumab|Drug: fludarabine|Drug: sirolimus|Drug: Busulfan|Drug: melphalan|Biological: stem cells|Device: CliniMACS,All,"2 Years to 21 Years   (Child, Adult)",https://ClinicalTrials.gov/show/NCT01625351
NCT01586767,Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy,Recruiting,No Results Available,Radiation: Proton radiation therapy|Radiation: Intensity-modulated radiotherapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01586767
NCT03054584,Genetic Basis of Melanocytic Nevi,Recruiting,No Results Available,Other: Collecting Nevi,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03054584
NCT01392352,HYPAZ: Hypertension Induced by Pazopanib,Terminated,No Results Available,Drug: Pazopanib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01392352
NCT01366144,"Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction",Suspended,No Results Available,Drug: Carboplatin|Other: Laboratory Biomarker Analysis|Drug: Paclitaxel|Other: Pharmacological Study|Drug: Veliparib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01366144
NCT01272817,Nonmyeloablative Allogeneic Transplant,Unknown status,No Results Available,Procedure: Nonmyeloablative Allogeneic Transplant,All,"18 Years to 72 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01272817
NCT00722228,Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors,Unknown status,No Results Available,Biological: Autologous or Allogeneic tumor cells,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00722228
NCT01194947,Classification and Longitudinal Follow-up of Common Melanocytic Nevi With in Vivo Reflectance Confocal Microscopy,Unknown status,No Results Available,Device: RCM imaging,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01194947
NCT02997553,Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery,Recruiting,No Results Available,Drug: Indocyanine green|Drug: Technetium99|Device: Optonuclear probe,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02997553
NCT03415126,A Study of ASN007 in Patients With Advanced Solid Tumors,Recruiting,No Results Available,Drug: ASN007: ascending doses|Drug: ASN007 RD,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03415126
NCT01709435,Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors,"Active, not recruiting",No Results Available,Drug: Cabozantinib S-malate|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study,All,"2 Years to 18 Years   (Child, Adult)",https://ClinicalTrials.gov/show/NCT01709435
NCT02431676,Survivorship Promotion In Reducing IGF-1 Trial,"Active, not recruiting",No Results Available,Drug: Metformin|Behavioral: Coach Directed Behavioral Weight Loss|Behavioral: Self-control weight loss,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02431676
NCT00937482,Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer,Terminated,No Results Available,Drug: cediranib maleate|Radiation: whole-brain radiation therapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00937482
NCT02029690,Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin,"Active, not recruiting",No Results Available,Drug: ADI-PEG 20,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02029690
NCT00101270,Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas,Completed,No Results Available,Drug: irinotecan hydrochloride|Drug: oxaliplatin,All,"1 Year to 21 Years   (Child, Adult)",https://ClinicalTrials.gov/show/NCT00101270
NCT03420963,Ex-Vivo Expanded Allogeneic NK Cells For The Treatment Of Pediatric Solid Tumors,Recruiting,No Results Available,Drug: Cyclophosphamide|Drug: Etoposide|Procedure: NK Cell Infusion|Drug: Mesna,All,"12 Months to 40 Years   (Child, Adult)",https://ClinicalTrials.gov/show/NCT03420963
NCT03093909,Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases,Recruiting,No Results Available,Drug: Gemcitabine,All,"12 Years to 50 Years   (Child, Adult)",https://ClinicalTrials.gov/show/NCT03093909
NCT01929720,"Cognitive-Behavioral Intervention for Worry, Uncertainty, and Insomnia for Cancer Survivors",Completed,No Results Available,"Behavioral: Cognitive-behavioral therapy for worry, uncertainty & insomnia",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01929720
NCT02097875,Safety Study of a Fluorescent Marker to Visualize Cancer Cells,Completed,No Results Available,Drug: BLZ-100,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02097875
NCT01505153,Phase I Intratumoral Pbi-shRNA STMN1 LP in Advanced and/or Metastatic Cancer,Completed,No Results Available,Biological: pbi-shRNA STMN1 LP,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01505153
NCT03291288,Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics),"Active, not recruiting",No Results Available,Drug: Tolbutamide|Drug: Midazolam|Drug: Pexidartinib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03291288
NCT00656227,A Trial to Investigate Scar Improvement Efficacy of RN1001 (Avotermin) After Head and Neck Naevi Excision,Unknown status,No Results Available,Drug: Avotermin,All,"18 Years to 85 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00656227
NCT02394132,Radiotherapy or Imiquimod in Complex Lentigo Maligna,Recruiting,No Results Available,Drug: Imiquimod|Radiation: Radiotherapy,All,"18 Years to 120 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02394132
NCT01161888,Effect of Topical Imiquimod on Lentigo Maligna,Completed,No Results Available,Drug: Imiquimod,All,"45 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01161888
NCT00707174,Combination Therapy With Imiquimod Cream 5% and Tazarotene Cream 0.1% for the Treatment of Lentigo Maligna,Completed,Has Results,Drug: Imiquimod Cream|Drug: Tazarotene Cream 0.1%,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00707174
NCT01954043,A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors,Completed,No Results Available,Drug: Dabrafenib 150 mg twice a day (BID)|Drug: Rabeprazole 40 mg once daily (OD)|Drug: Rifampin 600 mg OD,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01954043
NCT03239145,Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor,Recruiting,No Results Available,Drug: Pembrolizumab|Drug: Trebananib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03239145
NCT02082665,Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam,Completed,No Results Available,Drug: Rosuvastatin10 mg tablet|Drug: Midazolam 3 mg syrup|Drug: Dabrafenib 75 mg capsule,All,"18 Years to 65 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02082665
NCT00539383,"A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer",Completed,No Results Available,Drug: ANG1005,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00539383
NCT03094273,Prospective Study of 2 mm Margins for the Biopsy of Dysplastic Nevi,Completed,No Results Available,Procedure: Saucerization biopsy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03094273
NCT01193036,Symptom Burden in Patients With Cancer- and Treatment-Related Skin Problems,Terminated,No Results Available,Behavioral: Part 1: Interview + Questionnaires|Behavioral: Part 2: Multiple Questionnaires,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01193036
NCT01186601,Exploration of Tumor Accumulation of BAY94-9392 in Patients With Cancer,Completed,No Results Available,Drug: PET tracer (BAY94-9392),All,"18 Years to 90 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01186601
NCT01968681,Treatment of Nevus Flammeus With Alexandrite Laser,Completed,No Results Available,Procedure: Alexandrite laser,All,"10 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01968681
NCT00955578,Genetic Identification (ID) of Segmental Dysplastic Nevi,Unknown status,No Results Available,Procedure: Punch Biopsy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00955578
NCT00346502,Evaluation of 20% Betulinic Acid Ointment for Treatment of Dysplastic Nevi (Moderate to Severe Dysplasia),Suspended,No Results Available,Drug: 20% betulinic acid ointment|Drug: BA,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00346502
NCT01046487,Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate,Completed,No Results Available,"Drug: Imatinib mesylate, Cyclophosphamide (Dosing level 1 )|Drug: Imatinib mesylate, Cyclophosphamide (Dosing level 2)|Drug: Imatinib mesylate, Cyclophosphamide (Dosing level 3)|Procedure: Blood sampling",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01046487
NCT00900302,OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer,Completed,No Results Available,Genetic: protein expression analysis|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Procedure: biopsy,All,"up to 120 Years   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00900302
NCT00499733,Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer,Terminated,No Results Available,Drug: cyclophosphamide|Device: Cryoablation,All,"18 Years to 120 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00499733
NCT00538850,Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain,Completed,Has Results,Drug: Fentanyl sublingual spray|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00538850
NCT00096083,Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer,Completed,No Results Available,Drug: isolated perfusion|Drug: melphalan,All,"16 Years and older   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00096083
NCT00020579,MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma,Completed,No Results Available,Drug: entinostat,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00020579
NCT02697591,"An Open-Label, Dose-Escalation, Safety Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors",Recruiting,No Results Available,Drug: INCAGN01876,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02697591
NCT00002854,High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer,Completed,No Results Available,Biological: filgrastim|Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: ifosfamide|Drug: mesna|Drug: paclitaxel|Procedure: peripheral blood stem cell transplantation,All,18 Years to 55 Years   (Adult),https://ClinicalTrials.gov/show/NCT00002854
NCT02315066,Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566,"Active, not recruiting",No Results Available,Drug: PF-04518600|Drug: PF-04518600 plus PF-05082566,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02315066
NCT03767439,Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome,Not yet recruiting,No Results Available,Drug: Vismodegib|Drug: Nivolumab|Drug: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03767439
NCT02722798,A Study of KRN23 in Subjects With Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome,"Active, not recruiting",No Results Available,Drug: KRN23,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02722798
NCT02304367,Study of KRN23 in Adult Subjects With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS),"Active, not recruiting",No Results Available,Biological: KRN23,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02304367
NCT02100371,Study of BMS-833923 in Two Specific Patients With Basal Cell Nevus Syndrome,Completed,No Results Available,Drug: BMS-833923,Female,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02100371
NCT00957229,To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS),Completed,No Results Available,Drug: GDC-0449,All,"35 Years to 75 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00957229
NCT03703310,"Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome",Not yet recruiting,No Results Available,"Drug: Patidegib Topical Gel, 2%|Drug: Patidegib Topical Gel, Vehicle",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03703310
NCT03208296,Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS),Suspended,No Results Available,Biological: ASN-002,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03208296
NCT02354261,Open-label Trial of SUBA™-Itraconazole (SUBA-Cap) in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS),"Active, not recruiting",No Results Available,Drug: SUBA-Itraconazole,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02354261
NCT00154388,Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases,Completed,No Results Available,Drug: Imatinib mesylate,All,"15 Years to 70 Years   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00154388
NCT00253708,Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer,Completed,Has Results,Procedure: management of therapy complications|Procedure: massage therapy|Procedure: pain therapy|Procedure: psychosocial assessment and care|Procedure: quality-of-life assessment,All,"18 Years to 120 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00253708
NCT00049296,Thalidomide and Docetaxel in Treating Patients With Advanced Cancer,Completed,No Results Available,Drug: docetaxel|Drug: thalidomide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00049296
NCT00580736,Optical Clearing of the Skin in Conjunction With Laser Treatments,Completed,No Results Available,Device: Optical Clearing,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00580736
NCT00003597,Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors,Completed,No Results Available,Biological: recombinant human thrombopoietin|Drug: carboplatin|Drug: etoposide|Drug: ifosfamide|Biological: G-CSF,All,"1 Year to 21 Years   (Child, Adult)",https://ClinicalTrials.gov/show/NCT00003597
NCT01607905,Safety Study of KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer,Completed,No Results Available,Drug: KPT-330,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01607905
NCT01352884,"Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Patients With Advanced Cancer",Completed,No Results Available,Drug: AMP-224,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01352884
NCT00687622,"Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma",Completed,No Results Available,Drug: GSK1120212,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00687622
NCT02988960,"A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Subjects With Advanced Solid Tumors",Recruiting,No Results Available,Drug: ABBV-927|Drug: ABBV-181,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02988960
NCT03361228,"A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors","Active, not recruiting",No Results Available,Drug: INCB001158|Drug: Epacadostat|Drug: Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03361228
NCT02608268,Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.,Recruiting,No Results Available,Drug: MBG453|Drug: PDR001,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02608268
NCT02460224,Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.,"Active, not recruiting",No Results Available,Drug: LAG525|Drug: PDR001,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02460224
NCT01234012,Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1,Completed,No Results Available,Biological: IMF-001,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01234012
NCT00986661,A Study to Assess PV-10 Chemoablation of Cancer of the Liver,Recruiting,No Results Available,Drug: PV-10 (10% rose bengal disodium),All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00986661
NCT02000739,Genetically-informed Therapies for Patients With Metastatic Cancer,Withdrawn,No Results Available,Genetic: Genetically Informed Therapy,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02000739
NCT03009058,Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer,Terminated,No Results Available,Biological: IMM-101|Drug: Gemcitabine|Drug: Nabpaclitaxel|Drug: Capecitabine|Drug: Folinic Acid|Drug: Fluorouracil|Drug: Irinotecan|Drug: Oxaliplatin|Biological: cetuximab|Biological: Anti-PD1|Biological: Ipilimumab|Drug: Cyclophosphamide,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03009058
NCT00940225,Study of Cabozantinib (XL184) in Adults With Advanced Malignancies,Completed,No Results Available,Drug: XL184|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00940225
NCT03075072,"Whole Brain Radiation Versus Stereotactic Radiation (SRS) in Patients With 5-20 Brain Metastases: A Phase III, Randomized Clinical Trial",Recruiting,No Results Available,Radiation: Whole brain radiation|Radiation: Stereotactic radiation (SRS),All,"18 Years to 80 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03075072
NCT02922764,A Study of RGX-104 With or Without Nivolumab in Patients With Advanced Solid Malignancies and Lymphoma,Recruiting,No Results Available,Drug: RGX-104|Drug: Nivolumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02922764
NCT03241173,A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies,"Active, not recruiting",No Results Available,Drug: INCAGN01949|Drug: Nivolumab|Drug: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03241173
NCT03126110,"Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies",Recruiting,No Results Available,Drug: INCAGN01876|Drug: Nivolumab|Drug: Ipilimumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03126110
NCT02038218,Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome in Patients With Brain Tumors,Completed,No Results Available,Drug: 4-Demethyl-4-cholestryloxycarbonylpenclomedine,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02038218
NCT02923349,"A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors","Active, not recruiting",No Results Available,Drug: INCAGN01949,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02923349
NCT03347123,A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (ECHO-208),"Active, not recruiting",No Results Available,Drug: Epacadostat|Drug: Nivolumab|Drug: Ipilimumab|Drug: Lirilumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03347123
NCT03634982,Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors,Recruiting,No Results Available,Drug: RMC-4630,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03634982
NCT03565445,"A Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects With Advanced Solid Tumors",Recruiting,No Results Available,Drug: ASP1948,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03565445
NCT00861107,In-Situ Therapeutic Cancer Vaccine for Metastatic Cancer Combining AlloStim With Tumor Cryoablation,Completed,No Results Available,Biological: AlloStim-7|Procedure: percutaneous tumor cryoablation|Biological: AlloStim8 or AlloStim-9,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00861107
NCT03454243,Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors,Terminated,No Results Available,Drug: RXDX-106,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03454243
NCT03301896,Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies,Recruiting,No Results Available,Drug: LHC165|Biological: PDR001,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03301896
NCT00629200,Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies,Completed,No Results Available,Drug: Sodium Stibogluconate|Drug: Interferon Alpha-2b,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00629200
NCT00629187,Safety Study of High Dose Temozolomide to Treat Relapsed/Refractory Central Nervous System (CNS) Malignancy,Terminated,No Results Available,Drug: Temozolomide,All,"18 Years to 70 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00629187
NCT03071757,"A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors",Recruiting,No Results Available,Drug: ABBV-368|Drug: ABBV-181,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03071757
NCT02554812,A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley),Recruiting,No Results Available,Drug: Avelumab|Drug: Utomilumab|Drug: PF-04518600|Drug: PD 0360324,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02554812
NCT02817633,"A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors",Recruiting,No Results Available,Drug: TSR-022|Drug: anti-PD-1 antibody,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02817633
NCT02369029,"BAY1238097, First in Man",Terminated,No Results Available,Drug: BAY 1238097,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02369029
NCT02366546,Investigator Initiated Phase 1 Study of TBI-1301,"Active, not recruiting",No Results Available,Drug: TBI-1301|Drug: Cyclophosphamide|Drug: Fludarabine,All,"20 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02366546
NCT02313012,Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors,Terminated,No Results Available,Drug: CC-90003,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02313012
NCT02605083,A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors,Terminated,No Results Available,Drug: eFT508,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02605083
NCT02571036,"A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies",Recruiting,No Results Available,Drug: DCC-2618,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02571036
NCT02428036,A Study of TBI-1401(HF10) in Patients With Solid Tumors With Superficial Lesions,Completed,No Results Available,Biological: TBI-1401(HF10),All,"20 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02428036
NCT02096614,Investigator Initiated Phase 1 Study of TBI-1201,Recruiting,No Results Available,Drug: TBI-1201|Drug: Cyclophosphamide|Drug: Fludarabine,All,"20 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02096614
NCT01831726,Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib,Completed,Has Results,Drug: Dovitinib (TKI258),All,"18 Years to 100 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01831726
NCT01804634,Trial of Reduced Intensity Conditioning and Haploidentical BMT for High-risk Solid Tumors,Recruiting,No Results Available,Drug: Cyclophosphamide|Drug: Fludarabine|Radiation: low dose total body irradiation|Drug: Melphalan|Drug: Sirolimus,All,"up to 40 Years   (Child, Adult)",https://ClinicalTrials.gov/show/NCT01804634
NCT01772004,Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor),"Active, not recruiting",No Results Available,Drug: Avelumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01772004
NCT01624220,A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy,"Active, not recruiting",No Results Available,Radiation: Spinal SBRT (Standard Dose)|Radiation: Spinal SBRT (Higher Dose)|Procedure: Gold Seed Implantation|Behavioral: Questionnaires,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01624220
NCT00333502,Study of CRLX101 (Formerly Named IT-101) in the Treatment of Advanced Solid Tumors,Completed,No Results Available,"Drug: Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer",All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00333502
NCT01259284,Fish Oil Versus Statins Versus Placebos in Reducing Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer,Terminated,Has Results,Drug: Atorvastatin|Dietary Supplement: Fish Oil Supplement|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01259284
NCT01300533,A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer,Completed,No Results Available,Drug: BIND-014,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01300533
NCT01183663,"Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)",Completed,No Results Available,Drug: Lenalidomide|Drug: Bevacizumab|Drug: Sorafenib|Drug: Temsirolimus|Drug: Oxaliplatin|Drug: Leucovorin|Drug: 5-fluorouracil,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01183663
NCT00948961,A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1,Completed,No Results Available,Biological: CDX-1401 in combination with Resiquimod and/or Poly-ICLC|Biological: CDX-1401|Biological: Resiquimod|Biological: poly-ICLC,All,"18 Years to 99 Years   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00948961
NCT00827177,Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors,Completed,No Results Available,Drug: Treatment with ARQ 197 in combination with sorafenib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00827177
NCT00689065,Safety Study of CALAA-01 to Treat Solid Tumor Cancers,Terminated,No Results Available,Drug: CALAA-01,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00689065
NCT00496860,Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies,Completed,Has Results,Biological: ALT-801,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00496860
NCT00375245,Rapamycin With Grapefruit Juice for Advanced Malignancies,Completed,No Results Available,Drug: Rapamycin (sirolimus)|Other: Grapefruit Juice,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00375245
NCT00121420,Study of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain Metastases,Terminated,No Results Available,Drug: Motexafin gadolinium,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00121420
NCT03693612,GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors,Recruiting,No Results Available,Drug: GSK3359609|Drug: Tremelimumab|Drug: Docetaxel|Drug: Paclitaxel|Drug: Cetuximab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03693612
NCT02714374,Safety and Effect of GL-ONC1 Administered IV Prior to Surgery to Patients With Solid Organ Cancers Undergoing Surgery,"Active, not recruiting",No Results Available,Biological: GL-ONC1,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02714374
NCT02065063,"A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors",Completed,No Results Available,Drug: Trametinib|Drug: Palbociclib,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02065063
NCT03006887,Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Subjects With Selected Solid Tumors,"Active, not recruiting",No Results Available,Drug: lenvatinib|Drug: pembrolizumab,All,"20 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03006887
NCT00073944,BCX-1777 in Treating Patients With Refractory Cancer,Completed,No Results Available,Drug: forodesine hydrochloride,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00073944
NCT00066404,Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions,Unknown status,No Results Available,Biological: recombinant adenovirus-hIFN-beta,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00066404
NCT01138085,"Safety, Pharmacokinetics (PK) of AKT and MEK Combination",Completed,No Results Available,Drug: GSK1120212|Drug: GSK2141795,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT01138085
NCT00899496,Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants,Completed,No Results Available,Other: immunological diagnostic method|Other: physiologic testing,All,"up to 120 Years   (Child, Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT00899496
NCT03277352,INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies,"Active, not recruiting",No Results Available,Drug: INCAGN01876|Drug: Epacadostat|Drug: Pembrolizumab,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT03277352
NCT02000089,The Cancer of the Pancreas Screening-5 CAPS5)Study,Recruiting,No Results Available,Drug: Human synthetic secretin,All,"18 Years and older   (Adult, Older Adult)",https://ClinicalTrials.gov/show/NCT02000089